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Abstract 
ABSTRACT 
Cardiac development is a complex multi-step process involving a diverse network of 
genes. Defects in cardiac genes can lead to congenital heart defects (CHDs), and 
understanding the processes involved in normal cardiogenesis is crucial in elucidating 
the pathogenesis of disease. Mutations in a number of cardiac transcription factors 
have been associated with CHDs, including TBX5 and GATA-4. These transcription 
factors are high in the regulatory hierarchy and form a complex that is thought to direct 
and synergistically regulate common cardiac pathways. However, little is currently 
known about their joint targets. This study aimed to identify and analyse genes 
important in cardiogenesis, with focus on the combined targets of TBX5 and GAT A-4. 
Microarray expression analysis of TBX5 I GATA-4 double overexpression P19 cell 
lines led to the identification of a large number of genes, of which seven were selected 
for study; PA2.26, PETA-3, FUCA 1, FN, TPM1, DES, and RBMS1. Expression of 
these was confirmed in the embryonic chick heart at Hamburger and Hamilton (HH) 
stages 12 - 26. The cell cycle regulator and transcription factor RBMS1 was selected 
for investigation of its role in cardiac development. Morpholino knockdown of RBMS1 
expression in the developing chick resulted in defects in cardiac looping and atrial 
septation. Whilst further work is required to strengthen this data, this is a novel finding 
and opens up possibilities for future research into cardiac transcriptional networks. 
Microarray expression analysis using an in ovo model of TBX5 and GATA-4 double 
knockdown led to the identification of a number of interesting putative targets, 
including TFAP2B, GPC3, and CRABP1, which have known roles in cardiac 
development. TFAP2B is of particular interest as mutations in this gene are 
associated with the heart-hand disorder Char syndrome. LOC420770, a novel gene of 
unknown function, was also identified and displayed expression indicative of a heart-
limb profile. Further studies to attempt elucidation of the function of this gene may 
provide a novel candidate gene for CHD. Investigation of these genes will form the 
basis of future research, contributing to our current knowledge of the vast network of 
genes involved in development of the heart. 
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CHAPTER 1 
INTRODUCTION 
1.1 CARDIAC DEVELOPMENT 
The heart is the first organ to form in embryogenesis, developing by a complex and 
precisely co-ordinated process involving heart specification, formation of the linear 
heart tube, looping, and maturation to ultimately form a four-chambered structure 
[Martinsen, 2005]. Processes such as septation, valve development and coronary 
vasculature formation occur in parallel and are crucial. Cardiac development is 
regulated by a vast network of genes encoding growth factors, transcription factors, 
co-factors and regulators, signalling proteins, and structural molecules, some of which 
will be described here. Perturbations in the developmental process can lead to heart 
malformations, and understanding the molecular processes involved in normal cardiac 
development is important in elucidating the pathogenesis of congenital heart defects. 
The anatomical development of the heart has been widely studied in a number of 
organisms including human (Carnegie Stages I CS), mouse (Embryonic days I E), and 
chick (Hamburger and Hamilton stages I HH), and is detailed below. Processes that 
differ between mammals and the chick (namely atrial septation) are discussed. 
1.1.1 Pre-gastrulation and gastrulation 
At the pre-primitive streak stage, cardiac precursor cells are identifiable in the epiblast 
cell layer [Yutzey and Kirby, 2002]. The primitive streak is a triangular region found in 
the midline of the long axis of the oval disc in the area pellucida, darker than its 
surroundings due to cell ingression to this region before outward cell migration begins. 
At the onset of primitive streak formation, cardiac progenitor cells exist in the postero-
lateral epiblast [Hatada and Stern, 1994; Yatskievych et aI., 1997]. Interaction 
between the postero-Iateral epiblast and hypoblast is required for anterior lateral plate 
mesoderm formation, and this region gives rise to the heart [Ehrman and Yutzey, 
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1999]. The intermediate primitive streak extends from the posterior into the centre of 
the area pellucid a and contains precardiac cells in the anterior [Rawles, 1943] (Figure 
1.1A). The definitive primitive streak extends over most of the area pellucida. 
Gastrulation, where the three embryonic germ layers are established, is one of the first 
morphogenetic events to occur in development. Migration of cells from the upper 
layer of the primitive streak gives rise to the ectoderm, the earliest layer to form and 
the outermost. The endoderm is formed by inward migration of cells along the 
archenteron from the inner layer of the gastrula. The mesoderm, an additional layer 
between the ectoderm and endoderm, is formed from some of the cells migrating to 
form the endoderm. Each germ layer gives rise to specific body tissues. 
1.1.2 Formation of the primary heart field 
Precardiac cells are found in the anterior mesoderm and either side of the node 
[Linask and Lash, 1986]. The anterior intestinal portal, head process and head fold 
develop, and the cells that will form the heart move into two bilateral regions in the 
anterolateral region of the embryo called the primary heart field, first identified by 
Rawles in 1943 [Rawles, 1943] (Figure 1.1 B). This region gives rise to the 
myocardium and endocardium. Cardiac precursor cells (not yet fully committed) 
segregate into the splanchnic mesoderm layer during migration into the primary heart 
fields. This layer is adjacent to the endoderm, which is thought to induce 
differentiation of myocardial cells [Abu-Issa et aI., 2004]. Definition of the avian 
embryonic heart forming region (HFR) has been attempted through the use of early 
cardiac markers such as Nkx2.5 and GATA-4, and by cell lineage tracing studies 
[Redkar et aI., 2001]. The two methods yielded differing results, as with many 
previous studies, and the extent of the heart forming region remains unclear. As 
cardiac precursor cells reach a higher level of commitment, expression of cardiac 
genes is initiated [van den Hoff et aI., 2004]. The prospective heart forming regions 
migrate to form the cardiac crescent (Figure 1.1 C) (week 2 of human gestation I E7.5 
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in mouse), whilst the neural plate forms from the ectoderm, and folds to become the 
neural tube. 
1.1.3 Formation of the linear heart tube 
The cardiac crescent moves towards the embryonic neck and the cardiac plate folds 
into the primary heart tube at the embryonic ventral midline (Figure 1.1 D) [Moorman et 
aI., 20031, connected to the body by a posterior inflow (venous pole) and anterior 
outflow (arterial pole). The linear heart tube comprises two concentric layers of cells 
separated by an extensive matrix of cardiac jelly; the outer layer is made up of 
myocardial cells, and the inner layer consists of endocardial cells [Brutsaert, 20031. 
This structure, together with the remainder of the heart forming regions, takes the 
shape of an inverted Y. At this pre-looping phase, the heart is centrally positioned and 
undergoes rapid elongation along the craniocaudal axis of the embryo to form a long 
nearly symmetrical tube [Moorman et aI., 2003]. The primitive tubular heart begins to 
beat spontaneously soon after it is formed, at CS 10 (22 - 23 days) in humans, E8 in 
mouse, and HH10 in the chick [Franco et aI., 1998]. 
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Figure 1.1 Embryonic origin of the heart. Heart forming regions are displayed in 
red . A) Heart progenitor cells are located in the upper region of the primitive streak, 
under Hensen's node. B) Bilateral heart primordia are present in the anterior lateral 
plate mesoderm . C) Formation of the cardiac crescent following fusion of the anterior 
end of the two heart fields . D) Fusion of heart primordia to form a beating heart tube 
at the embryonic midline. Adapted from Yutzey et al., 2002 
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1.1.4 Looping of the heart 
The looping process can be subdivided into four phases following pre-looping (as 
described in 1.1.3); dextral-looping to form the c-shaped loop, transformation from the 
c-shaped loop to the s-shaped loop (early and late phases), and the positional 
changes which occur mainly in the primitive outflow tract (OFT) during cardiac 
septation [Manner, 2000]. These are represented in Figure 1.2. 
During dextral looping, the linear heart tube loops to the right to become c-shaped and 
asymmetric (Figure 1.2, 1). This process is essential in ventricle orientation and 
connection to the appropriate vessels, and is dependent on asymmetric signalling 
cascades [Kathiriya and Srivastava, 2000]. The right lateral furrow flattens, the left 
deepens, and the diameter of the heart tube increases particularly at the caudal end 
(an early manifestation of the thinner outflow portion (primitive conus) and thicker 
primitive ventricular region) [Manner, 2000]. The primitive ventricular region, 
composed of the primordia of the apical trabeculated regions of the left and right 
ventricles, bends to the right resulting in the ventral and dorsal sides of the heart tube 
becoming the convex right and concave left sides of the bend [Manner, 2000]. 
Myocardial precursor cells from the posterior region of the primary heart field 
contribute to the atria forming region, and cells from a second population of heart 
precursor cells in the pharyngeal mesoderm termed the secondary heart field, migrate 
into the cranial (arterial) pole of the heart, supporting growth of the outflow tract and 
right ventricle forming regions [Abu-Issa et aI., 2004; Kelly et aI., 2001; Kelly and 
Buckingham, 2002; Mjaatvedt et aI., 2001; Moorman et aI., 2007; Waldo et aI., 2001]. 
Cardiac neural crest (CNC) cells undergo epithelial-to-mesenchymal transition (EMT) 
and migrate away from the neural tube into the heart via the outflow tract and 
pharyngeal arch arteries [Boot et aI., 2003]. CNC cells are essential for correct 
outflow tract septation, cardiac innervation, aortic arch repatterning, and myocardial 
function [Kirby, 2002]. 
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Cardiac looping continues transforming the heart from a c-shape to an s-shaped 
structure via an early and late phase (Figure 1.2, 2-3). In the early phase, the caudal 
wall of the primitive conus, and cranial wall of the primitive atria move closer together, 
and the primitive ventricular bend shifts from a cranial to caudal position from the atria 
[Manner, 2009; Martinsen, 2005]. This transforms the heart to an immature s-shaped 
structure. In the late phase of s-Iooping, the proximal part of the outflow tract shifts to 
the left and ballooning of the chambers also occurs (described in 1.1.5) [Manner, 
2009]. The epicardium, myocardium, endocardium and cardiac jelly heart layers have 
also developed upon completion of this process. 
The last phase of looping is often referred to as the cardiac septation phase, since this 
is the main anatomical event occurring at this stage. A number of morphological 
changes occur resulting in positional changes of cardiac regions (Figure 1.2, 4). The 
proximal two thirds of the outlet section of the outflow tract shifts from a position lateral 
to the atria, to a position ventral to the right atrium, and the outflow tract and inner 
curvature of the ventricular bend are remodelled [Manner, 2009]. 
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Looping of the heart is represented in four phases. 1) Dextral-looping, where the linear heart tube loops to the right to become c-shaped and asymmetric. 2) 
Early phase s-Iooping, where the heart is transformed to an immature s-shaped structure. 3) Late phase s-Iooping, where the proximal part of the outflow 
tract shifts to the left and the heart is transformed to a mature s-shaped structure. 4) Cardiac septation , where a number of positional changes of card iac 
regions occur, mainly in the primitive outflow tract. Adapted from Manner, 2009 
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1.1.5 Chamber formation 
There have been two main theories about how the cardiac chambers form - the 
segmental theory, and the ballooning theory. According to the segmental model, the 
cardiac chambers form from segmental primordia along the anteroposterior axis of the 
heart tube, and this has been supported by apparent segmental expression of various 
cardiac genes [Franco et aI., 1998]. The heart tube contains caudal atrial and cranial 
ventricular regions which will give rise to the cardiac chambers (separated by the 
atrioventricular canal), and a cranial outflow tract. In this model, the outer curve of the 
looped heart gives rise to the right ventricle, whilst the inner bend gives rise to the left 
ventricle [De La Cruz et aI., 1989]. 
The ballooning model of chamber development is an alternative theory behind this 
process, and is now widely accepted. Cardiac ballooning is represented in Figure 1.3. 
Study of the expression pattern of a number of 'chamber specific' cardiac genes (ANF, 
Chisel, Irx5, and SERCA2a) showed that their expression is spatially restricted to the 
ventral side of the linear heart tube (Figure 1.3, A), and in the looped heart and mature 
heart, expression of these is observed in the outer curvature and chambers 
respectively (Figure 1.3, B & C) [Christoffels et aI., 2000]. This demonstrates the 
chambers originate from the outer region, 'ballooning' out from the heart tube. 
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A 
Figure 1.3 Representation of ballooning of the heart 
Prospective ventricular and atrial myocardium regions are shown in pink and blue 
respectively. Arrows denote the direction of blood-flow; grey arrows indicate blood-
flow into the ventricles , and black arrows indicate blood-flow through the outflow tract. 
Three phases of development are represented , A) the linear heart tube , 8) the mature 
s-Iooped heart, and C) the four chambered heart. The chambers originate from the 
outer region of the heart tube, 'ballooning' out. Adapted from Christoffe/s et al., 2000 
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1.1.6 Endocardial cushion formation and function 
Endocardial cushions are cell masses which initially appear as swellings in the cardiac 
jelly that form by EMT of the endothelial cell layer. In this process, endothelial cells 
delaminate, invade the cardiac jelly, proliferate, and complete the EMT process to 
differentiate into mesenchymal cells [Runyan and Markwald, 1983]. Cushions form in 
specific locations of the atrioventricular and conus regions, and are crucial in valve 
development and fusion of the septa to divide the chambers, atrioventricular (AV) 
canal, and outflow tract for formation of the aortic and pulmonary channels [Markwald 
et aI., 1977]. 
1.1.7 Septation 
Septation divides the heart into four distinct chambers, and separates the outflow tract 
region into the pulmonary and aortic channels. This compartmentalisation is critical in 
establishing and maintaining separate pulmonary and systemic circulations. Defects 
in septation, when left uncorrected, can lead to pulmonary vascular disease, atrial 
enlargement with a resulting predisposition to atrial arrhythmias, ventricular dilation, 
and a shortened life expectancy [Garg, 2006]. 
1.1.7.1 Atrial septation 
Development of the interatrial septum, which separates the left and right atria, begins 
with downward growth of the septum primum from the dorsal cranial wall of the 
common atrium into the atrial lumen, towards the endocardial cushions in the AV 
canal [Anderson et aI., 2003] (Figure 1.4A). The interatrial septum is identifiable from 
CS 13. The primary atrial opening (or foramen) between the septum primum and 
endocardial cushions is termed the ostium primum. The septum primum harbours a 
mesenchymal cap which becomes fused with the superior and inferior endocardial 
cushions in the AV canal (which also become fused with one another), closing the 
ostium primum [Wessels et aI., 2000]. In parallel, perforations form in the upper part 
of the septum as a result of apoptosis, and these coalesce to form a secondary atrial 
foramen termed the ostium secundum [Abdulla et aI., 2004] (Figure 1.48). 
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Development of an additional septum, the septum secundum, begins from the roof of 
the atrium wall and alongside the remnants of the septum primum [Lamers and 
Moorman, 2002] (Figure 1.4C). This leaves an opening called the foramen ovale. 
Following breakdown of the upper portion of the septum primum, the remaining part 
acts as a valve in this region and is termed the valve of foramen ovale [Anderson et 
aI., 2003). Once lung circulation begins postnatally, increased pressure in the left 
atrium results in fusion of the foramen ovale valve with the septum secundum to close 
the foramen ovale and complete atrial septation [Anderson et aI., 2003] (Figure 1.40). 
As mentioned, the process of atrial septation in the chick differs to that of mammals, 
and formation of the septum secundum does not occur. In the chick, the septum 
primum begins downward growth from the inner atrial wall at HH14 [Anderson et al., 
2003]. It becomes fused with dorsal and ventral endocardial cushions in the AV canal 
at HH 24 (4 days), and small perforations (foramina secunda) form in the mid-dorsal 
portion of the septum primum in parallel, maintaining communication between the atria 
[Hendrix and Morse, 1977]. These increase in number and size from days 5 to 8, 
creating cords of endocardium covered tissue [Morse and Hendrix, 1980]. This cord 
tissue thickens during days 8 to 15, reducing the size of the foramina secunda. By 
day 2 post hatching, the interatrial perforations are closed, and atrial septation is 
complete [Hendrix and Morse, 1977]. This variation between species means that 
particular atrial septal defects which arise from disturbances in septum secundum 
formation cannot be modelled in the chick (discussed in section 1.2). Cardiac 
development in the chick is discussed further in Chapter 4. 
1.1.7.2 Atrioventricular septation 
The atrioventricular septum separates the atria and ventricles. Atrioventricular 
cushions form at the superior and inferior borders of the AV canal, and lateral 
cushions form on the left and right borders in parallel. The superior and inferior 
cushions continue to grow and extend into the lumen, becoming fused with one 
another and developing into the mature AV septum [Sadler, 2006]. 
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1.1.7.3 Outflow tract septation 
The aorticopulmonary septum divides the common outflow tract (truncus arteriosus) 
and conus region into aortic and pulmonary channels. Migration of cardiac neural 
crest cells (CNCs) into the outflow tract region via the pharyngeal arches contributes 
to the formation of cushions in this region [Kirby, 1987; Waldo et aI., 1998J. A pair of 
opposing ridges termed the left and right superior truncus swellings form in the 
truncus, and distal growth of these towards one another results in fusion to form the 
aorticopulmonary septum [Sadler, 2006J. In parallel, cushions also form on the right 
dorsal and left ventral walls of the conus region. These grow distally, and towards one 
another to join with the truncus septum, dividing the conus into anterolateral and 
posteromedial portions [Sadler, 2006J. The vessels rotate to connect with the 
appropriate chamber, with the aorta joining the left ventricle, and the pulmonary artery 
connecting to the right ventricle, generating separate pulmonary and systemic 
circulations. Alignment and fusion of the aorticopulmonary septum, ventricular 
septum, AV septum, and base of the atrial septum occurs to produce a four-
chambered heart. 
1.1.7.4 Ventricular septation 
The muscular interventricular septum, which separates the left and right ventricles, 
forms as a result of growth between the inlet and outlet regions of the ventricular 
section [Lamers et aI., 1992J (Figure 1.4C-D). The ventricular medial walls become 
apposed and merge, giving rise to the muscular portion of the interventricular septum 
which is identifiable from week 5 (CS 15) [Lamers and Moorman, 2002]. At this stage, 
communication between the two ventricles via the interventricular foramen can still 
occur. Proliferation of the conus cushions and completion of conus septation 
(described in section 1.1.7.3) results in shrinkage of the interventricular foramen. 
Outgrowth from the inferior endocardial cushion to the muscular interventricular 
septum occurs, closing the interventricular foramen. The right and left conus cushion 
and inferior endocardial cushion proliferations form the membranous portions of the 
13 
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interventricular septum. Ventricular septation is complete by CS 23 [Lamers et al., 
1992]. 
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Figure 1.4 Human atrial and ventricular septation 
A) 30 day embryo. The septum primum grows from the roof of the atrial chamber and 
extends towards the AV canal. The space between the septum primum and 
endocardial cushions is termed the ostium primum. B) 33 day embryo. The septum 
primum fuses with the endocardial cushions in the AV canal , resulting in closure of the 
ostium primum. The ostium secundum forms as a result of perforations in the septum 
primum. Development of the septum secundum , also from the roof of the atrial 
chamber, begins. This does not occur in the ch ick . C) 37 day embryo. Growth of the 
septum secundum towards the valve of foramen ovale occurs . The ventricular medial 
walls become apposed and merge, giving rise to the muscular portion of the 
interventricular septum. D) Newborn. The septum secundum and valve of foramen 
ovale fuse to divide the atria. Outgrowth from the inferior endocardial cushion to the 
muscular interventricular septum occurs, closing the interventricular foramen . The 
conus cushion and inferior endocardial cushion proliferations form the membranous 
portions of the interventricular septum . Adapted from Langman's Medical 
Embryology, 1 dh Edition 
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1.1.8 Valve development 
Cardiac valves are thin fibrous structures which open and close in a precise manner, 
allowing unidirectional blood flow through the heart. Two sets of valves form in the 
heart; the semilunar valves (aortic and pulmonary) form in the outflow tract, and 
atrioventricular (AV) valves (tricuspid and mitral) in the AV canal between the atria and 
ventricles. Valvulogenesis is a complex process involving the remodelling of primitive 
endocardial cushions into valve leaflets [Chin et aI., 1992]. The cell surface protein 
JB3 is expressed in endocardial cushion tissue early in development, and its utilisation 
as a marker of endothelial derived cells has demonstrated that AV cushion cells 
differentiate into connective tissue fibroblast cells [Wunsch et aI., 1994]. Development 
of valves is initiated by signals from the myocardium which promote endocardial cells 
to undergo EMT forming endocardial cushions composed of proliferative valve 
progenitor cells in an extracellular matrix [Armstrong and Bischoff, 2004]. Endocardial 
cushions becomes cellularised by proliferation of mesenchymal cells, they elongate 
and are remodelled to form functional valves composed of three main layers - the 
atrialis (elastin-rich), spongiosa (proteoglycan-rich), and fibrosa (collagen-rich) [Hinton 
et aI., 2006]. This is represented in Figure 1.5. Valve remodelling is characterised by 
this increase in ECM organisation and complexity, and also by a decrease in 
endocardial cushion cell proliferation [Hinton et aI., 2006; Lincoln et aI., 2004]. Altered 
expression of specific genes also marks this process; expression of remodelling 
enzymes (such as matrix metalloproteinases) decreases, and there is an increase in 
expression of constituents of valvular ECM such as the proteoglycans aggrecan and 
versican [Shelton and Yutzey, 2007]. The molecular mechanisms regulating valve 
morphogenesis and remodelling are not well understood. Correct positioning of 
valves is critical, and BMP2 and TBX2 play roles in regulating this process [Harrelson 
et aI., 2004; Ma et aI., 2005]. TBX20 expression antagonises the transition from 
endocardial cushions to remodelled valves [Shelton and Yutzey, 2007]. Notch 
signalling is important in development of the endocardial cushions that give rise to 
cardiac valves [Timmerman et aI., 2004], and mutations in the human NOTCH1 gene 
can result in abnormal aortic I mitral valve development [Garg et aI., 2005]. 
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Remodelling 
The heart tube is composed of an outer myocardial cell layer, and an inner endothelial 
cell layer, with a layer of extensive extracellular matrix (ECM) in between, termed the 
cardiac jelly. Specified endothelial cells at the future valve site undergo epithelia l-to-
mesenchymal transformation (EMT) (they delaminate, differentiate , and migrate into 
the cardiac jelly layer). Cardiac cushions undergo remodell ing to form cardiac valves. 
Adapted from Armstrong and Bischoff et al. , 2004 
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1.1.9 The cardiac conduction system 
The co-ordinated and rhythmic contraction of the heart occurs as a result of precisely 
timed action potentials generated via the cardiac conduction system (CCS) [Moorman 
et aI., 1997]. The CCS comprises the sino-atrial node (SA node) also known as the 
pacemaker, the atrioventricular node (AV-node), and the His-Purkinje system 
[Moorman et aI., 1997]. The SA node is found in the wall of the right atrium, and 
generates the pacemaker impulse which determines the rhythm of myocardial 
contraction [Moorman et aI., 1997]. The AV node is located at the base of the 
interatrial septum, and serves to slow transmission of the impulse to the ventricles, 
causing a delay which allows blood to exit the atria prior to ventricular contraction 
[Moorman et aI., 1997]. Signals from the AV node are transmitted via the AV bundle 
and bundle branches, activating contraction of the ventricles via the Purkinje fibre 
network system [Moorman et aI., 1997]. As the atrial septum is important in this 
pathway, defects in atrial septation can lead to altered atrial conduction routes [James, 
1970]. 
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1.2 CONGENITAL HEART DEFECTS 
Congenital heart defects (CHD) are a leading cause of infant mortality, with an 
incidence of around 7.5 cases per 1000 live births [Samson and Kumar, 2004]. 
Development of the heart is a complex process and defects can occur at a number of 
stages leading to a variety of heart malformations, some of which are represented in 
Figure 1.6. Selected CHDs are described below. 
1.2.1 Cardiac septation defects 
Defects in cardiac septation account for approximately 50% of CHD cases [Hoffman 
and Kaplan, 2002]. Atrial septal defects (ASDs), where the atria are not fully septated, 
can be divided into two categories. Ostium secundum defects are the most common 
form of ASD, and this type of defect occurs due to excessive degeneration of the 
septum primum, or inadequate development of the septum secundum [Blom et aI., 
2005]. This condition is associated with mitral valve prolapse in 10 - 20% of sufferers 
[Leachman et aI., 1976]. Ostium primum defects occur less frequently than ostium 
secundum defects, usually in association with Trisomy21 [Kaur et al., 2008]. The 
ostium primum is usually sealed by fusion of superior and inferior endocardial 
cushions, and ostium primum defects usually occur as a result of failure of ostium 
primum closure due to defects in the AV endocardial cushions. As these endocardial 
cushions are also required for mitral and tricuspid valve formation, ostium primum 
defects are usually accompanied with valve abnormalities [Balchum et aI., 1956]. 
Atrioventricular septal defects (AVSDs), where both the atria and ventricles are not 
fully septated, arise due to malformation of the atrioventricular canal cushions, which 
lead to inadequate fusion with the atrial or ventricular septum [Sadler, 2006]. Two 
types of ventricular septal defects (VSDs) may occur. Muscular ventricular septal 
defects arise as a result of incomplete proliferation of cardiomyocytes in the muscular 
portion of the interventricular septum ISoto et aI., 1980]. Peri membranous ventricular 
septal defects arise due to defects in the membranous portion of the septum, 
occurring as a result of endocardial cushion defects ISoto et aI., 1980]. 
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1.2.2 Conotruncal and aortic arch artery defects 
Cardiac outflow tract and aortic arch defects account for 20 - 30% of CHD cases 
[Hoffman and Kaplan, 2002]. Since cardiac neural crest cells contribute to this region, 
many conotruncal defects arise due to defects in their differentiation or migration. 
Double outlet right ventricle (DORV) is where both great arteries align with the right 
ventricle, and occurs as a result defects in neural crest cell migration, or incomplete 
rotation of the outflow tract [Obler et aI., 2008]. Persistent truncus arteriosus (PTA) 
occurs due to a failure of conus ridge fusion and truncus septation, resulting in the 
pulmonary artery arising from the common truncus [Sadler, 2006]. This is always 
accompanied by a ventricular septal defect as the conus ridges also play a part in 
interventricular septation. This condition can arise through defects in neural crest cell 
migration [Kirby, 1987]. Transposition of the great arteries (TGA) occurs when the 
conotruncal septum does not follow its normal course, leading to connection of the 
aorta to the right ventricle, and the pulmonary artery to the left ventricle [Sadler, 2006]. 
This can be due to defects in looping, or in the migration of neural crest cells, which 
are important in forming the truncal cushions [Kirby et aI., 1983]. Anterior 
displacement of the conotruncal septum and unequal division of the conus region 
leads to tetralogy of Fallot (TO F), a heart disorder comprising four anatomical defects; 
narrow right ventricular outflow region, a ventricular septal defect, overriding aorta, 
and right ventricular hypertrophy [Sadler, 2006). The ductus arteriosus is the arterial 
connection between the pulmonary artery and aorta, and serves to shunt blood from 
the right ventricle away from the lungs, allowing them to be bypassed during foetal 
development. The ductus normally constricts and closes shortly after birth, and failure 
to do so results in patent ductus arteriosus (PDA) [Sadler, 2006]. There is evidence 
that this disorder may arise as a result of defects in cardiac neural crest cell 
differentiation or migration [Char, 1978], or altered smooth muscle cell contractility in 
the aorta [Guo et aI., 2007; Zhu et al., 2006]. 
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Development of the heart is a complex process and defects can occur at a number of stages leading to a variety of heart malformations, some of which are 
represented . AVSD - atrioventricular septal defect, TGA - transposition of the great arteries , PTA - persistent truncus arteriosus, DORV - double outlet right 
ventricle, TOF - tetralogy of Fallot, ASD - atrial septal defect, VSD - ventricular septal defect, PDA - patent ductus arteriosus. OT - outflow tract, RV - right 
ventricle, LV -left ventricle, AV- atrioventricular canal, At - atrium . Adapted from Sakabe et a/., 2005 
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1.3 GROWTH FACTOR SIGNALLING IN CARDIAC DEVELOPMENT 
Patterning of the developing embryo is governed by a group of signalling pathways 
that co-operate with one another to provide positional information and allow complex 
cross-talk between tissues for the development of specific organs and structures. 
This is a tightly regulated process and involves a vast array of signalling molecules. 
Some of the signalling pathways involved in development of the heart are discussed. 
1.3.1 TGF-p type receptor signalling 
Transforming growth factor-j3 signalling is important in early developmental pathways, 
and plays a crucial role in mesoderm formation and cardiogenesis, mediating 
processes such as cell specification, proliferation, differentiation, and apoptosis [Ladd 
et aI., 1998]. Members of the TGF-j3 superfamily of signalling molecules (such as 
bone morphogenetic proteins (BMPs), Nodals and Activins) bind to type I or type II 
receptors which possess intrinsic serine/threonine kinase activity [Derynck, 2008]. 
Ligand binding induces a conformational change leading to cell surface assembly of 
type II type II receptor complexes. Type II receptors then phosphorylate and activate 
the kinase domain of type I receptors, leading to phosphorylation of a subgroup of 
Smad proteins termed receptor-activated Smads (R-Smads), for example Smad2 and 
Smad3 [Derynck, 2008]. This leads to their migration towards the nucleus, and during 
this process they associate with Co-Smads such as Smad4 and Smad4j3. Following 
translocation into the nucleus, multisubunit Smad complexes (Smad4/Smad2/Fast-1) 
are recruited to DNA where they can activate transcription of target genes [Derynck, 
2008]. Association with DNA-binding partners allows selective activation of genes. 
TGF-13 signalling is required for cardiac progenitor differentiation, and has a role in 
regulation of EMT during endocardial cushion formation [Yamagishi et aI., 2009; 
Yatskievych et aI., 1997]. Mutations in several genes which are involved in the TGF-j3 
signalling pathway, such as fibrillin1 (FBN1), transforming growth factor 13 receptor 1 
(TGFf3R1), and transforming growth factor 13 receptor 2 (TGFf3R2), lead to up-
regulation of TGF-13 signalling, and are associated with aortic aneurysms [ten Dijke 
and Arthur, 2007]. Deletion of the type I receptor Alk3 (BMPR1a) in mouse embryonic 
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hearts results in impaired EMT in the AV canal with drastically reduced numbers of 
mesenchymal cells here, demonstrating that BMP signalling via this receptor is 
essential for endocardial cushion morphogenesis in this region [Song et aI., 2007]. 
Deletion of Smad4 in embryonic cardiomyocytes during mouse development results in 
severe heart defects, and expression of the cardiac transcription factors Nkx2.S, 
GATA-4 and MEF2C is disrupted [Oi et aI., 2007]. Targeted disruption of Smad6 (an 
inhibitory Smad) results in cardiac valve hyperplasia and defects in outflow tract 
septation, indicating a role for Smad6 in endocardial cushion development [Galvin et 
al.,20001· 
1.3.1.1 BMPs 
BMPs are multifunctional signalling proteins belonging to the TGFI3 family. During 
development, BMPs such as BMP2 and BMP4 secreted by the endoderm cause 
commitment of mesodermal cells lateral to the Hensen's node to the cardiac cell 
lineage following gastrulation [Barron et aI., 2000; Lough and Sugi, 2000; Yamada et 
aI., 20001. BMP2 is involved in correct positioning of heart valves [Harrelson et aI., 
2004; Ma et aI., 200S]. BMP2 induces expression of the cardiac transcription factors 
Nkx2.S and GATA-4 in the developing chick [Andree et aI., 1998], and also acts 
upstream of the cardiac transcription factor MEF2A, activating its expression in 
neonatal cardiomyocytes [Wang et aI., 2007]. BMP2 null mice do not express Nkx2.5 
and display severe defects in heart formation including a failure to undergo looping 
[Zhang and Bradley, 1996]. BMP4 is expressed asymmetrically in the heart tube, and 
is important in cardiac looping [Breckenridge et aI., 2001]. BMP4 null mice display a 
reduction or total lack of mesodermal differentiation, and Brachyury (a mesodermal 
marker) is not expressed [Winnier et aI., 1995]. GAT A-4 is a downstream 
transcriptional mediator of BMP4 signalling in the lateral mesoderm in mice [Rojas et 
aI., 2005]. BMP4 activates Smad1, 5 and 8 when added to the outflow tract of the 
developing chick (E4.5), inducing expression of Sox9 and aggrecan in the semilunar 
valves, a transcription factor and proteoglycan characteristic of cartilage cell types 
[Zhao et aI., 2007]. 
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1.3.2 Receptor tyrosine kinase signalling 
Receptor tyrosine kinases (RTKs) mediate growth factor signalling and are important 
in processes such as embryogenesis, cell prOliferation, and apoptosis [Schlessinger, 
2000]. Ligand binding causes receptor dimerisation, activation of tyrosine kinase 
activity and autophosphorylation of the intracellular domain. Phosphorylated tyrosines 
in this region serve as binding sites for the Src homology 2 I phosphotyrosine binding 
domains of signalling proteins, which are phosphorylated upon binding to become 
activated [Schlessinger, 2000]. This can activate several pathways including the Ras 
I MAPK pathway, which leads to phosphorylation and activation of transcription 
factors in the nucleus, regulating expression of target genes. Some examples of 
growth factors that signal via receptor tyrosine kinases during heart development are 
discussed below. 
1.3.2.1 Fibroblast growth factors 
Fibroblast growth factors (FGFs) are a large family of polypeptide growth factors 
involved in a range of cellular processes including apoptosis, cell-cell adhesion, cell 
migration, differentiation, and proliferation [Bottcher and Niehrs, 2005]. FGF signalling 
during early embryonic development is important in induction, gastrulation, and 
patterning of the embryo [Bottcher and Niehrs, 2005], and is required for cardiomyocte 
differentiation [Zhu et aI., 1996]. FGFs signal via binding to fibroblast growth factor 
receptors (FGFRs), a subfamily of receptor tyrosine kinases. This can lead to 
activation of three possible FGF signal transduction pathways - the Ras I MAPK 
pathway (which leads to phosphorylation and activation of target transcription factors), 
the PLCy I Ca2+ pathway (activating protein kinase C and also stimulating intracellular 
Ca2+ release), and the PI3 kinase I Akt pathway (involved in mesoderm induction) 
[Bottcher and Niehrs, 2005]. FGF2 signalling plays a role in commitment of 
mesodermal cells to a cardiac lineage during development [Sugi et aI., 1993]. FGF2 
is expressed early in cardiac development in the trabeculated region of the ventricular 
myocardium, and is involved in the regulation of myocyte proliferation and 
differentiation [Consigli and Joseph-Silverstein, 1991]. FGF4 increases MAPK 
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phosphorylation and signalling, resulting in increased expression of genes that 
characterise tendon cell types in avian semilunar valves [Zhao et aI., 2007]. Inhibition 
of the FGF signalling pathway in Xenopus prevents mesoderm induction. The 
Xenopus genes sprouty2 and spred1 have been identified as targets and mediators of 
FGF signalling, with roles in mesodermal specification [Sivak et aI., 200S]. FGFB is 
expressed in the mesoderm and participates in directing mesodermal cells to the 
cardiogenic cell lineage, co-operating with BMP2 in this role [Alsan and Schultheiss, 
2002; Lopez-Sanchez et aI., 2002; Lough et aI., 1996; Zhu et aI., 1996]. Cardiogenic 
induction is thought to be via activation of expression of cardiac transcription factors 
such as members of the Tbox, GAT A and NK families. Both FGFB and BMP2 are 
required for expression of Nkx2.S and MEF2C [Alsan and Schultheiss, 2002]. FGFB 
can also direct limb development and induces expression of Wnt2b and WntBc (at the 
forelimb and hindlimb levels respectively) in the intermediate mesoderm of the 
chicken embryo [Crossley et aI., 1996; Kawakami et aI., 2001]. FGF10 plays a crucial 
role in limb development, with TBX5 as an upstream regulator, and there is reciprocal 
regulation of TBX5 expression by FGF signalling [Ohuchi et aI., 1997]. In zebrafish, 
FGF24 has been shown to act downstream of TBXS to regulate FGF10 expression 
[Fischer et aI., 2003]. 
1.3.2.2 Vascular Endothelial Growth Factor 
Vascular Endothelial Growth Factor (VEGF) is important in vascular development and 
heart morphogenesis [Tomanek et aI., 2006], and plays an important role in heart 
valve formation [Lee et aI., 2006]. VEGF signalling occurs via VEGFR1 I Flt1 and 
VEGFR2 I Flk1 receptors. The downstream targets of VEGF signalling are not fully 
characterised. The gene Down syndrome candidate region 1 (DSCR1) has been 
identified as one downstream mediator of VEGF signalling, with a role in endothelial 
cell migration and angiogenesis [Iizuka et aI., 2004]. VEGF has also been shown to 
up-regulate Nkx2.S in differentiated embryonic stem cells [Chen et aI., 2006]. Single 
allelic loss of VEGF in mice results in defects in endocardial cushion formation, 
septation, and chamber formation [Stalmans et aI., 2003]. Overexpression of VEGF 
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results in altered expression of eHand (an important cardiac transcription factor) and 
consequent defects in heart looping [Nagao et aI., 2007]. 
1.3.2.3 Epidermal Growth Factors 
Epidermal Growth Factors (EGFs) signal via the four tyrosine kinase receptors of the 
ErbB family, ErbB1 - ErbB4. EGF signalling is important in embryonic development, 
in processes such as cell proliferation and differentiation. In the heart, EGF signalling 
via ErbB2 and ErbB4 is important in trabeculae development [Gassmann et aI., 1995; 
lee et aI., 1995], whilst signalling via ErbB3 is important in endocardial cushion and 
cardiac valve formation [Erickson et aI., 1997]. Mouse knockout of heparin-binding 
EGF-like growth factor (HB-EGF) results in enlarged heart valves and postnatal 
lethality in around 50% of cases, demonstrating a role for this type of signalling in 
correct valve development and function [Nanba et aI., 2006]. 
1.3.2.4 Cytokine signalling 
Janus kinases {JAKs} are a family of cytosolic tyrosine kinases associated with 
membrane receptors that do not possess intrinsic kinase activity. Cytokine binding to 
these transmembrane receptors leads to receptor-kinase complex dimerisation, 
kinase activation and receptor phosphorylation [Heinrich et aI., 1998]. This allows 
binding of the SH2 domain of signal transducer and activators of transcription 
(STATs), a family of transcription factors that become phosphorylated upon binding 
and translocate into the nucleus to activate transcription of target genes [Heinrich et 
aI., 1998]. The cytokine family members Interleukin-6 (IL-6) and Leukaemia Inhibitory 
Factor {LlF} are important in the heart, and function through activation of the JAK I 
STAT pathway which leads to phosphorylation of STAT3 [Heinrich et aI., 1998]. 
STAT3 phosphorylation (mediated by JAK1 or JAK2) results in dimerisation, nuclear 
translocation, DNA binding, and transcriptional activation [Heinrich et aI., 1998]. 
MAPK also phosphorylates STAT3 at a separate site to influence its transcriptional 
activity [Jain et aI., 1998]. STAT3 directly regulates expression of the cardiac 
transcription factors TBX5, GATA-4 and Nkx2.5, and is required for differentiation of 
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P19 cells into cardiomyocytes [Snyder et al.]. In addition, the JAKISTAT pathway is 
important in ischemic preconditioning [Xuan et aI., 2001], with STAT3 mediating 
cardioprotection against ischemia/reperfusion injury [Oshima et aI., 2005]. LlF 
promotes cardiac cell commitment to the endothelial cell lineage for 
neovascularisation during tissue remodelling [Mohri et aI., 2006]. In the heart, IL-6 is 
important in cardioprotection, formation of blood vessels, and cell-cell adhesion [Fujio 
et aI., 2004; Oshima et aI., 2005; Osugi et aI., 2002]. 
1.3.3 Wnt signalling 
Wnt genes, defined by their homology to the Drosophila wingless gene, encode 
secreted lipid-modified glycoproteins that are involved in the activation of different 
intracellular signalling pathways via interaction with seven-transmembrane frizzled 
receptors [Brade et aI., 2006]. There are three known Wnt signalling pathways - the 
canonical W n t l ~ - c a t e n i n n pathway, and non-canonical WntlPCP and WntlCa2+ 
pathways [Brade et aI., 2006]. The best characterised is the Wntl13-catenin pathway, 
in which ligand binding stabilises cytoplasmic l3-catenin, allowing it to enter the 
nucleus for regulation of gene expression through interaction with HMG-box 
transcription factors [Logan and Nusse, 2004]. This pathway plays a dual role in 
myocardial specification, promoting cardiac differentiation in early development, and 
inhibiting this process at later stages [Ueno et aI., 2007]. Non-canonical Wnt 
signalling pathways, which are also important during cardiac development, act via G-
protein mediated intracellular calcium influx for activation of calcium sensitive 
enzymes such as protein kinase C (PKC) or calcineurin, rho family GTPases, and jun 
N-terminal kinase (JNK) [Veeman et aI., 2003]. Wnt11, via non-canonical signalling, 
promotes differentiation of mesodermal cells to a cardiac lineage in early development 
[Eisenberg and Eisenberg, 1999]. Loss of this gene is associated with abnormal heart 
tube formation [Pandur et aI., 2002]. In addition, this type of signalling also regulates 
morphogenetic movements during development through regulation of cad herin-
mediated cell adhesion and polarity [Torres et aI., 1996; Toyofuku et aI., 2000; Ulrich 
et aI., 2005]. A large number of Wnt ligands (Wnt2, Wnt2b, Wnt3a, Wnt5a, Wnt5b, 
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Wnt7a, Wnt8c, Wnt9, Wnt11) and frizzled receptors (Fz2, Fz4, Fz9) have been 
identified during murine and/or avian cardiac development, suggestive of distinct but 
potentially overlapping roles [Dealy et aI., 1993; DeRossi et aI., 2000; Eisenberg and 
Eisenberg, 1999; Hume and Dodd, 1993; Jaspard et aI., 2000; Liu et aI., 1999; 
Takada et aI., 1994; van Gijn et aI., 2001; Wang et aI., 1999]. 
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1.4 TRANSCRIPTIONAL REGULATION OF CARDIOGENESIS AND GENE 
REGULATORY NETWORKS 
Cardiac transcription factors play a key role in regulating expression of the many 
regulatory and structural genes involved in growth and patterning of the heart, and 
mutations in a number of important cardiac transcription factors are associated with 
CHDs. Members of the NK2, Tbox, GATA, MEF2, and HAND gene families form a 
core cardiac regulatory network which transcriptionally regulates downstream cardiac 
genes, and additionally, these transcription factors can also regulate expression of 
one another. Key members of these gene families are described in this section. The 
target genes of these transcription factors are largely unknown and this area is being 
widely researched. Figure 1.7 represents this core network and known upstream 
activators. Nkx2.5, GATA-4, Isl1 and Foxh1 are targets of inductive signals. Nkx2.5 
and GATA-4 are upstream activators in the primary heart field, and Isl1 and Foxh1 are 
upstream activators in the secondary heart field [Cai et aI., 2003; Dodou et aI., 2004; 
Lin et aI., 1997; von Both et aI., 2004]. Cardiac transcription factors function within 
complex gene regulatory networks, as previously described with respect to GATA-4, -
5 and -6, GATA-4 and Nkx2.5 [Peterkin et aI., 2005], and overall during various 
developmental stages of mesendoderm formation in Xenopus [Loose and Patient, 
2004]. 
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Figure 1.7 Transcriptional networks involved in heart development 
The core cardiac regulatory network comprising members of the NK2, MEF2, GATA, 
Tbx and Hand gene families is represented with upstream activators, which are 
activated by inductive signals, Members of these gene families transcriptionally 
regulate important downstream genes (structural and regulatory) , and can also 
regulate expression of one another. Nkx2,5 and GATA-4 are upstream activators of 
primary heart field formation, and Isl1 and Foxh1 are upstream activators of the 
secondary heart field . The scanning electromicrograph image is of a mouse heart at 
E14.5, and regions arising from the primary and secondary heart fields are displayed 
in blue and pink respectively. Regions arising from both i.e. the atria , are shown in 
purple. a - atrium , rv - right ventricle, Iv -left ventricle. Adapted from Olson, 2006 
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1.4.1 Nkx2.5 
Nkx2.5 is an evolutionarily conserved member of the NK2 class of homeodomain 
transcription factors. It is a homologue of the Drosophila tinman gene, which is 
required for formation of the heart [Azpiazu and Frasch, 1993; Bodmer, 1993]. Nkx2.5 
is a central component of the cardiac regulatory hierarchy and one of the earliest 
cardiac markers [Harvey, 1996]. It contains an N-terminal TN domain, a 
homeodomain which confers binding specificity, and a C-terminal NK2 specific 
domain (NK2-SD). A C-terminal tyrosine rich domain (YRD) has also been identified, 
not essential for DNA-binding, but critical in cardiomyocyte differentiation in vitro and 
in vivo [Elliott et aI., 2006]. Analysis of the effect of heterozygous mutations in 
humans has shown Nkx2.5 is essential for normal heart development including 
development of the conduction system [Harvey et aI., 2002; Jay et aI., 2004]. 
Mutations in the NKX2.5 gene in humans have been associated with a vast array of 
congenital heart defects including AV conduction block, atrial septal defects, 
ventricular septal defects, hypoplastic left heart syndrome, tetralogy of Fallot, 
persistent truncus arteriosus, double outlet right ventricle, and transposition of the 
great arteries [Benson et aI., 1999; Elliott et aI., 2003; McElhinney et aI., 2003; 
Pashmforoush et aI., 2004; Schott et aI., 1998]. 
Nkx2.5 is expressed in heart precursor cells in the primary and secondary heart fields 
during mouse development [Komuro and Izumo, 1993], and is highly expressed in the 
adult heart, with the protein detectable in myocytes of the atria and ventricles 
[Kasahara et aI., 1998]. Mouse knockout of Nkx2.5 results in an arrest in cardiac 
looping, leading to embryonic lethality at E9/10 [Lyons et aI., 1995; Tanaka et aI., 
1999). Ventricular restricted knockout has demonstrated a crucial role for Nkx2.5 in 
development and function of the cardiac conduction system [Pashmforoush et aI., 
2004], and in line with this, a transient increase in Nkx2.5 expression is seen in 
developing myocardial conduction cells during development of the conduction system 
[Thomas et aI., 2001]. 
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Nkx2.5 transcriptionally regulates expression of an array of cardiac genes including 
myosin light chain 2v (MLC2v), a-cardiac actin, connexin 40, myocardin, ANF, 
MEF2C, and eHAND [Biben and Harvey, 1997; Bruneau et aI., 2001; Chen and 
Schwartz, 1996; Lyons et aI., 1995; Tanaka et aI., 1999; Ueyama et aI., 2003], 
Nkx2.5 interacts with several important cardiac transcription factors including some 
members of the GATA and T-box families, SRF, and others (section 1.5). 
1.4.2 The T·box family oftranscription factors 
The T-box gene family encodes a group of transcription factors important in the 
patterning of the vertebrate embryo, and is characterised by a conserved 180 amino 
acid DNA-binding motif, the T -box. They regulate critical developmental processes 
such as cell type specification and morphogenesis, and mutations in several T -box 
genes lead to developmental defects. 
TBX1 - TBX5, TBX18 and TBX20 are all expressed in the developing heart [Bussen 
et aI., 2004; Chapman et aI., 1996; de Lange et aI., 2004; Stennard et aI., 2003]. 
Mouse knockout studies have been carried out on each of these genes, and all result 
in perinatal or embryonic lethality [Bussen et aI., 2004; Davenport et aI., 2003; 
Harrelson et aI., 2004; Jerome and Papaioannou, 2001; Lindsay, 2001; Lindsay et aI., 
2001; Stennard et aI., 2005; Takeuchi et aI., 2003]. TBX1 heterozygotes display 
abnormal development of the aorta, pulmonary artery, and fourth pharyngeal artery 
[Jerome and Papaioannou, 2001; Lindsay et aI., 2001], whilst heterozygotes of the 
other T-box genes are viable and fertile I apparently normal [Bussen et aI., 2004; 
Davenport et aI., 2003; Harrelson et aI., 2004; Naiche and Papa ioannou, 2003; 
Stennard et aI., 2005]. TBX1 is important in proliferation of cells forming the 
secondary heart field (which contributes to OFT formation) [Xu et aI., 2004; Zhang et 
aI., 2006]. In humans, TBX1 haploinsufficiency results in DiGeorge syndrome 
[Merscher et aI., 2001], a disorder whose symptoms include outflow tract defects. 
Mutations in TBX3 have been associated with Ulnar Mammary syndrome [Bam shad 
et aI., 1997], a rare disorder characterised by upper limb malformation and abnormal 
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development of the mammary glands, nipples, teeth, genitalia, and apocrine glands 
[Schinzel, 1987]. Ventricular septal defects have also been observed, therefore this 
gene is sometimes considered a 'heart-hand' gene [Linden et aI., 2009]. TBX4, 
together with wnt8c and fgf10, is involved in development of the lower limbs [Takeuchi 
et aI., 2003], and TBX4 mutations are associated with small patella syndrome 
[Bongers et aI., 2004]. There is evidence of a role for TBX20 in promotion of cell 
proliferation in valve precursor cells in endocardial cushions during development 
[Shelton and Yutzey, 2007]. TBX20 heterozygotes display mild dilated left ventricular 
cardiomyopathy [Stennard et aI., 2005], and mutations in humans have been 
associated with cardiomyopathy and defects in septation and valve development [Kirk 
et aI., 2007]. TBX22 mutations are associated with cleft palate [Packham and Brook, 
2003]. 
1,4.2,1 TBX5 
TBX5 is a member of the T -box family of transcription factors, and plays an important 
role in heart development and specifying forelimb identity [Isaac et aI., 1998]. 
Mutations in TBX5 are associated with Holt-Oram syndrome (HOS) [Basson et aI., 
1997; Fan et aI., 2003; Li et aI., 1997], a congenital disorder characterised by upper 
limb and heart abnormalities. These are usually atrial septal defects (ostium primum 
or ostium secundum) or ventricular muscular septal defects, but other abnormalities 
may also occur including mitral valve defects, electrophysiological defects such as AV 
conduction block, tetralogy of Fallot, and left-sided abnormalities including hypoplastic 
left heart syndrome, defective trabeculation, and endocardial cushion defects [Basson 
et aI., 1994; Bruneau et aI., 1999; Newbury-Ecob et aI., 1996; Sletten and Pierpont, 
1996]. The majority of HOS associated TBX5 mutations are found in the T-box [Mori 
and Bruneau, 2004]. 
TBX5 displays expression in the heart and upper limbs during embryogenesis 
[Chapman et aI., 1996]. Expression is initiated early in development, where it is 
observed throughout the cardiac crescent and in the forelimb field [Begemann and 
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Ingham, 2000]. Analysis of the cardiac expression pattern of TBXS in the developing 
mouse and chick has correlated its expression with the sites of defects observed in 
HOS; TBXS is expressed throughout the early heart tube, later becoming restricted to 
the posterior regions which give rise to the sinus venosus, atria, and left ventricle 
[Bruneau et aI., 1999]. TBXS is subsequently expressed in the left ventricle, left side 
of the ventricular septum, trabeculae, and also in the atrial walls, atrial septa, and 
atrial side of the AV valves, consistent with the ASDs, VSDs, and left-sided 
malformations seen in HOS [Bruneau et aI., 1999]. 
Studies involving TBXS knockout I overexpression have allowed elucidation of its 
function in cardiogenesis. Overexpression of wild type TBX5 transcripts both in vitro 
and in vivo (in the embryonic chick) results in an inhibitory effect on cardiomyocyte 
proliferation, with a resulting decrease in heart size [Hatcher et aI., 2001]. 
Conversely, TBXS heterozygous null mice, in addition to ventricular and atrial septal 
defects, display an overall enlargement of the heart, with dilation of the right atrium 
and ventricle [Bruneau et aI., 2001]. Complete knockout of mouse TBX5 results in 
embryonic lethality by E10.S; heart fails to undergo looping, and hypoplasia 
(underdevelopment) of the sinuatria and left ventricle occurs [Bruneau et aI., 2001]. 
These findings indicate a regulatory role for TBX5 in chamber morphogenesis. TBX5 
can interact with other transcription factors including Nkx2.S and GATA-4, for 
synergistic regulation of cardiac genes (section 1.5). 
1.4.3 The GAT A family of transcription factors 
GATA transcription factors contain two conserved zinc fingers (Cys-X2-CYS-X17-CyS-
X2-Cys) that bind to the consensus DNA sequence (AfT) GATA (NG), a regulatory 
sequence first identified during studies into the tissue specific expression of erythroid-
speCific nuclear protein factors [Plumb et aI., 1989]. Six members of the GAT A family 
of transcription factors have been identified to date, GATA 1 - 6. Each is expressed 
in a lineage restricted pattern, regulating expression of genes within specific tissues 
and playing a major role during development. The GATA factors have been 
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subdivided into two groups based on their protein structure and expression pattern; 
GAT A-1, -2 and -3 which are important in haematopoiesis and ectodermal patterning 
[Leonard et aI., 1993], and GAT A-4, -5 and -6, which are expressed in mesoderm and 
endoderm derived organs and are important in cardiac development [Peterkin et aI., 
2005]. Conservation of particular factors between species is higher than conservation 
of different GAT A factors within the same species [Jiang and Evans, 1996] Le. 
individuality of the GATA genes has been conserved through evolution implying a 
unique function for each. 
1.4.3.1 GATA·4 
Mutations in the human GAT A-4 gene have been associated with atrial and ventricular 
septal defects [Garg et aI., 2003], and tetralogy of Fallot [Nemer et aI., 2006]. GATA-4 
contains two zinc finger domains, a C-terminal nuclear localisation sequence (for 
DNA-binding and protein-protein interactions), and two N-terminal transcriptional 
activation domains (TAD), that are conserved within the GATA-4/5/6 subfamily 
[Morrisey et aI., 1997b]. Expression of GATA-4 is seen in the cardiac ventral 
mesoderm at the time of linear heart tube formation, and subsequently in the 
developing atria and ventricles, and in the endocardium but not myocardium [Kelley et 
aI., 1993]. 
A number of knockdown I knockout studies have been performed to assess the 
specific functions of GATA-4 in cardiogenesis. The P19 mouse embryonal carcinoma 
cell line can be induced to differentiate into beating cardiac muscle cells and is thus a 
widely used in vitro model system of cardiac cell differentiation. The effect of a 
reduction in GAT A-4 protein has been investigated in this cell line through stable 
transfection with GATA-4 antisense expression vectors [Grepin et aI., 1995]. 
Presence of antisense transcripts results in a marked reduction in active GAT A-4 
protein, but has no effect on the morphology of the cells. However, antisense clones 
displayed very poor differentiation in comparison to the wild type and control clones, 
indicating GATA·4 is required for differentiation of cardiac cells. In addition, clones 
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also failed to express important cardiac muscle markers such as BNP, TpC, a-MHC, 
I3-MHC, and MLC-1A, consistent with the theory that GATA-4 is essential for 
activation of cardiac cell differentiation. 
GATA-4 null mouse embryos do not survive past early embryonic development, 
arresting at E7.0 - E9.5 due to defects in ventral morphogenesis and linear heart tube 
formation [Molkentin and Olson, 1997]. This means they cannot be used to study 
GATA-4 function later in development or in the adult heart. This has been overcome 
through the use of Cre/LoxP technology to conditionally inactivate GAT A-4 expression 
in the mouse myocardium at selected time points in order to study its role in cardiac 
development [Zeisberg et aI., 2005]. GA TA-4-loxP-targeted mice were crossed with 
mice containing either an Nkx2-5 locus or an a-MHC promoter that drives Cre 
recombinase expression early or late in development respectively. Early myocyte 
restricted deletion of GATA-4 by Nkx2-sCre showed no effect on overall development 
at E9.5. Whole mount examination of embryos at E9.5 showed cardiac 
malformations, most commonly a single predominant ventricular chamber. 
Histological sections showed myocardial hypoplasia, and small atrioventricular and 
OFT endocardial cushions, suggesting a defect in the EMT of endocardial cells. This 
was confirmed by selective inactivation of GATA-4 in endothelial derived cells which 
resulted in failure of endothelium to undergo EMT resulting in hypocellular cushions 
i.e. GATA-4 is required to form AV cushion mesenchyme which is essential in valve 
development [Rivera-Feliciano et aI., 2006]. GATA-4 is also required subsequently in 
the remodelling of AV endocardial cushions for ventricular septation. At E10.0, 
embryos displayed a mild delay in development and pericardial effusions which signify 
heart failure. Embryonic lethality occurred by E11.5. GATA-4-loxP-targeted mice 
(Gata4f1lfl) have also been crossed with mice containing an a-MHC or ~ - M H C C
promoter driven ere transgene to study the function of GATA-4 in the adult heart [Oka 
et aI., 2006]. The resulting mice survived into adulthood despite a 70-95% reduction 
in GATA-4 protein. Cardiac function was compromised as a result of GATA-4 deletion 
from the heart; the cardiac hypertrophic response was attenuated, cardiac cell death 
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increased, and basal gene expression significantly altered. It was concluded that 
GAT A-4 transcriptionally regulates gene expression, hypertrophy, stress 
compensation, and myocyte viability in the heart. 
1.4.3.2 GATA·5 
GATA-5 is expressed in the precardiac mesoderm from E7.0 I E8.0, in the atrial and 
ventricular chambers of the heart at E9.5, and is restricted to the atrial endocardium 
by E12.5 [Morrisey et aI., 1997a]. It is also expressed in the developing lung, 
urogenital ridge, bladder and gut. The expression pattern of GATA-5 shows marked 
differences to that of GATA-4 and GATA-6, and unlike GATA-4 and GATA-6 null mice 
which do not survive into adulthood, GATA-5 null mice and viable and fertile 
[Molkentin et aI., 2000]. Females display defects in the genitourinary system (males 
are unaffected) suggesting a unique role for GAT A-5 in development of this region. 
One explanation for the mild phenotype is that GATA-4/-6 may compensate for the 
loss of GAT A-5. 
1.4.3.3 GAT A·6 
Like GATA4·1• mice, GATAfJ1• mice also fail to develop beyond gastrulation due to its 
necessity in the visceral endoderm [Koutsourakis et aI., 1999; Morrisey et aI., 1998]. 
This has similarly been overcome through the use of Cre I LoxP technology to create 
a conditional loss of function allele [Sodhi et aI., 2006]. Conditional inactivation of 
GATA-6 in vivo in VSMCs and in the cardiac neural crest results in cardiovascular 
abnormalities including aortic arch and outflow tract defects, indicating a role for 
GAT A-6 in patterning of these regions [Lepore et aI., 2006]. 
As mice heterozygous for GATA-4 or GATA-6 null mutations appear to be normal, and 
GATA-4 and GATA-6 have a similar protein structure and expression pattern, it was 
hypothesised that they may act co-operatively during cardiac development. This was 
tested by crossing GA TA-4+1• and GA TA-6+1• heterozygotes to produce compound 
heterozygotes [Xin et aI., 2006]. Lethality with complete penetrance occurred at 
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E13.5. E10.0 embryos displayed enlargement and disorganisation of cranial and 
intersomitic vasculature suggesting defects in vessel development. Furthermore, 
mutants displayed failure of septation of the cardiac outflow tract, thinning of the 
myocardium, and vascular defects. Expression of some cardiac genes was altered, 
for example J3-MHC and MEF2C were down-regulated. This demonstrates that a 
certain level of GATA-4 and GATA-6 expression is required for cardiovascular 
development. 
1.4.4 The MADS family of transcription factors 
The MADS family of transcription factors contain a 57 amino acid 'MADS box' which is 
important in homodimerisation and DNA-binding [Shore and Sharrocks, 1995]. 
Members of the MADS family can recruit other transcription factors to form regulatory 
complexes, which are important in regulation of target genes [Shore and Sharrocks, 
1995; Sprague, 1990]. Relevant members of this family are described below. 
1.4.4.1 Serum Response Factor (SRF) 
Serum response factor (SRF) is a member of the MADS family that was initially 
discovered as an activator of growth factor and cell cycle genes, now known to be 
highly expressed in differentiating cardiac, skeletal and smooth muscle cells [Belaguli 
et aI., 1997]. SRF is a key regulator of the expression of number of contractile genes, 
acting through binding to the CArG box (CC(A/T)6GG) [Belaguli et aI., 1997]. The role 
of SRF in cardiovascular development has been studied by cardiac and smooth 
muscle cell-restricted inactivation in Cre recombinase mice [Miano et aI., 2004]. 
Inactivation of the transgene at E8.5 in mice leads to progressively decreasing levels 
of SRF expression in cardiomyocytes and aortic smooth muscle cells, and poorly 
developed trabeculations and sarcomeric disorganisation at E10.5. Studies of SRF 
null mice also show that it is required for cardiac mesoderm formation [Arsenian et aI., 
1998]. Myocardin is a member of the SAP (SAF-NB, Acinus, PIAS) domain family of 
nuclear proteins which have broad regulatory functions relating to transcription and 
chromatin organisation [Aravind and Koonin, 2000; Kipp et aI., 2000]. Myocardin 
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associates with SRF to act as a highly potent transcriptional co-activator, and has an 
important function in cardiomyocyte differentiation [Wang et aI., 2001]. Myocardin is 
expressed in cardiac and smooth muscle cells throughout the heart both during 
development (beginning at the same time as Nkx2.5) and postnatally [Wang et aI., 
2001], contributing to the muscle specificity of SRF [Wang et aI., 2003b]. Mouse 
knockout of myocardin leads to embryonic lethality by E10.5, with mice displaying 
developmental delay and severe vascular defects [Li et aI., 2003]. Interestingly, 
abnormalities are smooth muscle cell specific and cardiac morphogenesis is normal, 
possibly due to functional redundancy with additional myogenic regulators in cardiac 
muscle cells. 
1.4.4.2 The myocyte enhancer factor (M EF) family of transcription factors 
Myocyte enhancer factors 2 (MEF2s) belong to the MADS family of transcription 
factors and contain a conserved N-terminal MADS box and MEF2 domain, and C-
terminal transactivation domain. Vertebrates possess four MEF2 genes, MEF2A -
MEF2D, thought to have arisen from a common ancestral gene. They act as homo-
or heterodimers and bind to the sequence CAT(A/T)4TAG/A [Black and Olson, 1998; 
McKinsey et aI., 2002], which has been identified in the regulatory region of a number 
of muscle genes for transcriptional control of muscle development. Targets include a-
MHC [Molkentin and Markham, 1993], MLC1/3 [McGrew et aI., 1996; Rao et aI., 
1996], MLC2v [Lee et aI., 1994], a-skeletal actin [Muscat et aI., 1992], tropomyosin I 
[Lin et aI., 1996), cardiac troponin T [Wang et aI., 1994), cardiac troponin C 
[Gahlmann and Kedes, 1993; Parmacek et aI., 1994), cardiac troponin I [Nakayama et 
aI., 1996), desmin [Kuisk et aI., 1996; Li and Capetanaki, 1994), and dystrophin 
[Klamut et aI., 1997; Nishio et aI., 1994]. 
1.4.4.2.1 M EF2C 
MEF2C is expressed early in cardiac development, detectable in the cardiac 
mesoderm (from which the heart tube originates) at E7.5, and in the myocardium at 
E8.5 [Edmondson et aI., 1994). MEF2C knockout mice die by E9.5 as a result of 
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cardiac and vascular defects [Lin et aI., 1997]. Conditional mef2c'°xPlloxP knockout in 
mice results in failure of hearts to undergo looping, absence of right ventricle 
formation, and lack of expression of a subset of cardiac muscle genes, highlighting its 
importance in early heart development [Lin et aI., 1997]. Nkx2.5 and MEF2C have an 
up-regulatory effect on the expression of one another and induce cardiomyocyte 
differentiation on P19 cells [Skerjanc et aI., 1998]. MEF2C is involved in a physical 
interaction with TBX5 which is essential in cardiogenesis [Ghosh et aI., 2009]. 
1.4.4.2.2 MEF2A 
MEF2A is expressed in the myocardium during mouse embryogenesis from E8.5 
[Edmondson et aI., 1994]. It is involved in cardiac development, and mouse knockout 
of this gene results in right ventricular dilation and an increased likelihood of sudden 
perinatal death due to conduction defects, thought to result from a mitochondrial 
deficiency in cardiac muscle [Naya et aI., 2002]. A deletion in exon 11 of the human 
MEF2A gene was found to be associated with coronary artery disease (CAD) in a 
large family of sufferers (Wang et aI., 2003a], and a number of missense mutations in 
this gene were subsequently identified in sporadic CAD patients [Bhagavatula et aI., 
2004; Gonzalez et aI., 2006; Weng et aI., 200S]. 
1.4.5 The HAND family of transcription factors 
The HAND gene family are a group of basic helix-loop-helix cardiac transcription 
factors. dHand and eHand are co-expressed in the precardiac mesoderm at E7.7S, 
and later display regionally restricted expression in the ventricle forming regions of the 
heart tube; dHand is expressed in the right ventricle forming regions, and eHand in 
the left ventricle forming regions [Srivastava et aI., 1997]. 
Gene deletion of dHand results in embryonic lethality by E10.S, and a wide spectrum 
of abnormalities are observed in cardiac looping, septation, and ventricular formation 
[Srivastava et aI., 1997]. Transgenic mice expressing dHand under control of the f3-
MHC promoter show it is essential for interventricular septum formation and 
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trabeculation during heart development [Togi et aI., 2006]. dHand upregulates ANF, 
BNP and connexin 40 expression in H9c2 cells and also in transgenic embryos 
overexpressing dHand. Targeted deletion of dHand in CNC derived cells causes 
misalignment of the aortic arch arteries and ouflow tract, resulting in DORV and VSDs 
[Holler et al.]. 
Mice homozygous for an eHand allele die at E8.5 - E9.5 with defects in heart looping, 
hypoplasia of the left ventricle, and outflow tract abnormalities, demonstrating the 
importance of this gene in cardiac development [Firulli et aI., 1998]. In humans, 
mutations in the eHand gene are associated with septal defects, outflow tract 
abnormalities, and hypoplasia [Reamon-Buettner et aI., 2008; Reamon-Buettner et aI., 
2009]. This left-sided ness in expression of eHand is abolished in mouse embryos 
lacking Nkx2.S, showing Nkx2.S plays a role in control of this asymmetric expression 
[Biben and Harvey, 1997]. 
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1.5 CO-OPERATIVE ACTIVITY OF CARDIAC TRANSCRIPTION FACTORS 
A number of important cardiac transcription factors physically interact to direct and 
synergistically regulate important pathways and key genes. 
TBX5 and GATA-4 form a complex, and the TBX5 mutations G80R and R237W, 
which are associated with cardiac septal defects in HOS patients [Bass on et aI., 
1999], disrupt this interaction [Garg et aI., 2003]. Functional analysis of a number of 
other TBX5 mutations found in HOS has shown diminished binding of TBX5 to both 
GATA-4 and Nkx2.S, and a resulting decrease in transcriptional activation of ANF and 
FGF10 [Boogerd et al.]. The GATA-4 mutation G296S has been linked to ASDs in 
humans, and also disrupts the TBXS / GATA-4 interaction [Garg et aI., 2003]. These 
findings together account for the fact that similar heart defects are seen as a result of 
both GAT A-4 and TBX5 mutations, and indicate that these transcription factors direct 
and synergistically regulate common pathways important in septation. Gata4+1• Tbx5+1-
compound heterozygous mice were generated during the time of this research (2009) 
and displayed embryonic lethality with almost full penetrance [Maitra et aI., 2009]. 
Mice displayed defects in AV septation and myocardial thinning. MYH6, encoding 0-
myosin heavy chain, is a joint target of TBX5 and GATA-4 [Ching et aI., 2005; Huang 
et aI., 1995; Molkentin et aI., 1994], and is down-regulated in Gata4+1- Tbx5+1-
compound heterozygote mice [Maitra et aI., 2009]. Brahma-associated factor (BAF) 
complexes belong to the SWI/SNF family of multi-subunit chromatin remodelling 
complexes which are important developmentally and can act both as activators and 
repressors of transcription [Ho and Crabtree]. BAF complexes can interact with a 
variety of transcription factors in different cell or tissue types, and show context-
specific functions depending on their interaction partners [Ho and Crabtree]. Baf60c, 
a cardiac-specific subunit of BAF chromatin-remodelling complexes, acts by physically 
linking transcription factors to these complexes during cardiogenesis and is necessary 
for their function here [Lickert et aI., 2004]. TBX5 and GATA-4, in combination with 
Baf60c (which is essential), can induce a full cardiac transcriptional programme and 
direct ectopic differentiation of the non-cardiogenic posterior mesoderm and 
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extraembryonic mesoderm of the amnion (of mouse) into beating cardiomyocytes 
[Takeuchi and Bruneau, 2009]. Interestingly, TBX5, GATA-4 and MEF2C in 
combination are able to reprogramme mouse postnatal fibroblasts into functional 
cardiomyocytes [Ieda et al.]. 
Tbx5 and Nkx2.5 specifically associate with one another via the N-terminal domain 
and N-terminal portion of the T -box of TBX5, and the homeodomain of Nkx2.5 [Hiroi et 
aI., 2001]. This interaction is crucial for cardiomyocyte differentiation. TBX5 and 
Nkx2.5 directly bind to the ANF promoter for synergistic activation [Bruneau et aI., 
2001; Ghosh et aI., 2001; Hiroi et aI., 2001]. The TBX5 mutations G80R and R237Q 
are both associated with HOS, and both disrupt the interaction with GATA-4 [Garg et 
aI., 2003]. The former mutation results in a severe cardiac phenotype, whilst the latter 
results primarily in upper limb abnormalities with little effect on the heart [Basson et 
aI., 1999]. The G80R mutation has an inhibitory effect on cardiomyocyte 
differentiation, and results in significantly diminished activation of the ANF promoter 
(with Nkx2.5), whilst the R237Q mutation has little or no effect on these, in line with 
the vast difference in severity of cardiac malformations these mutations underlie [Hiroi 
et aI., 2001]. In a separate study, both mutations have been reported to eliminate 
target site binding [Ghosh et aI., 2001]. 
TBX5 and MEF2C associate via their DNA binding domains to synergistically activate 
the MYH6 promoter [Ghosh et aI., 2009]. TBX5 and Nkx2.5 act co-operatively to 
activate expression of connexin 40 [Bruneau et aI., 2001], a gap junction protein 
crucial in conduction in the heart [Kirchhoff et aI., 1998; Simon and Goodenough, 
1998], suggesting one possible explanation for the conduction abnormalities seen in 
HOS. Purkinje fibres of the cardiac conduction system express high levels of Nkx2.5 
and GATA-4 [Bruneau, 2002; Thomas et aI., 2001]. Nkx2.5, GATA-4, and TBX5 act 
together with .the nuclear factor Sp1 to regulate expression of connexin 40 via 
elements in its minimal promoter region [Linhares et aI., 2004]. Nkx2.5 and GATA-4 
are able to synergistically activate the promoter, whilst TBX5 counteracts this effect. 
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TBX20 directly associates with Nkx2.5 and GATA-4 [Stennard et aI., 2003] and is also 
able to interact with the connexin 40 promoter. It represses activation by Nkx2.5 and 
GAT A-4, whilst acting as an activator when the same reporter is stimulated with 
Nkx2.5 and GATA-5. This demonstrates that Tbx20 can function as a transcriptional 
activator or repressor depending on its binding partner. TBX20 also associates with 
TBX5, activating or repressing ANF promoter activity in a concentration dependent 
manner [Brown et aI., 2005]. 
Mutations in both GATA-4 and Nkx2.5 are associated with familial ASD [Hirayama-
Yamada et aI., 2005]. Nkx2.5 and GATA-4 associate via helix III of the homeodomain 
of Nkx2.5 and the C-terminal zinc finger of GATA-4 [Lee et aI., 1998]. These 
transcription factors can activate ANF individually, and in combination for synergistic 
activation in a manner which requires full transcriptional activity of both (including co-
factor activity). The ANF promoter contains binding sites for TBX5, Nkx2.5, GATA 
(proximal and distal), and SRF [Small and Krieg, 2003]. Mutation of the TBX5, SRF or 
distal GATA site results in a strong reduction in ANF promoter activity. Mutation of the 
Nkx2.5 and proximal GATA site singly and together results in perSistent expression in 
the ventricles and outflow tract. This suggests a repressor complex may bind to these 
sites for atrial specific ANF expression. 
Nkx2.5 and SRF together stimulate promoter activity of a-cardiac actin, and the 
presence of serum response elements (SREs) is crucial [Chen et aI., 1996]. The C-
terminal and MADS box of SRF are required for activation with Nkx2.5, and Nkx2.5 
alone has no effect. Nkx2.5 and SRF, with GATA-4, also synergistically activates the 
a-cardiac actin promoter [Sepulveda et aI., 2002]. SRF and GATA-4, in combination 
with mutant Nkx2.5 which lacks binding capability, are able to activate this promoter. 
However, Nkx2.5, GATA-4 and mutant SRF (which lacks binding capability) are 
unable to activate the promoter, and sequential deletion of the four SRE sites in this 
region results in corresponding decreases in promoter activity. These findings 
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together demonstrate that SRF binding is necessary for recruitment of Nkx2.5 and 
GATA-4 to the a-cardiac actin promoter via a physical interaction. In addition, DNA 
recruitment assays have demonstrated that Nkx2.5 and GAT A-4 together strongly 
enhance the formation of SRF dependent promoter binding complexes, possibly 
through conformational changes that increase SRF DNA binding efficiency 
[Sepulveda et aI., 2002]. Combinatorial expression of these three transcription factors 
also synergistically activates the ANF gene in a co-operative manner [Nishida et aI., 
2002]. 
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1.6 THE EXTRACELLULAR MATRIX 
The extracellular matrix (ECM) consists of cells such as fibroblasts, collagens, 
glycoproteins, proteoglycans, growth factors, and proteases that form a dynamic 
macromolecular complex which plays an important role in cardiac development and 
growth by providing structural support for cells and facilitating intercellular 
communication. Throughout formation of the heart, the processes of cell 
differentiation, adhesion, migration, and apoptosis are crucial for tissue remodelling 
and occur in a precisely timed and spatially regulated manner, mediated extensively 
through signalling that occurs via the ECM. Additionally, ECM composition has an 
impact on the process of EMT, which is important in cardiac remodelling at various 
developmental stages including gastrulation, endocardial cushion formation, 
valvulogenesis, and neural crest cell differentiation (and also in chronic disease states 
such as hypertension and heart failure). Defects in the remodelling process can lead 
to loss of organisation and abnormalities such as valve dysfunction and abnormal 
septation. Components of the ECM and their specific functions are discussed below. 
Non-myocyte cells make up approximately 70% of the heart cell population [Nag, 
1980; Zak, 1974) and include cardiac fibroblasts, the proportion of which varies 
depending on species, developmental age and physiological condition [Banerjee et 
aI., 2007]. Fibroblasts are connective tissue cells that synthesise and deposit various 
ECM components including collagens and fibronectin [Fries et aI., 1994] in addition to 
secreting cytokines, growth factors, and matrix metalloproteinases [Powell et aI., 
1999]. Cardiac fibroblasts are interconnected to form a network of cells within a 
collagen matrix, which serves to provide structural integrity through cell-cell and cell-
ECM interactions [Baxter et aI., 2008]. 
Collagens are a family of fibrous proteins that are important in maintaining tissue 
structure. Collagens I, III, IV, V, and VI have been identified in the heart where they 
each have specific functions [Schaper and Speiser, 1992; Speiser et aI., 1991; 
Speiser et aI., 1992]. Collagens I and III account for over 90% of total collagens and 
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are important in maintaining tissue and blood vessel structure, whilst collagens IV and 
VI form part of the basal lamina, and allow interaction with receptors such as integrins 
[Weber, 1989]. 
Integrins are large transmembrane ECM receptors consisting of a and 13 subunits, a 
large extracellular domain, and a small cytoplasmic signalling domain [Hynes, 1992]. 
They are essential in interaction with cardiac fibroblasts and myocytes, and mediate 
cell-cell and cell-ECM communication bidirectionally to regulate cell migration and 
survival during development and in pathological hypertrophy [Bowers et al.). Integrins 
act as receptors for a broad range of ligands which include collagen, laminin and 
fibronectin [Humphries et aI., 2006]. 
Laminins are glycoproteins that are synthesised by cardiac myocytes, vascular 
smooth muscle cells (VSMCs), and endothelial cells, and are located in the basement 
membrane of cardiomyocytes [Corda et aI., 2000; Jane-Lise et aI., 2000). Laminins 
contain binding domains for ECM components, and mouse knockout of laminin 
subunits results in cardiac abnormalities [Jane-Lise et aI., 2000). 
Fibronectin is an adhesive extracellular matrix glycoprotein involved in cytoskeletal 
organisation, cell adhesion, cell migration, and cell spreading [Smith et aI., 1990). 
Fibronectin associates with multiple ECM components and is crucial during 
development, with loss of this gene in mice resulting in severe developmental defects 
to the entire body including the heart [George et aI., 1993). 
Periostin is an ECM protein most often secreted by fibroblast or fibroblast-like cells, 
which can bind to several integrin receptors and also interact with ECM proteins such 
as collagens and fibronectin. During development, the expression pattern of periostin 
follows that of endocardial cushion and cardiac valve formation [Lindsley et aI., 2005], 
and loss of this gene in mice results in valve defects [Norris et aI., 2008]. Periostin is 
also involved in cardiac hypertrophy and remodelling [Borg and Caulfield, 1980]. 
47 
Introduction 
Matrix metalloproteinases (MMPs) are a family of secreted zinc-dependent enzymes 
which are capable of ECM degradation and are therefore important developmentally 
and during pathologic remodelling in cardiovascular disease [Nagase and Woessner, 
1999]. MMPs can be classified into four groups according to their substrate 
specificity; collagenases (MMP-1 and MMP-13), gelatinases (MMP-2 and MMP-9), 
stromelysins (MMP-3), and membrane-type MMPs (MT1-MMP) [Fedak et aI., 2005]. 
MMPs also have regulatory functions during normal ECM protein processing [Mann 
and Spinale, 1998]. 
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1.7 THE CONTRACTILE APPARATUS 
Contraction of the heart is dependent upon expression of a set of sarcomeric and Z-
disc proteins that form the contractile apparatus, represented in Figure 1.8. The 
sarcomeric thick filament is composed of myosin heavy chains, myosin light chains, 
myosin binding protein C, and titin. Actins and troponins make up the thin filament. In 
addition to sarcomeric proteins having an important role in the structure and 
contractility of the heart, they are now also known to be important in developmental 
processes such as cardiac septation. Mutations in sarcomeric proteins have been 
linked to various cardiomyopathies and congenital cardiovascular malformations such 
as ASDs, VSDs, PDA, and Ebstein anomaly. The mechanism by which mutations in 
sarcomeric genes can lead to CHDs such as atrial septal defects is unknown. Genes 
that are mutated in human cardiovascular conditions are represented in Figure 1.8, 
and relevant muscle genes are described in this section. 
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Figure 1.8 Sarcomeric and Z-disc proteins 
The sarcomeric thick filament is composed of myosin heavy chains, myosin light 
chains, myosin binding protein C, and titin . Actins and troponins make up the 
sarcomeric thin filament. Genes that are mutated in human cardiovascular conditions 
are shown in orange. Adapted from Morita, 2005 
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1.7.1 Myosin heavy chains 
Sarcomeric complexes in cardiac muscle contain myosin thick and actin thin 
filaments. Myosin heavy chains (comprising alpha- and beta-myosin heavy chain (a-
MHC/13-MHC», and myosin light chains (MLC) form the thick filaments. MYH6, which 
encodes a-MHC, is predominantly expressed in the atria [Somi et aI., 2006]. 
Mutations in MYH6 in humans are associated with hypertrophic and dilated 
cardiomyopathy [Morita et al.. 2005]. and atrial septal defects [Ching et al.. 2005]. 
TBX5 and GATA-4 are transcriptional regulators of MYH6 [Ching et al.. 2005; Huang 
et al.. 1995; Molkentin et al.. 1994]. 13-MHC. encoded by the MYH7 gene. is a 
downstream target of the cardiac transcription factors GATA-4/5/6, Nkx2.5, and 
MEF2C [Morkin. 2000]. It is expressed throughout the heart tube during development 
(studied in the chicken), later becoming restricted to the ventricles [Somi et al.. 2006]. 
Mutations in MYH7 are associated with various cardiomyopathies [Meredith et aI., 
2004; Seidman and Seidman. 2001; Tajsharghi et al.. 2003]. atrial septal defects 
[Budde et aI., 2007] and Ebstein anomaly (a CHD characterised by displacement of 
the tricuspid valve leaflets) [Kaneda et al.. 2008]. 
1.7.2 Myosin light chains 
Myosin light chains are a component of the sarcomeric thick filament and can be 
classified as either essential or regulatory [Franco et aI., 1998]. Regulatory myosin 
light chains are subject to phosphorylation which influences their sensitivity to calcium 
during muscle contraction. thereby modulating this process [Szczesna et al.. 2002]. 
These categories can be subdivided into fast and slow isoforms, and multiple isoforms 
also exist. Three essential isoforms are expressed in the heart; MLC3f (a fast 
isoform). MLC1V (expressed in the ventricular myocardium). and MLC1 a (expressed 
in the atrial myocardium) [Hailstones and Gunning. 1990; Kelly et al.. 1995; Lyons et 
al.. 1990; McGrew et al.. 1996]. Three regulatory isoforms are expressed in the heart 
during cardiac development; MLC2a (expressed in the atrial myocardium). MLC2v 
(expressed in the ventricular myocardium). and MLC2f (a fast isoform that is 
tranSiently expressed in the heart during embryonic development) [Faerman and 
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Shani,1993]. Mutations in essential myosin light chain (MYL3) and regulatory myosin 
light chain (MYL2) result in hypertrophic cardiomyopathy (HeM) [Bos et aI., 2007; 
Burkett and Hershberger, 2005; Morita et aI., 2005]. 
1.7.3 Actins 
Actins are a major component of the sarcomeric thin filament. There are four isoforms 
of actin occurring in muscle; the striated a-skeletal and a-cardiac actins which are the 
primary isoforms in skeletal and cardiac muscle respectively, and a- and v- smooth 
muscle actins, primarily expressed in smooth muscle cells. Alpha-smooth muscle (0-
SM) actin is the earliest expressed actin isoform in the developing heart [Ruzicka and 
Schwartz, 1988]. Mouse knockout of the a-SM actin gene ACTA2 results in impaired 
vascular contractility and blood flow [Schild meyer et aI., 2000; Tomasek et aI., 2006]. 
Mutations in the human ACTA2 gene are associated with a variety of vascular 
diseases such as coronary artery disease (CAD), ischemic strokes, Moyamoya 
disease (MMD), and thoracic aortic aneurysms and dissections (TAAD) [Guo et aI., 
2009]. PDA has also been reported in patients with ACTA2 mutation [Guo et aI., 
2009]. The striated a-skeletal and a-cardiac actins become the predominantly 
expressed actin isoforms in the heart following dextral looping [Ruzicka and Schwartz, 
1988]. Missense mutations affecting conserved amino acids in the cardiac actin gene 
ACTC have been identified in two separate families with idiopathic dilated 
cardiomyopathy (IDC) [Olson et aI., 1998], and mutations in this gene are also are 
associated with atrial and ventricular septal defects [Matsson et aI., 2008; Monserrat 
et aI., 2007]. 
1.7.4 Tropomyosin 
Tropomyosin (TM) is a dimeric a-helical coiled actin-binding protein, important as a 
contractile component of the sarcomeric thin filament and necessary for myocardial 
function [Perry, 2001]. More than twenty isoforms of tropomyosin have been identified 
in mammalian species, encoded by four genes, TPM1 - TPM4 in humans, which give 
rise to a-, 13-, V-, and IS-tropomyosin respectively [Pittenger et aI., 1994]. These are 
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expressed predominantly in skeletal, smooth, and cardiac muscle, and at lower levels 
in non-muscle cytoskeletal and actin associated cells [Pittenger et aI., 1994]. Familial 
hypertrophic cardiomyopathy has been linked to missense mutations in TPM1 which 
encodes alpha-tropomyosin [Thierfelder et aI., 1994]. E40K and E54K mutations in a-
tropomyosin cause dilated cardiomyopathy due to decreased sensitivity to Ca2+ [Mirza 
et aI., 2007]. Alpha-tropomyosin null mice do not survive past E11.S, whilst 
heterozygous mice are viable and able to reproduce but display a 50% reduction in 
cardiac muscle a-TM mRNA, with no differences in myocardial and myofilament 
function between these and control mice [Rethinasamy et aI., 1998). 
1.7.5 Troponins 
Cardiac troponin is located along the actin thin filament, and the troponin complex 
comprises three troponin subunits, cardiac troponin C (cTnC), cardiac troponin T 
(cTnT), and cardiac troponin I (cTnl) which are involved in striated muscle contraction 
via interaction with Ca2+ [Farah and Reinach, 1995]. Each of these subunits has a 
distinct role; cTnC acts as a Ca2+ sensor, cTnT binds to tropomyosin and transmits the 
Ca2+ binding signal from troponin to tropomyosin, and cTnl is inhibitory and prevents 
actin and myosin association in the absence of Ca2+ [Farah and Reinach, 1995]. 
Mutations in cTnl and cTnT are associated with restrictive cardiomyopathy [Knoll mann 
et aI., 2003]. 
53 
Introduction 
1.8 CARDIAC MODEL SYSTEMS RELEVANT TO THIS THESIS 
1.8.1 The P19 cell line as a model of cardiomyocyte differentiation 
Cardiac cell lines have been used extensively to model cardiomyocyte differentiation 
and gene regulation. The P19 mouse embryonal carcinoma cell line is pluripotent and 
can be induced to differentiate by the addition of non-toxic drugs. Retinoic acid 
induces differentiation to neuroectodermal derived cell types, and dimethyl sulfoxide 
(DMSO) induces differentiation to endodermal and mesodermal derived cell types 
such as skeletal and cardiac muscle cells [McBurney, 1993). Addition of DMSO at 0.5 
- 1% (v/v) induces the formation of beating cardiomyocytes at days 6 - 7, thus the 
P19 cell line provides an excellent in vitro model of early development and 
cardiomyocyte differentiation and is widely used. It has previously been used in a 
number of functional studies looking at the effect of a reduction or increase in 
expression of cardiac genes such as TBX5 and GAT A-4 [Fijnvandraat et aI., 2003; 
Grepin et aI., 1995; Hirai et aI., 2001]. 
1.8.2 The developing chick as a model of cardiogenesis 
The chicken embryo is one of the most widely used non-mammalian vertebrate 
models of development. Chickens have a short gestational period of 21 days, and 
development occurs in ovo rather than in utero, which means ease of manipulation 
with particular advantages for temporal studies. Complete sequencing of the chicken 
genome [2004] and the availability of expressed sequence tag (EST) libraries mean 
sequences are readily available and can be utilised for technologies such as 
morpholino antisense knockdown in order to study gene function. Additionally, avian 
cardiac development is very similar to human cardiac development. The primary 
difference occurs during atrial septation. where a septum secundum forms in the 
human but not the chicken. This means that ostium primum defects that arise from 
defects in the septum secundum cannot be modelled. Since this study will be 
focusing on defects of the septum primum. this is not a major concern. 
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1.9 BACKGROUND TO THIS THESIS 
Holt-Oram syndrome (HOS) is a human genetic disorder associated with mutations in 
the TBX5 gene [Li et aI., 1997], characterised by upper limb deformities and heart 
defects, usually in atrial or ventricular septation [Lehner et aI., 2003]. The TBX5 
mutations G80R and R237W, which are associated with cardiac septal defects in 
HOS patients [Basson et aI., 1999], disrupt the physical interaction between TBX5 and 
GATA-4 [Garg et aI., 2003]. The GATA-4 mutation G296S has been linked to ASDs in 
humans, and also disrupts the GATA-4 I TBX5 interaction [Garg et aI., 2003]. These 
findings together account for the fact that similar heart defects are seen as a result of 
both GATA-4 and TBX5 mutations, and highlight the potential importance of this 
complex in synergistic regulation of genes involved in septation of the heart. 
Identification of these downstream targets is crucial in gaining an understanding of the 
mechanism via which mutations in these transcription factors lead to heart defects. 
TBX5 and GATA-4, and their combined downstream targets are the focus of this 
thesis. 
This study is based on the work of Jonathan Ronksley (a former PhD student in Prof J 
David Brook's group) who aimed to identify genes co-ordinately regulated by TBX5 
and GATA-4 using the P19CL6 mouse embryonal carcinoma cell line as a model of 
cardiac development [Ronksley, 2007]. The full length human GATA-4 gene was 
cloned into a pcDNA3.1/Zeo vector and used to create cell lines overexpressing 
GATA-4. The full length human TBX5 gene was then additionally cloned in to create 
double overexpression cell lines. Overexpression of TBX5 and GAT A-4 was 
confirmed by western blot analysis and ANF luciferase reporter assays. Two P19 
TBX5 I GATA-4 overexpression cell lines were selected for further analysis, named 
G10 and G22. Microarray expression analyses were then performed using the 
Ocimum Biosolutions Mouse 1400 pmol30K V2 Oligo set (AlBIC), which contains 50-
base pair oligonucleotide probes (1 per gene) for detection of 27 530 targets. A dye 
swap method (Cy3 and Cy5) was employed in order to eliminate dye bias. 
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For identification of downstream targets of TBX5 and GATA-4, microarray expression 
analysis of TBX5 I GAT A-4 overexpression cell line RNA in comparison to wild type 
RNA (at day 0) was carried out. This revealed 80 up-regulated, and 154 down-
regulated genes (by >2 fold on 3 out of 4 replicate arrays). Surprisingly, ANF and 
connexin 40 (which are known targets of TBX5 and GATA-4) could not be detected in 
any of the wild type or overexpression arrays. However, cardiac troponin I, which is 
synergistically regulated by TBX5 and GATA-4 (Dr Tushar Ghosh, unpublished data), 
and alpha cardiac actin (a predicted target of TBX5) [Ghosh et aI., 2001] were up-
regulated post-differentiation in response to overexpression of TBX5 and GAT A-4. 
For additional expression profiling of wild type P19 cell differentiation, cells were 
induced to differentiate by addition of DMSQ, and RNA extracted at days 0, 2, 5, 7 
and 10. This provided a means to study expression of genes of interest during normal 
differentiation into cardiomyocytes. QPCR analysis of TBX5 and GATA-4 expression 
was also carried out during wild type P19 cell differentiation, and revealed significant 
up-regulation of GATA-4 on days 2, 5 and 7. TBX5 expression was not detectable at 
day 2, and displayed significant up-regulation on days 5 and 7. 
A subset of genes was chosen for further study based on expression changes and 
current literature. Six down-regulated genes are shown in Table 1.1, and sixteen up-
regulated genes in Table 1.2, with average fold changes in expression. 
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Table 1.1 Genes down-regulated in microarray expression analysis of TBX5 I 
GATA-4 overexpression cell lines 
Gene NCBI Accession 10 Fold change 
Annexin A2 AK012563 2.91 
VEGF-b BC046303 2.57 
RBBP6 NM_011247 2.22 
Annexin A4 AK032703 3.01 
Galanin R2 AF042784 2.41 
A2-macroglobulin NM_175628 9.87 
Average expression of double overexpression cell lines G10 and G22 at day 0, 
measured against wild type P19 cells at day O. 
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Table 1.2 Genes up-regulated in microarray expression analysis of TBX5 I 
GATA-4 overexpression cell lines 
Gene NCBI Accession 10 Fold change 
Gamma Filamin BC060276 2.24 
Tropomyosin M22479 2.23 
Glutaredoxin AB013137 2.97 
S100A10 NM_OO9112 3.84 
Fibronectin X93167 2.45 
Calreticulin AK075605 2.77 
ERp57 AK088721 2.18 
Mest / Peg1 AF482999 2.34 
HNRPDL NM_016690 2.50 
RBMS1 BC057866 2.51 
PMM2 XM_354942 2.65 
PA2.26 AJ250246 3.36 
PETA-3 AF033620 2.65 
Neurofilament 3 AK051696 2.19 
AP4e1 BC042530 3.17 
Alpha-I-fucosidase AKOO2230 2.22 
Average expression of double overexpression cell lines G10 and G22 at day 0, 
measured against wild type P19 cells at day O. 
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1.10 AIMS AND OBJECTIVES 
This P19 overexpression study was the first study of its kind to attempt identification of 
the combined targets of TBX5 and GATA-4. Microarrayexpression profiling resulted 
in identification of a large number of potential targets. This thesis aimed to build on 
this research as follows: 
1) Use of the P19 overexpression study as a starting point for identification of a 
subset of genes likely to be important in cardiogenesis, taking into account 
expression, bioinformatic, and functional information 
2) Development of a novel model system of combined knockdown of TBX5 and 
GAT A-4 allowing phenotypic characterisation, and independent assessment 
of the responsiveness of candidate genes to these transcription factors 
3) Investigation of the role of one or more selected genes in cardiogenesis, with 
the aim to validate and characterise function in a developmental system for 
evidenced presentation of new cardiac genes 
4) Use of the model system for identification of new synergistic targets of TBX5 
and GATA-4 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 Molecular methods 
50x TAE buffer (1 litre) 
DNA size markers 
242 g Tris, 100 ml 0.5M EDT A pH 8.0, 
57.1 ml glacial acetic acid 
Hyperladder IV (Bioline) and 1 Kb+ DNA 
ladder (Invitrogen) 
PfuUltra II Fusion HS DNA polymerase 2.5 U f ~ I I (Stratagene) 
HotStar Taq 
DNase I 
RNaseOUT 
SuperScript III 
5 U fIJI (Qiagen) 
Lyophilised DNase I (1500 kunitz units) 
dissolved in 550 IJI RNase free water 
(Qiagen) 
40 U f ~ I I (Invitrogen) 
200 U fIJI (Invitrogen) 
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2.1.2 Microbial techniques 
LB media (1 litre) 
SOC media (1 litre) 
MacConkey agar plates 
Ampicillin stock 
T4 DNA ligase 
Taq DNA polymerase 
2.1.3 DNA purification techniques 
Shrimp Alkaline Phosphatase 
Exonuclease I 
Materials and Methods 
10 9 tryptone, 5 9 yeast extract, 10 9 NaCI 
20 9 tryptone, 5 9 yeast extract, 0.5 9 NaCl, 
10 ml 250 mM KCI, 20 mM glucose, 5 ml2 M 
MgCI2, 20 ml1 M glucose. pH adjusted to 7.0 
with NaOH 
52 g MacConkey agar per litre, ampicillin 
added to a final concentration of 50 ~ g g I ml 
3 U I ~ I I (Promega) 
5 U I ~ I I (NEB) 
1 U I ~ I I (Promega) 
20 U I ~ I I (NEB) 
2.1.4 Whole mount In situ hybridisation (WISH) 
Chick saline solution (1 litre) 71.9 9 NaCI 
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PBST 
4% paraformaldehyde (1 litre) 
Proteinase K 
Pre-hybrid isation solution 
DEPC treated H20 
20x SSC (1 litre) 
2.0x SSC with 0.1 % Tween20 
(1 litre) 
0.2x SSC with 0.1 % Tween20 
(1 litre) 
KTBT 
NTMT 
Levamisole 
Materials and Methods 
PBS (Sigma) containing 0.1 % Triton X-100 
40 9 PFA, 100 ml 10x PBS, pH adjusted to 
9.1-9.3 using NaOH 
10 mg I ml in DEPC treated H20 
50% deionized formam ide, 5x SSC, 2% 
blocking powder, 0.1% Triton X-100, 0.1% 
CHAPS, 50 j.lg I ml yeast RNA, 5 mM EDTA, 
50 j.lg I ml heparin 
0.5 ml DE PC per litre H20 
175 9 NaCI, 88 9 sodium citrate, pH adjusted 
to 7.0 with HCI 
100 ml20x SSC, 10 m110% Tween20 
10 ml20x SSC, 10 m110% Tween20 
50 mM Tris-HCI (pH 7.5), 150 mM NaCI, 10 
mM KCI, 1% Triton X-100 
100 mM NaCI, 100 mM Tris (pH 9.5),50 mM 
MgCI2, 0.1% Triton X-100 
50 mg I ml in DEPC treated H20 
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Colour reagent (1 ml) 
Sacll 
Spel 
T7 RNA polymerase 
SP6 RNA polymerase 
2.1.5 Western blotting 
RIPA buffer (100 ml) 
PMSF (0.1 M) 
5x sample loading buffer (50 ml) 
Electrophoresis buffer (1 litre) 
Transfer buffer (1 litre) 
Materials and Methods 
3 fJl 75 mg I ml NBT in 70% OMF, 2.3 fJl 50 
mg I ml in OMF BCIP, 1 ml NTMT 
20 U I fJl (NEB) 
10 U I fJl (NEB) 
20 U I fJl (Roche) 
20 U I fJl (Roche) 
50 mM Tris-HCI, 150 mM NaCl, 1mM EOTA, 
1% Triton X-100, 1% sodium deoxycholate, 
0.1% SOS, 100 fJl 0.1 M PMSF, one 
complete 
(Roche) 
mini inhibitor cocktail tablet 
0.17 9 PMSF, made up to 10 ml in 
isopropanol 
1.25 9 SOS, 24.02 9 urea, 5 ml 13-
mercaptoethanol, 10 ml glycerol, 20 ml 0.5 M 
Tris-HCI, 0.05 g bromophenol blue 
3 9 Tris, 14 g glycine, 1 g SOS 
9 9 Tris, 42 9 glycine, 600 ml methanol 
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TBS (1 litre) 
Materials and Methods 
1.2 g Tris, 8.75 g NaCl, pH adjusted to 7.5 
with HCI 
TBST 1x TSS containing 0.1% Tween20 
2.1.6 Morpholino knockdown 
F127 pluronic gel (100 ml) 15 g F127 pluronic gel made up to 100 ml 
with HBSS (Sigma) 
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Table 2.1 Primers used for PCR amplification of mouse genomic regions of 
RBMS1 
Primer name Primer sequence (5' - 3') 
RBMS1 mouse intron 1 F1 CACCTCTCTCTACCTGAAAAGATGG 
RBMS1 mouse intron 1 F2 ATGGCTAATTATGTTAGGGCCTTGT 
RBMS1 mouse intron 1 R1 AAAGCTTTGCATCACAGCATCTTAT 
RBMS1 mouse intron 1 R2 GAGATCATGAAGTCACTCACGGTAA 
RBMS1 mouse 3' UTR F1 TAAGACAAAAGATGACGAAGCACTG 
RBMS1 mouse 3' UTR F2 TGTTCCCCTGAACAGGTTTATTTTA 
RBMS 1 mouse 3' UTR R 1 AAAAACCGACAGGAAGAAGAAAGTT 
RBMS1 mouse 3' UTR R2 AATGTCGCTGACATCTATCATCAAA 
RBMS1 mouse 5' UTR F1 CTCCTCCAAAGACACTTTCCAAATA 
RBMS1 mouse 5' UTR F2 CCCAAGTTTGTAGCTCCTACTGAAA 
RBMS1 mouse 5' UTR F3 GTGGGACAATTTGAGCATCTACAAA 
RBMS1 mouse 5' UTR R1 TGCAGATACTGGGGGTAGTAATAGG 
RBMS1 mouse 5' UTR R2 GGGTAGTAATAGGTGGCGTACTGAG 
RBMS1 mouse 5' UTR R3 CTATAGTTAGCAACCCCAGCACTTG 
Table 2.2 Primers used for Introduction of Sacl restriction sites 
Primer name Primer sequence (5' - 3') 
RBMS1 Int1 Sacl primer F GATCGAGCTCCACCTCTCTCTACCTGAAAAGATGG 
RBMS1 Int1 Sacl primer R GATCGAGCTCAAAGCTTTGCATCACAGCATCTTAT 
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Table 2.3 QPCR assays designed to candidate genes in the chick 
Gene Accession ID Primer name Primer sequence (5' - 3') Position Probe· 
PA2.26 F1 CAGAGTTTGAGGAATTACCGACA 368- 390 
PA2.26 XM_001231272.1 44 
PA2.26 R1 CTTCCAAACTGCAAGAGATTTGT 418 - 440 
PA2.26 F2 TTGGAATCATAGTAGCTGTTGGAA 602 - 625 
PA2.26 XM_001231272.1 151 
PA2.26 R2 CGAGTACCTGCCTGACATCTT 658 - 678 
PETA-3F CGTCGGAATTTGCTAAGAGTGT 510 - 531 
PETA-3 NM_001006472.1 2 
PETA-3 R GCCAGGATTCCAGCAATG 569- 586 
FUCA1 F AACTGGAATTCTTTGGACACG 409 - 429 
FUCA1 XM_ 417835.2 33 
FUCA1 R CAGTCCGTAGCGTATGTTGTTC 476 - 498 
TPM1 F GTGGCTCGTAAGCTCGTGAT 668-687 
TPM1 NM_205401.1 1 
TPM1 R TAGTTCAGCACGCTCCTCAG 711-730 
Fibroneclin F GAGGGTGATGAGCCACAGTAT 2287 - 2307 
Fibronectin XM_ 421868.2 76 
Fibronectin R CAGGAAGCAAGTCAGGGATG 2340 - 2359 
Desmin F CTGCTTTCAGAGCTGACGTG 684 -703 
Desmin XM_ 427965.2 80 
Desmin R TCTCCTCCTGCAGGGACTC 746 -764 
RBMS1F CTGTGAGATGCCCGGTGT 1228 - 1245 
RBMS1 NM_205024.1 80 
RBMS1R ACACCGGGCATCTCACAG 1266 -1287 
GAPDH F GGTCTTATGACCACTGTCCA 568 - 587 
GAPDH NM_204305.1 76 
GAPDH R TCCACAGCTTCCCAGAGG 622 - 640 
TBPF GATGTCTTCCGGATGTTTTCA 98 -118 
TBP NM_205103.1 151 
TBPR CGAAAAGGTTTTTGACCCTCT 153 -173 
RPLPO F ATGGGGAAGAACACGATGAT 186 - 205 
RPLPO NM_204987.1 80 
RPLPO R GCAGCAGCTTCTCCAAGG 244 - 261 
EEF1A1 F GTTGGAACGGGGACAACAT 584 - 602 
EEF1A1 NM_204157.2 37 
EEF1A1 R CTTTCCGGGTAACCTTCCAT 639 -658 
a-MHC F GACCTGGAGAATGACAAGCAG 190 - 210 
a-MHC NM_001001302.1 65 
a-MHC R CGAGCATTGAGTGTGTTGAGTT 245 - 266 
*Probe identifiers refer to pre-designed Universal ProbeLibrary probes (Roche). Each 
probe binds to a specific nucleotide sequence. Probe sequence information can be 
found online at https:/Iwww.roche-applied-science.com). 
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Table 2.4 Primers designed to the chicken RBMS1 gene 
Primer name Primer sequence (5' - 3') 
RBMS1 exon1F CCAGTATCTGCAGGCGAAC 
RBMS1 exon2F ACCCAATGGCTCCTCCTAGT 
RBMS1 exon5F TTGCCACTTTCAATGGATGA 
RBMS1 exon8F CCAACCACAGCTGCTTTACA 
RBMS1 exon3R TGCACTTGTTTGTTGTCTTATCC 
RBMS1 exon5R TCTTGTTGCTTTGCCATTTG 
RBMS1 exon9R TATGTGGAAACCGGAGAAGC 
RBMS1 exon10R GCTGCATCCAAGAAGGACTC 
RBMS1 intron2F GCACTCAGGTTAGGGCAGAG 
RBMS1 intron2R CCTCACCAGAAACGGACAAT 
Table 2.5 QPCR assays designed to the a-actin genes in the chick 
Gene EnsembllD Primer name Primer sequence (5' - 3') Position Probe· 
a-sma F GCACCTGAGGACATTGACATAG 3-24 
a-sma ENSGAL TOOOOO039927 56 
a-sma R TTACAGAGCCCTGAGCCATT 67-86 
a-ske a F GCTCTGGACTTTGAGAACGAG 439 - 459 
a-ske a ENSGAL TOOOOO018064 65 
a-ske a R CCCATCAGGCAGCTCATAG 498-516 
a-ca F TGAGAATGAAATGGCCACAG 625 - 644 
a-ca ENSGAL TOOOOO016005 80 
a-ca R ACCATCAGGCAATTCGTAGC 672 -691 
*Probe identifiers refer to pre-designed Universal ProbeLibrary probes (Roche). Each 
probe binds to a specific nucleotide sequence. Probe sequence information can be 
found online at https://www.roche-applied-science.com). 
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Table 2.6 Primers used in RT -peR expression analysis of genes identified in 
microarray analysis of TBX51 GATA-4 double knockdown embryos 
Gene Accession 10 Primer name Primer sequence 
TFAP28 F GGCCGTTTGTCTTTGCTTAG 
TFAP2B NM_204895.1 
TFAP2B R CCACCAGGGAGGTGAGTAAA 
PTPRZ1 F CCTTCTGGTTACGTGGGAAA 
PTPRZ1 XM_001231942.1 
PTPRZ1 R CGTGCAGACCATTAGAGCAA 
FIGFF ACCAGATTTGCTGCTGCTTT 
FIGF NM_204568.1 
FIGF R TGCAGCTCAGACTCTCCTCA 
NR2E1 F CCAGGCTTTACAGGAGGTTG 
NR2E1 NM_205170.1 
NR2E1 R GATTGGTACATTCCCGATGG 
LOC420770 F TGCTTGAGGAAACGAGTGTG 
LOC420770 XM_ 429784.2 
LOC420770 R TTTGCTGCAGGCACTATTTG 
SUZ12 F ATGAAGCACGGGTTTATTGC 
SUZ12 XM_ 415658.2 
SUZ12 R GGGAGGTCGATTCTCCTTTC 
CRABP1 F AGGACGGGGACCAGTTCTAC 
CRABP1 NM_001030539.1 
CRABP1R CCTCATCCCAGGTGACAAGT 
GOLGA4F GAAAGAGGCACTGCAGGAAC 
GOLGA4 XM_ 418856.2 
GOLGA4 R TGCATTTGTCGCTTTGTCTC 
GPC3F GGAGAGGTACAGTCCCCACA 
GPC3 XM_001232891.1 
GPC3R AGCCTCTGCCACAGTCATCT 
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Table 2.7 Morpholinos used in the TBX51 GAT A-4 knockdown study 
Morpholino Sequence (5' - 3') 3' tag 
Standard control CCTCTTACCTCAGTTACAATTTATA Fluorescein 
TBX5AUG GGCTCCTTCCTCCCGGTGCAAAGC Fluorescein 
TBX5 AUG 5-mismatch G G A T C A T T C C T Q C C G G T A C ~ C C Fluorescein 
TBX5 AUG 7-mismatch* G ~ C T Q C T T Q C T Q C C ~ G T ~ ( G ) C A A A ~ C C Fluorescein 
GATA-4AUG CATGGCTAAGCTCTGGTACATCTCG Lissamine 
GAT A-4 AUG 5-mismatch C A T £ G C T A A ~ C T C T ~ G T A Q A T Q T C G G lissamine 
GATA-4 AUG 7-mismatch C A T C C C T A A ~ C T Q T ~ G T A Q A T Q T C G G Lissamine 
Bases altered in mismatch control morpholinos are underlined and shown in bold. All 
morpholinos were synthesised by Gene-Tools USA. 
*An error was made by Gene-Tools during the design of this morpholino and an extra 
base (guanine, shown in brackets) inserted at position 19 
Table 2.8 Morpholinos used in the RBMS1 knockdown study 
Morpholino Sequence (5' - 3') 3' tag 
RBMS1 E212 AAGTATCGTACTTACGGTTGGCATA Fluorescein 
RBMS1 E212 5-mismatch A A ~ T A T C ~ T A Q T T A C £ G T T G £ C A T A A Fluorescein 
RBMS1 E818 GTGTACCAGCACTTAACATACCCAT Lissamine 
Bases altered in mismatch control morpholinos are underlined. All morpholinos were 
synthesised by Gene-Tools (USA). 
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2.2 METHODS 
2.2.1 Molecular methods 
2.2.1.1 Genomic DNA extraction 
Genomic DNA extractions were performed using the Wizard SV Genomic DNA 
Purification system (Prom ega), following manufacturer's instructions. A 275 IJI volume 
of digestion solution mastermix was added to the tissue sample (maximum 20 mg). 
Samples were incubated overnight at 55 ·C in a heat block, and centrifuged at 2000 x 
g. Supernatant was transferred to a new microcentrifuge tube and 250 !JI lysis buffer 
added followed by vortexing. This was transferred to a minicolumn assembly and 
centrifuged at 13000 x g for 3 minutes. Following removal of eluate, 650 !JI wash 
solution was added to the column followed by centrifugation at 13000 x g for 1 minute. 
This wash step was repeated 3 times followed by an additional centrifugation step 
without addition of wash solution in order to remove any traces of ethanol. The 
column was placed in a new microcentrifuge tube and 250 !JI H20 pipetted directly 
onto the membrane followed by incubation for 2 minutes at room temperature. DNA 
was eluted by centrifugation at 13000 x g for 1 minute. This elution step was repeated 
to obtain a final elution volume of 500 !JI, and DNA concentration assessed by 
spectrophotometry (section 2.2.1.3). 
2.2.1.2 RNA extraction 
RNA extractions were performed using the Qiagen RNeasy mini kit or microkit as 
appropriate, following manufacturer's instructions. RNA/ater stabilised tissue was 
placed in 600 !JI buffer RL T containing 1 % ~ - m e r c a p t o e t h a n o l l and homogenised using 
a sterile needle (SD Microlance 25G 5/8) and syringe. The resulting lysate was 
centrifuged at maximum speed for 3 minutes, and supernatant transferred to a new 
microcentrifuge tube for addition of 1 volume of 70% ethanol. This was transferred to 
an RNeasy spin column placed in a 2 ml collection tube, centrifuged for 15 seconds at 
maximum speed, and the flow-through discarded. On-column DNase digestion was 
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carried out in all cases using the RNase-free DNase set (Qiagen). Buffer RW1 (350 
~ I ) ) was added to the column and centrifugation carried out at maximum speed for 15 
seconds. A 1 0 ~ I I volume of DNase I stock solution was added to 70 1-'1 buffer RDD 
and pipetted into the membrane for a 15 minute incubation at room temperature. A 
350 ~ I I volume of buffer RW1 was added to the column and centrifugation carried out 
at maximum speed for 15 seconds. A 500 1-'1 volume of wash buffer RPE was added 
to the column followed by centrifugation for 15 seconds at maximum speed to wash 
the column-bound RNA. The flow-through was discarded, and a further 500 1-'1 of 
buffer RPE added to the column for centrifugation for 2 minutes at maximum speed. 
The column was placed in a new collection tube and centrifuged at full speed for 1 
minute to remove any traces of ethanol. The column was placed in a new 
microcentrifuge tube, and 30 1-'1 RNase-free H20 pipetted directly onto the centre of 
the membrane followed by centrifugation at full speed for 1 minute for RNA elution. 
RNA purity and concentration was assessed by spectrophotometry (section 2.2.1.3), 
and RNA stored at -80 °c. 
2.2.1.3 Nucleic acid quantification 
Quantifications were performed using the NanoDrop® ND-1000 spectrophotometer. 
A 1 1-'1 volume of sample was pi petted onto the lower measurement pedestal, followed 
by lowering of the sampling arm, drawing the sample between the two measurement 
pedestals for spectral analysis. 
2.2.1.4 Reverse Transcription 
Reverse transcription reactions were carried out in 20 ~ I I reaction volumes. Total RNA 
(1 ~ g ) ) was combined with 2 1-'1 50 ng I ~ I I random hexamers and 1 ~ I I 10 mM dNTPs, 
and made up to 12 1-'1 with H20. Samples were heated at 65 °C for 5 minutes then 
placed on ice before addition of 4 ~ I I 5x first strand buffer, 2 ~ I I 0.1 M DTT and 1 ~ I I 40 
U I ~ I I RNaseOUT (Invitrogen). Samples were incubated at 37 °C for 2 minutes prior 
to addition of 1 ~ I I SuperScript III (Invitrogen), excluding -RT controls. Samples were 
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incubated at 25 ·C for 10 minutes, 37 ·C for 50 minutes, 70°C for 10 minutes before 
storage at -80°C. 
2.2.1.5 Primer design 
Primers were most frequently designed using online Primer3 software 
(http://frodo.wLmit.edu/primer3/), or manually when a very specific primer location was 
required (such as in cases of high homology with other genes or transcripts). Primers 
were generally 18 - 25 bp in length, with melting temperatures of 55 - 65 ·C. Blast 
searches were carried out for all primers in Ensembl 
(http://www.ensembl.org/Multi/blastview). 
2.2.1.6 Polymerase chain reaction (peR) 
2.2.1.6.1 HotStar Taq 
PCR reactions were carried out in 25 IJI reaction volumes using 2 IJI 10 IJM forward 
and reverse primers, 2.5 IJI 10x buffer (Qiagen), 1 IJI 10 mM dNTPs, 0.25 IJI 5U /IJI 
HotStar Taq (Qiagen), 16.25 IJI H20, and 1 IJI DNA template. Thermal cycling 
conditions were based on the following: 95°C for 15 mins, 35 cycles of 94°C for 30 
secs, 60°C for 30 secs and 72 °c for 30 secs, and 72 ·C for 10 mins. 
2.2.1.6.2 PfuUltra 11 Fusion HS DNA Polymerase 
PCR reactions were carried out in 50 IJI reaction volumes using 1.0 IJI 10 IJM forward 
and reverse primers, 5.0 IJI 10x PfuUltra II reaction buffer (Stratagene), 5.0 1J110 mM 
dNTPs, 1.0 IJI PfuUltra II Fusion HS DNA polymerase (Stratagene), 36.0 IJI H20, and 
1 IJI 100 ng /IJI genomiC or plasmid DNA template. Thermal cycling conditions were 
based on the following: 95°C for 5 mins, 35 cycles of 94°C for 30 secs, 60°C for 30 
secs and 72 °c for 30 secs, and 72 °c for 5 mins. 
2.2.1.7 Agarose Gel Electrophoresis 
Agarose gels were made up and electrophoresed in TAE buffer. Ethidium bromide 
was added to a final concentration of 0.1 IJg / ml. DNA samples were combined with 
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5x loading buffer (Bioline) and loaded alongside 10 ~ I I 1 Kb+ DNA ladder (Invitrogen) 
or 5 ~ I I Hyperladder IV (Bioline). Gels were run at 100 - 150 V. 
2.2.1.8 DNA sequencing 
Sequencing reactions were carried out using 0.5 ~ I I BigDye Terminator v3.1 (Applied 
Biosystems), 2 ~ I I 5x sequencing buffer (Applied Biosystems), 0.4 ~ I I 10 ~ M M primer, 
and 3 - 20 ng PCR product 1150 - 300 ng plasmid DNA, made up to a total volume of 
10 ~ I I with water. Reactions were performed under the following conditions: 96°C for 
16 min, followed by 28 cycles of 96 °C for 10 seconds, 50°C for 5 seconds, 60°C 
degrees for 4 minutes. Samples were ethanol precipitated (section 2.2.3.4) and run 
on an ABI prism ™ 3130xl Genetic Analyser (Applied Biosystems) at the Biopolymer 
Synthesis and Analysis Unit (University of Nottingham, UK). Sequences were 
analysed using Chromas software (Technelysium Pty Ltd). 
2.2.1.9 Quantitative PCR (QPCR) for validation of mouse targets 
2.2.1.9.1 Methodology 
There are two main methodologies for QPCR analysis of gene expression, the 
Relative Standard Curve method and the Comparative Cr (LlLlCr ) method, described 
here. The Relative Standard Curve method involves the construction of standard 
curves from known quantities of DNA for both the target and endogenous control on 
each reaction plate, with sample DNA amplified simultaneously under Identical 
conditions. This allows interpolation of sample target and endogenous reference 
quantities from the standard curves, and assay efficiency data is generated In parallel, 
producing highly accurate data. Due to the requirement of standard curves and all 
samples on each reaction plate, this method uses a large quantity of reagents and is 
suitable when sample numbers are low. The Comparative Cr method uses arithmetic 
formulae for relative quantification calculations. It requires the construction of 
standard curves for all target and control genes for assessment of amplification 
efficiencies prior to quantification experiments, and these values are incorporated into 
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relative quantification calculations. The use of standard curves on each plate is not 
required, which means this method has economical advantages over the Relative 
Standard Curve method. It is ideal for high throughput studies where there are a 
large number of targets and / or samples, such as in the validation of microarray data, 
and will be used for this purpose here. 
2.2.1.9.2 Assay design and experimental conditions 
Assays were designed by Jonathan Ronksley using the online Roche Universal 
ProbeLibrary assay design centre (https:!lwww.roche-applied-science.com). QPCR 
analyses of gene expression in the mouse P19 cell line were performed using the 
Comparative CT method [Livak and Schmittgen, 2001]. Quantitative PCR was 
performed in a total volume of 25 ~ I I using 12.5 ~ I I SensiMix (Quantace), 0.25 ~ 1 1 0 0 ~ M M
probe (5' FAM labelled and 3' labelled with a dark quencher dye, Universal 
ProbeLibrary, Roche), 1.0 ~ I I 1 0 ~ M M forward primer, 1.0 ~ I I 10 IJM reverse primer, 1.0 
~ I I 50mM Mg2+, 4.0 IJI cDNA and 5.25 IJI dH20. Reactions were performed using the 
Applied Biosystems 7500 Fast Real-time PCR system under the following thermal 
cycling conditions: 95°C for 15 mins, and 40 cycles of 94°C for 15 secs and 60°C for 
1 min. Negative RT and water controls were included. Primer sequences and probe 
numbers are shown in Table 2.1. Real-time PCR efficiencies for each assay were 
calculated from the exponential phase of the slope in the SDS v1.3.1 software, using 
the equation E = 10 [-1/slope]. Reactions were performed in duplicate at five serial 
dilutions of HH19 wild type cDNA (1, 0.1, 0.01, 0.001, and 0.0001). Quantitative PCR 
reactions were performed in triplicate on cDNA reverse transcribed from RNA used in 
the initial microarray analysis. Expression quantifications were corrected for peR 
efficiency, with the equation R = 2·MC1 modified to the equation R = (Etarget) ~ C t t
target (control- sample) / (Eret) ~ C t t ref (control- sample). 
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2.2.1.10 QPCR for expression analysis In the chick 
2.2.1.10.1 Assay design 
QPCR assays were designed using the online Roche Universal ProbeLibrary assay 
design centre (https:/lwww.roche-applied-science.com). For genes with high 
similarity to other sequences, regions of lowest homology were input and only specific 
assays selected. Blast searches were carried out for all primers to ensure specificity. 
2.2.1.10.2 Amplification conditions 
Quantitative PCR was performed in a total volume of 28 ~ I I using 12.5 ~ I I TaqMan 
Universal PCR Master Mix (Applied Biosystems), 0.5 j.JI10 j.JM probe (5' FAM labelled, 
Universal ProbeLibrary, Roche), 0.75 ~ 1 1 0 0 ~ M M forward primer, 0.75 ~ 1 1 0 0 IJM reverse 
primer, 5.0 IJI cDNA, and 5.5 IJI dH20. Reactions were performed using the Applied 
Biosystems 7500 Fast Real-time peR system under the following thermal cycling 
conditions: 95°C for 15 mins, and 40 cycles of 94°C for 15 secs and 60°C for 1 min. 
Negative RT and water controls were included in each plate. Primer sequences and 
probe numbers are shown in Tables 2.4 and 2.5. Data was analysed using Applied 
Biosystems 7500 v2.0.1 software. 
2.2.1.10.3 Comparative CT method vs Relative Standard Curve method 
QPCR analyses of gene expression in the chick were carried out using the Relative 
Standard Curve method. This method is ideal for the detection of small changes in 
expression as would be expected in an in ovo system, and also when sample 
numbers are low in order that both standard curves and all samples can be run 
simultaneously in one reaction plate. Reliable quantification depends on accurately 
constructed standard curves; therefore data generated in this study has only been 
used when both standard curves meet a stringent set of parameters. These are 
discussed further in the next section. 
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2.2.1.10.4 Specification of experimental parameters 
For generation of accurate and reproducible data, a strict set of experimental 
parameters was set out. Data was used only if both standard curve slopes were in 
the range -3.2 to -3.6 (a linearity of -3.33 corresponds to an assay efficiency of 100%). 
Standard curve linearity was a minimum of 0.99 for both genes on the reaction plate. 
2.2.1.10.5 Preparation of standard curves 
The preparation of a standard curve requires a cDNA standard which expresses the 
target and endogenous control genes. This can be obtained from a source 
independent to the study samples, which has advantages when working with material 
in low supply. It also allows cDNA standard production on a large scale for 
comparison of data across all experiments. HH24 whole embryo cDNA was the 
chosen standard for this study. Dilutions were carried out immediately after cDNA 
synthesis for storage in single use aliquots to prevent repeated freeze I thaw cycles, 
and for consistency across reaction plates. RNA preparations often contain inhibitors 
(such as proteins) which can affect subsequent QPCR reactions. To minimise this, all 
cDNA was diluted prior to use. cDNA for standards was used at a starting dilution of 1 
in 16, and subsequent dilutions were made from this. Sample cDNA dilutions were 
carried out such that following amplification they would fall within the mid-range of the 
standard curve. The fold-dilution of standards was selected according to the expected 
magnitude of expression change. A 4-fold dilution series was chosen as relatively 
small expression changes were expected due to the fact this experiment was 
performed in ovo. 
2.2.1.11 Microarray expression analysis 
Microarray technology allows gene expression profiling of different sample groups on 
a genome-wide scale. It involves the use of individual spotted probes immobilised on 
a support in a known arrangement for detection of hybridisation. Sample RNA is 
reverse transcribed to produce cDNA which is then labelled with fluorescent dyes, 
most commonly Cy3 I CyS. Samples are then hybridised onto arrays and scanned 
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using a confocal laser to produce images from which the relative fluorescent intensity 
of spots can be assessed for calculation of relative gene expression. Microarray 
studies were carried out using the Affymetrix service provided by the Nottingham 
Arabidopsis Stock Centre (NASC). using the Affymetrix GeneChip® Chicken Genome 
Array (900590). Microarray expression data was analysed using GeneSpring version 
11 software (Agilent). 
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2.2.2 Microbial techniques 
2.2.2.1 A-tailing procedure for cloning Into the pGEM-T Vector 
PCR products amplified using the PfuU/tra 11 Fusion HS DNA polymerase are blunt 
ended and need to be modified using an A-tailing procedure for cloning into the 
pGEM-T Vector. Reactions were set up as follows: 1 - 7 1.11 gel purified PCR product, 
1 1.I110x Taq standard PCR buffer containing MgCI2 (NEB), 0.41.11 5 mM dATP, 1 1.115U 
/1.11 Taq DNA polymerase (NEB), and dH20 to a final volume of 10 1.11. Samples were 
incubated at 70 ·C for 30 minutes, and 1 - 2 IJI used per ligation reaction. 
2.2.2.2 Ligation of vector - insert 
Ligations were carried out using the TOPO cloning kit (Promega). Reactions were set 
up with 5 IJI 2x rapid ligation buffer, 1 IJI vector (50 ng /IJI), 1 IJI T4 DNA ligase, and 
insert at an approximate insert:vector molar ratio of 3:1, made up to a total volume of 
10 IJI with dH20. Samples were incubated at room temperature for 1 hour, or at 4 °C 
overnight. Positive controls (containing vector and control insert) and background 
controls (containing vector and no insert) were included in each set of ligations / 
transformations. 
2.2.2.3 Transformation 
The Eschericia coli (E.co") DHSa strain was used in all bacterial work. DH5a cells 
were thawed on ice (30 1.11 aliquots) and 2 1.11 ligation reaction added, mixed by flicking, 
then placed on ice for 25 - 30 minutes. Cells were subjected to heat-shocking at 42 
°C for 45 seconds, placed on ice for 2 minutes, and 950 1.11 SOC media added for 
incubation at 37°C shaking for 1 hour. Cells were pelleted by centrifugation at 1000 g 
for 10 minutes, resuspended in 3001.11 SOC media, and spread onto MacConkey agar 
plates containing 50 I.Ig / ml ampicillin for overnight incubation at 37°C. MacConkey 
agar is selective for gram negative bacteria (due to the fact it contains crystal violet 
and bile salts). It also differentiates between lactose fermenting bacteria (which do 
not contain an insert) and appear pink, and non lactose fermenting bacteria 
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(containing an insert) which appear colourless. Colour screening can therefore be 
used to accurately detect transformed colonies. 
2.2.2.4 Colony PCR 
Colony PCR reactions were performed for detection of the presence I absence of 
insert. PCR reactions were carried out in 25 ~ I I reaction volumes using 2 ~ I I 10 ~ M M
forward and reverse primers, 2.5 JJI 10x buffer (Qiagen), 1 JJI 10 mM dNTPs, 0.25 JJI 
5U I JJI HotStar Taq (Qiagen), and 16.25 JJI H20. Reactions were inoculated using 
individual colonies picked from agar plates. Colonies picked from the positive control 
plate were used as negative insert controls, in addition to a standard negative PCR 
control. Thermal cycling conditions were based on the following: 95 ·C for 15 mins, 
35 cycles of 94 ·C for 30 secs, 60 ·C for 30 secs and 72 ·C for 30 secs, and 72 ·C for 
10 mins. 
2.2.2.5 Overnight cultures 
Single colonies were used to inoculate 5 ml LB media containing ampicillin (50 JJg I 
ml), and a negative control was included with each set of overnight cultures to verify 
sterility. Cultures were incubated at 37 ·C shaking overnight. 
2.2.2.6 Preparation of glycerol stocks 
A 200 JJI volume of glycerol was added to 800 JJI fresh overnight culture (final 
concentration 20%). Samples were mixed and stored at -80 ·C. 
2.2.2.7 Plasmid DNA isolation (Miniprep) 
For plasmid minipreps, DNA was extracted from 3 ml of bacterial culture. This was 
divided into two 1.5 ml aliquots which were sequentially centrifuged at maximum 
speed for 1 minute to pellet the cells. DNA was extracted using the GenElute Plasmid 
Miniprep Kit (Sigma) according to manufacturer's instructions. The bacterial pellet 
was resuspended by addition of 200 ~ I I resuspension solution and vortexing. Cells 
were lysed by addition of 200 JJI lysis solution and gentle inversion. Cell debris was 
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precipitated by addition of 350 IJI of neutralisation/binding solution and gentle mixing, 
followed by centrifugation at maximum speed for 10 minutes. Following column 
preparation, the cleared lysate was transferred to the column and centrifuged at 
maximum speed for 1 minute. A 750 IJI volume of wash solution was added to the 
column, a 1 minute centrifugation performed, and the flow-through discarded prior to a 
second centrifugation for 2 minutes to remove any traces of ethanol. The column was 
transferred to a clean microcentrifuge tube and 100 IJI H20 pipetted directly onto the 
membrane followed by centrifugation for 1 minute at maximum speed to elute DNA. 
DNA was quantified using the NanoDrop® ND-1000 spectrophotometer (section 
2.2.1.3). 
2.2.2.8 Plasmid DNA Isolation (Maxiprep) 
A single colony was picked from a plate and used to inoculate a 3 ml starter culture in 
LB media which was incubated for 8 hours at 37 ·C shaking. A volume of 200 IJI 
starting culture was made up to 100 ml (1 1500 dilution) with LB media and grown at 
37 ·C shaking overnight. DNA was extracted from 100 ml bacterial culture using the 
Plasmid Maxi kit (Oiagen). Cells were harvested by centrifugation at 6000 x g for 15 
minutes at 4 ·C. The bacterial pellet was resuspended in 4 ml buffer P1, followed by 
addition of 4 ml of lysis buffer P2 and incubation at room temperature for 5 minutes. 
Chilled buffer P3 was then added at a volume of 4 ml, mixed, and incubated on ice for 
15 minutes. This was followed by centrifugation at maximum speed at 4 ·C for 30 
minutes. The supernatant was removed and re-centrifuged under identical conditions 
for 15 minutes. The supernatant was then applied to an equilibrated OIAGEN-tip and 
allowed to enter the resin. The tip was then washed twice with 10 ml buffer OC, and 
DNA eluted in 5 ml buffer OF. DNA was precipitated by addition of 3.5 ml 
isopropanol, mixing, and centrifugation at maximum speed for 30 minutes at 4 ·C. 
The supernatant was carefully removed and the DNA pellet washed with 2 ml 70% 
ethanol followed by centrifugation at maximum speed for 10 minutes. The 
supernatant was carefully decanted and the DNA pellet allowed to air-dry prior to 
80 
Identification of downstream targets of TBX5 and GAT A-4 in the mouse P19 cell line 
being re-dissolved in an appropriate volume of H20. DNA was quantified using the 
NanoDrop® ND-1 000 spectrophotometer (section 2.2.1.3). 
2.2_2.9 Plasmid linearization by restriction digestion 
Digests were performed using restrictions enzymes, buffers, and BSA (if required) 
from NEB. Reactions were set up as follows: 1 - 2 )Jg plasmid DNA, 1 )JI restriction 
enzyme, 2 )JI 10x buffer, 1 )JI 20x BSA if necessary, made up to 20 )JI with H20. 
Samples were incubated at 37 ·C for 3 - 4 hours, or overnight. Agarose gel 
electrophoresis was performed using 100 ng to confirm digestion was complete. 
2.2.2.10 Introduction of restriction sites by peR amplification for subcloning 
into the pGL3-Basic and pGL3-Promoter vectors 
Primers incorporating restriction sites (in this case Sacl) were designed and used for 
PCR amplification of insert (as described in section 2.1.1.5.2) using plasmid DNA as 
template, for subcloning into a second vector. Products were subjected to agarose 
gel electrophoresis, and purified by gel extraction (section 2.1.3.3). 
2.2.2.11 Restriction digestion and vector dephosphorylation 
For subcloning into a second vector, the destination vector and modified insert were 
cut using the same restriction enzyme to produce complementary ends. Linearised 
vector DNA was dephosphorylated using Shrimp Alkaline Phosphatase (SAP) to 
prevent recircularisation by removal of 5' phosphate groups from both termini. 
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2.2.3 DNA purification techiques 
2.2.3.1 Shrimp Alkaline Phosphatase / Exonuclease I treatment 
This is a simple enzymatic procedure for preparing PCR products for sequencing. 
SAP catalyses the dephosphorylation of 5' phosphates from DNA, removing excess 
dNTPs. Exonuclease I (Exol) digests single stranded DNA in the 3' to 5' direction, 
removing unincorporated primers. PCR products were purified for sequencing in 7 1-11 
reaction volumes using 1.5 IJI 1 U /1-11 SAP (Promega) and 0.5 1-11 20 U /1-11 Exol (NEB) 
with 5 IJI PCR product. Samples were incubated at 37 ·C for 1 hour, followed by an 
enzyme inactivation step of 80 ·C for 20 mins. 
2.2.3.2 Column purification of PCR products 
PCR products > 100 bp were purified using the Sigma GenElute PCR clean up kit 
according to manufacturer's instructions. Briefly, following column preparation, 5 
volumes of binding solution was combined with PCR product. This was applied to the 
column for centrifugation at maximum speed for 1 minute, and the eluate discarded. 
Column-bound DNA was then washed by addition of 0.5 ml wash solution and 
centrifugation at maximum speed for 1 minute. Following eluate disposal, the column 
was centrifuged for a further 2 minutes at maximum speed to remove any traces of 
ethanol. The column was transferred to a fresh collection tube and 50 1-11 water 
pipetted directly onto the centre of the membrane followed by incubation at room 
temperature for 1 minute. DNA was eluted by centrifugation at maximum speed for 1 
minute, and stored at -20 ·C. 
2.2.3.3 DNA extraction from agarose gels 
DNA was purified using the QIAquick Gel Extraction Kit (Qiagen) according to 
manufacturer's instructions. Briefly, the DNA fragment was visualised under UV light 
and excised from the agarose gel using a scalpel blade. The gel slice was then 
weighed and 3 volumes of buffer QG added followed by incubation at 50 ·C for 10 
minutes with vortexing every 2 - 3 minutes, allowing the gel to dissolve. Isopropanol 
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was added to the sample at 1 gel volume, mixed, and applied to the column for 
centrifugation for 1 minute at maximum speed. The eluate was discarded and 
column-bound DNA washed by addition of 0.75 ml buffer PE and centrifugation for 1 
minute at maximum speed. The column was re-centrifuged for an additional minute to 
remove all traces of ethanol. The column was placed in a clean microcentrifuge tube 
and 50 ~ I I water pi petted directly onto the centre of the membrane for DNA elution by 
centrifugation at maximum speed for 1 minute. DNA was stored at -20 ·C. 
2.2.3.4 Ethanol precipitation of DNA 
Ethanol was added at 2.5 volumes, and 1/10 volume of 3 M NaOAc pH 5.5 added to 
each sample, mixed by inversion, and incubated at room temperature for 15 minutes. 
Samples were centrifuged at 13000 rpm for 30 minutes and the supernatant carefully 
removed. The DNA pellet was washed with 70% ethanol, and centrifuged at 13000 
rpm for 10 minutes. The supernatant was carefully removed and the pellet air-dried 
before resuspension in an appropriate volume of H20. 
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2.2.4 Chick embryo techniques 
2.2.4.1 General care and conditions 
Fertile white Leghorn eggs (Henry Stewart & Co Ltd) were stored at 12 °C prior to 
use. Eggs were incubated at 37 °C gently rotating in a humidified incubator for the 
appropriate time. 
2.2.4.2 Embryo staging 
A small opening was created at the top of each egg and 4 ml albumen removed. 
Individual embryos were staged visually whilst in the egg according to Hamburger & 
Hamilton (HH) chicken developmental stages [Hamburger and Hamilton, 1992]. Chick 
developmental stages are further described in Appendix A. 
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2.2.5 Chick expression studies 
2.2.5.1 Collection of chick embryonic tissue for RT -PCR, QPCR, and microarray 
expression analysis 
Embryos were excised and placed in sterile ice cold PBS (Sigma). Membranes were 
removed and the relevant tissue was isolated at the required stage of development 
and immediately placed in RNAlater (Ambion) for storage at -20°C. In the case of 
morpholino treated embryos (section 2.1.4.5). embryos were excised from the egg 
and placed in sterile ice cold PBS. The outer and inner membranes were quickly 
removed, and the embryo placed in RNAlater for assessment of morpholino uptake 
under fluorescent light using a Zeiss Stemi SV11 microscope. Embryos were 
photographed where necessary and morpholino positive hearts isolated and stored in 
RNAlater at -20°C prior to extraction of RNA. 
2.2.5.2 Whole mount in situ hybridisation (WISH) 
2.2.5.2.1 Embryo collection and preparation 
Embryos were placed in ice-cold sterile chick saline solution for membrane removal 
followed by overnight fixation in 4% paraformaldehyde (PFA). Embryos were 
subjected to 3x 5 minute washes in PBS with 0.5% Tween (PBST). bleached for 1 
hour in 3% H20 2 (Sigma) in PBS, followed by 5 minute washes in a graded methanol 
series of PBST, 25% methanol (in PBST). 50% methanol (in PBS). 75% methanol (in 
DE PC treated water). and 100% methanol. then stored in 10 ml of methanol for a 
minimum overnight at -20°C (maximum 1 week). Embryos were subjected to 5 
minute washes in the methanol series ending in PBST. then digested with proteinase 
K in PBS (HH16: 10 I-Ig I mi. HH19 and HH24: 20 1-19 I ml) for 20 minutes. Samples 
were washed for 10 minutes in PBST. fixed for 20 minutes in 4% PFA with 0.2% 
gluteraldehyde. and subjected to two 10 minute washes in PSBT. PBST was 
removed and samples incubated in pre-hybridisation solution at 65°C for 2 hours. 
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The pre-hybridisation solution was replaced with fresh pre-hybridisation solution and 
embryos stored at -20 DC for up to 10 days prior to use. 
2.2.5.2.2 Probe synthesis and digoxygenin (DIG) labelling 
Single stranded DIG-labelled RNA probes were synthesised using the DIG RNA 
Labelling Mix (Roche) by in vitro transcription with SP6 or T7 RNA polymerases, 
which incorporate DIG-11-UTP at approximately every 20 - 25 bases. Reactions 
were set up on ice as follows: 500 ng - 1 ~ g g linearised plasmid DNA, 2 ~ I I 10x DIG 
RNA labelling mix, 2 ~ I I 10x transcription buffer, 2 ~ I I 20 U I ~ I I SP6 or T7 RNA 
polymerase, sterile RNase free water to a final volume of 20 ~ 1 . . Reactions were 
incubated at 37 DC for 3 hours, then template DNA was removed by addition of 2 ~ I I
DNase I (RNase free) and further incubation at 37 DC for 30 minutes. Reactions were 
stopped by addition of 1 ~ I I 0.5 M EDTA pH 8.0, and 9 ~ I I DEPC treated H20 added. 
2.2.5.2.3 Probe purification and quantification 
Probes were purified using Microspin G-50 columns (Illustra) according to 
manufacturer's instructions. Briefly, column preparation involved resuspension of the 
resin by vortexing, the cap was then loosened by one quarter of a turn, and the 
bottom closure snapped off prior to placement in the collection tube. The column was 
pre-spun for 1 minute at low speed (735 x g). The column was placed in a new 
microcentrifuge tube. DIG labelling reactions were made up to a volume of 50 ~ I I with 
Probe Elution and Storage Buffer, carefully applied to the top centre of the resin, and 
centrifuged at 735 x g for 2 minutes for elution. Probes were quantified using the 
NanoDrop® ND-1000 spectrophotometer and stored at -80 DC. 
2.2.5.2.4 In situ hybrldisatlon 
Prepared embryos were warmed in a hybridisation oven (Biometra OV3) at 65 DC for 2 
hours. Pre-hybridisation solution was replaced with fresh pre-warmed pre-
hybridisation solution containing probe at 150 ng I ~ I , , and samples incubated at 65 DC 
for 22 hours. Embryos were subjected to 10 minute wash steps at 65 DC in each of 
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the following: 100% pre-hybridisation solution, 75% pre-hybridisation solution / 25% 
2x SSC, 50% pre-hybridisation solution / 50% 2x SSC, 25% pre-hybridisation solution 
/ 75% 2x SSC, 100% 2x sse, then 4x 15 minute washes at 65 DC in 0.2 x sse. 
Embryos were then subjected to 5 minute washes at room temperature in the 
following: 75% 0.2x sse /25% KTBT, 50% 0.2x SSC /50% KTBT, 25% 0.2x SSC / 
75% KTBT, 100% KTBT. Embryos were blocked in KTBT containing 10% sheep 
serum (Invitrogen) and 2 mg / ml BSA (Fisher SCientific) for 3 hours at room 
temperature (sheep serum was inactivated by incubation at 65 De for 30 minutes prior 
to use). This was followed by incubation with anti-DIG-AP Fab fragment (Roche) at 1 
/ 5000 in blocking solution at 4 De overnight. Embryos were subjected to 5x 1 hour 
washes in KTBT gently rotating at room temperature, and then 2x 15 minute washes 
in fresh NTMT (containing levamisole at 25 jJg / ml). Colour reagent was made 
immediately before use and 2 ml added to each sample for initial incubation in the 
dark at room temperature for 20 minutes, then longer as necessary. The colour 
reaction was stopped by 2x 15 minute rinses in KTBT and one 15 minute wash in 
PBS. Embryos were taken through in a graded methanol series ending in 100% 
methanol, where they were incubated until sufficient background was removed. 
Embryos were then rehydrated through the methanol series ending in PBS, and 
transferred to 70% glycerol for photography. Embryos were washed in PBS and 
stored in pH 5.5 PBS containing 1 mM EDT A at 4 De in the dark. 
2.2.5.3 Western blotting 
2.2.5.3.1 Collection of tissue 
HH24 wild type embryonic tissue was isolated as sample material for initial technique 
development. Embryos were excised from the egg and placed in sterile ice cold PBS. 
The outer and inner membranes were quickly removed, and if necessary, assessment 
of morpholino uptake carried out under fluorescent light using a Zeiss Stemi SV11 
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microscope. Embryos were photographed where necessary and morpholino positive 
hearts isolated and snap frozen in liquid nitrogen prior to extraction of protein. 
2.2.5.3.2 Preparation of tissue Iysates 
Embryonic tissue was isolated and placed in approximately 5x volume of chilled RIPA 
buffer (containing 1 mM PMSF and protease inhibitor cocktail (Roche». Samples 
were immediately homogenised using a sterile needle (BO Microlance 25G 5/8) and 
syringe, and placed on ice for 30 minutes. Samples were centrifuged at maximum 
speed for 10 minutes and the supernatant removed and stored at -80°C prior to use. 
2.2.5.3.3 HeLa cell growth and Isolation 
Cells were grown and isolated by Sukrat Arya. Passage 8 HeLa cells were grown in 
20 ml complete media (Dulbecco's minimal essential media (DMEM) with 10% vlv 
foetal bovine serum and peninstrep). Media was discarded and dead cells removed 
by washing with PBS. A 2 ml volume of trypsin was spread gently around the flask 
and incubated at 37°C for 4 minutes to detach and round the cells. A volume of 18 
ml complete media was added to the cells, mixed, and centrifuged at 1500 rpm for 3 
minutes. The supernatant was discarded and cells were resuspended in 10 ml PBS 
prior to centrifugation at 1500 rpm for 3 minutes. The supernatant was discarded and 
the pellet stored on ice prior to immediate extraction of protein. 
2.2.5.3.4 Preparation of HeLa ceillysates 
HeLa cell pellets were dissolved in 300 IJI chilled RIPA buffer and placed on ice for 30 
minutes. Samples were mixed by flicking then subjected to two 5 - 10 minute freeze I 
thaw cycles at -80°C. Samples were centrifuged at 12000 rpm for 15 minutes, and 
the supernatant removed and stored at -80 DC. 
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2.2.5.3.5 Protein quantification 
Protein content was measured by Bradford assay using the Biorad protein assay kit, 
using a 50 ~ g g 1 ml - 1 mg 1 ml BSA standard curve. Absorbances were measured at 
750 nm on a Biorad SmartSpec ™ 3000 spectrophotometer. 
2.2.5.3.6505 PAGE and western blotting 
Samples were combined with 5x sample buffer and boiled for 10 minutes at 100°C 
prior to loading onto 5 - 20% SDS PAGE gradient gels (20 - 30 ~ g g total protein loaded 
per lane). Samples were electrophoresed using Atto apparatus alongside the 
Precision Plus Protein Standard (BioRad) at 100 V for approximately 90 minutes in 
electrophoresis buffer. Protein was transferred onto a Hybond C Extra nitrocellulose 
membrane (Amersham Biosciences) by a semi-dry blotting technique, using a transfer 
sandwich comprising gel and membrane, sandwiched between 2 layers of absorbent 
paper (Atto) soaked in transfer buffer on either side. Electroblotting was performed 
with Atto apparatus at 20 V for 2 hours. Following transfer, membranes were washed 
in deionised water and blocked in the appropriate agent overnight at 4 °C with gentle 
shaking. Membranes were subjected to three 10 minute washes in TBST, then 
incubated with primary antibody at the appropriate dilution for 1 hour at room 
temperature with gentle shaking. Membranes were again subjected to three 10 
minute washes in TBST, and then incubated with secondary antibody for 1 hour at 
room temperature with gentle shaking. Membranes were again subjected to three 
washes in TBST. Eel reactions were then performed using the Western Lightning 
Chemiluminescence Reagent Plus kit (PerkinElmer) for protein detection. 
2.2.5.3.7 Conditions tested for antibody optimisation 
For GAPDH detection, membranes were blocked with 5% milk powder in TBS and 
incubated with a mouse monoclonal antibody (ab8245, Abcam) at a dilution of 1 1 
1000. Rabbit anti-mouse HRP conjugated secondary antibody (P0260, Dako) was 
used at 1 11500, and a 36 kDa band successfully detected. 
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For TBX5 detection, a rabbit polyclonal antibody to TBX5 (ab49308, Abcam) was 
tested in 5% milk powder / PBS. Swine anti-rabbit HRP conjugated secondary 
antibody (P0217, Dako) was used at 1 /5000. A band of unexpected size (- 75 kDa, 
expected size 50 - 53 kDa) was detected. 
For detection of GATA-4, a rabbit polyclonal antibody to GATA-4 (ab25992, Abcam) 
was tested in two blocking agents - 5% milk powder / TBS, and 5% BSA I TBS. 
Swine anti-rabbit HRP conjugated secondary antibody (P0217, Dako) was tested at 1 
/1500. A very high level of background resulted in both cases and it was not possible 
to accurately distinguish any bands. 
For RBMS1 detection, membranes were blocked with 5% milk powder in TBS and 
incubated with a rabbit polyclonal antibody (ARP40428_ T1 00, Aviva Systems Biology) 
at a dilution of 1 / 100. Swine anti-rabbit HRP conjugated secondary antibody (P0217, 
Dako) was used at 1 I 1500. Antibodies were tested on HeLa cell lysate and chick 
tissue lysate. A band of unexpected size (- 120 kDa, expected size 46 kDa) was 
detected. 
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2.2.6 Morpholino knockdown 
2.2.6.1 Morpholino knockdown technology 
Morpholino knockdown is an antisense loss-of-function technology used widely in 
developmental studies. A morpholino oligomer is a synthetic DNA analogue usually 
consisting of around 25 subunits, with a morpholine moiety replacing the riboside 
moiety and phosphorodiamidate intersubunit linkages instead of phosphodiester 
linkages [Summerton and Weller, 1997]. These modifications confer stability to the 
oligomer, and cellular enzymatic degradation does not occur [Hudziak et aI., 1996]. 
Morpholinos have high affinity for RNA and do not elicit an immune response. They 
can be end-labelled with 3' carboxyfluorescein or lissamine (sulforhodamine B) for 
confirmation of uptake. 
Morpholinos function by two major gene targeting strategies. They can be designed 
to bind to the initiating AUG sequence (or in close proximity) in order to sterically 
blocking ribosomal binding and inhibit translation [Summerton and Weller, 1997]. 
Translational blocking morpholinos are most effective when designed within a 100 bp 
region between the 75 bp upstream and 25 bp downstream region of the initiating 
AUG. Morpholinos can also be designed to target nuclear processing and modify pre-
mRNA splicing through complementary binding to splice sites [Morcos, 2007]. 
Morpholinos have been utilised to study the effect of gene knockdown in cultured 
cells, and in the developing embryos of a number of organisms such as Xenopus 
[Falk et aI., 2007], zebrafish [Draper et aI., 2001], and chick [Voiculescu et aI., 2008]. 
They are particularly useful for temporal gene knockdown studies, where the role of a 
particular gene at specific stages of development can be elucidated. 
2.2.6.2 Identification of target regions for morpholino design 
Human homologues of genes of interest were identified on the NCBI database 
(http://www.ncbLnlm.nih.gov/) and their genomic location noted. Protein sequences 
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were blasted in the BBSRC ChickEST database (http://www.chick.manchester.ac.ukl). 
ESTs were then blasted in Ensembl (http://www.ensembl.org) against the chick 
genome in order to locate the corresponding chick gene, and viewed in a 
chromosomal contig view. Synteny of the chick genomic location against the 
expected human genomic region was confirmed. Translation software 
(http://expasy.orgftoolsf) was used to aid identification of the initiating ATG. ESTs 
around this region were aligned with the theoretical mRNA sequence for sequence 
confirmation using sequence alignment software (http://align.genome.jpf). The region 
75 base pairs upstream and 25 base pairs downstream of the initiating ATG was 
identified for morpholino design. Where it was not possible to design a morpholino to 
this region, morpholinos were designed to modify pre-mRNA splicing by targeting 
exon I intron boundaries (splice sites). These were predicted to result either in 
deletion of an exon and cause a frameshift and premature termination, or retention of 
an intron causing insertion of incorrect amino acids followed by a premature stop. 
2.2.6.3 Morpholino design and preparation 
Morpholino antisense oligonucleotides were designed to a 25 base pair region using 
the following guidelines: 40% - 60% GC content, maximum 36% G, maximum run of 3 
Gs, avoidance of G or A on 3' end where possible (http://www.genetools.com). 
Morpholinos had either 3' carboxyfluorescein or 3' lissamine end modifications for 
confirmation of uptake. Morpholinos were resuspended at 2 IJM in HBSS and stored 
at -20 ·C. 
2.2.6.4 Morpholino delivery 
Morpholinos are most commonly introduced into embryos by microinjection, and in the 
case of the chick, by electroporation [Kos et aI., 2003]. However, this method is not 
always effective for knockdown outside the central nervous system, particularly 
mesenchymal tissues [Kos et aI., 2003]. In recent years the use of F127 pluronic gel 
has been employed as an alternative method of morpholino delivery into the chick 
embryo [Ching et aI., 2005; Rutland et aI., 2009]. 
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F127 pluronic gel is a non-ionic co-polymer of polyethylene oxide and polypropylene 
oxide with thermosensitive properties. Upon reaching physiological temperatures it 
undergoes a liquid to gel phase transition, and in terms of in vivo application, this 
means it is injectable and will polymerise locally in situ i.e. it has potential uses as a 
vehicle for drug delivery. It has been tested in a number of biomedical applications 
such as the local delivery of an anti-tumour agent into mice [Yang et aI., 2009], ocular 
delivery of ophthalmic agents [EI-Kamel, 2002; Miyazaki et aI., 2001], and in vaccine 
delivery systems [Coeshott et aI., 2004]. It has also been used for local application of 
antisense phosphorothioate oligodeoxynucleotides into major blood vessels in vivo for 
loss of function studies [Abe et aI., 1994; Castier et aI., 1998; Herbert et aI., 1997]. 
For gene knockdown in the developing chick, pluronic gel can be combined with 
morpholino antisense oligonucleotides and applied directly onto the embryo where it 
undergoes gelation, facilitating morpholino entry into the embryo. This is the method 
of choice for this study. 
2.2.6.5 Application of morpholino via F127 pluronic gel to embryos in ovo 
Eggs were opened as described previously and embryo ages assessed. Prior to use, 
morpholinos were heated to 65°C for 5 minutes, incubated on ice, and combined with 
HBSS and F127 pluronic gel (BASF) at a final concentration of 15%, for a final 
morpholino concentration of 250 J,JM or 500 J,JM. In the case of double knockdown, 
morpholinos were combined at this stage, each at a final concentration of 250 J,JM. A 
7 J,JI volume of morpholino I F127 pluronic gel mix was pipetted directly onto the chick 
(usually at HH12 - HH16). Eggs were sealed using tape and incubated at 37°C until 
the required stage of development was reached. 
93 
Identification of downstream targets ofTBX5 and GAT A-4 in the mouse P1 g cell line 
2.2.7 Phenotypic analysis of embryos 
2.2.7.1 Embryo isolation and processing 
Chick embryos were excised from the egg, placed in PBS, and the outer and inner 
membranes carefully removed to avoid damage to the embryo. Morpholino uptake 
was assessed under fluorescent light, and embryos photographed where appropriate 
at 1.6x and 4.0x zoom using a Zeiss Stemi SV11 microscope. Embryos were 
incubated in 4% PFA at room temperature for 90 mins, and stored at 4 °C in PBS for 
up to 1 week. Embryos were dehydrated by 2x 15 minute incubations in each of the 
following; dH20, 75% ethanol, 95% ethanol, 100% ethanol, and xylene (room 
temperature). A final 50% xylene I 50% wax incubation was carried out at 65°C 
before transfer into wax at 65 °C overnight. 
2.2.7.2 Embedding and sectioning 
Embryos were correctly positioned and left to set at room temperature overnight. 
Embryos were sectioned in a coronal orientation at 10 microns using a Leica DSC1 
microtome. Sections were floated in a heated water bath (40°C) and mounted onto 
glass slides. Slides were air-dried overnight at room temperature. 
2.2.7.3 Haemulum staining and mounting of slides 
Sections were de-waxed and rehydrated by 5 minute incubations in the following: 
100% xylene x 2, 100% ethanol x 2,95% ethanol, 75% ethanol, 50% ethanol, dH20. 
Excess water was blotted away before incubation in Mayer's Haemulum (Raymond A 
Lamb) for 3 minutes. Slides were washed then dehydrated by 5 minute incubations in 
the following: dH20, H20, dH20, 50% ethanol, 75% ethanol, 95% ethanol, 100% 
ethanol, 100% xylene. Slides were removed from xylene, mounted with DPX (Bios 
Europe) and allowed to dry overnight before photography. 
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2.2.7.4 Photography and analysis 
Sections were photographed at 2.5x and 5.0x magnification under a Zeiss Axioscope 
40 microscope connected to a Macintosh computer and Open Lab software 
(PerkinElmer, UK). 
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CHAPTER 3 
IDENTIFICATION OF DOWNSTREAM TARGETS OF TBX5 and 
GATA-4IN THE MOUSE P19 CELL LINE 
3.1 AIMS 
This chapter aims to use the P19 study as a basis for further research into the 
combined targets of TBX5 and GAT A-4 as follows: 
a) Validation of previous microarray data by QPCR 
b) Selection of genes for further study based on expression data and review of 
current literature 
c) Bioinformatic analysis of candidate gene promoter regions for identification of 
evolutionarily conserved TBX5 and GATA-4 binding sites 
d) luciferase reporter assays to test promoter activation of one or more genes 
by TBX5 and GAT A-4 
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3.2 RESULTS 
3.2.1 QPCR validation of microarray data 
Genome-wide microarray expression analyses allow identification of a large number 
of targets which display differential regulation. These results are often variable, and 
validation by an independent method with greater sensitivity is necessary. QPCR is 
one of the most precise methods of expression quantification available, and was used 
to confirm and more accurately quantify previous microarray gene expression data. 
QPCR validation experiments were performed in collaboration with Jonathan 
Ronksley. 
3.2.1.1 Assay design 
QPCR assays were designed by Jonathan Ronksley using the online Roche Universal 
ProbeLibrary assay design centre (https:/Iwww.roche-applied-science.com). Assays 
spanned a 60 - 100 bp region including an exon-exon boundary where possible, and 
were used with an annealing temperature of 60°C. Primer sequences and assay 
information are given in Appendix B. These primers were used for RT -PCR 
amplification to confirm products sizes and single product amplification prior to QPCR, 
using cDNA from wild type (day 0 and 7) and overexpression cell lines (day 0) (not 
shown). 
3.2.1.2 Selection of endogenous controls 
Selection of an appropriate endogenous control gene for normalisation is crucial and 
allows correction of any skewing of data arising from small differences in starting 
quantity of total nucleic acid. The endogenous control must be expressed at the same 
time as the target gene, and display uniform expression across all samples i.e. 
expression should not be affected by sample treatments. A total of six genes were 
selected for assessment of their suitability as controls, based on stable expression in 
the original microarray study - j3-tubulin, non-POU-domain containing I nono, 
97 
Identification of downstream targets ofTBX5 and GATA-4 in the mouse P19 cell line 
ribosomal protein L 13a I rpl13a, bolA-like 2 I bola2, dynactin, and transmembrane 
protein 131/tmem131. 
3.2.1.2.1 Analysis of endogenous control variation across study samples 
In order to determine suitability of the above genes as endogenous controls, their 
expression across all study samples was measured for assessment of variability. 
Real time reactions were performed in triplicate, and relative expression was 
measured against undifferentiated P19 wild type cells. Baseline and threshold values 
were set manually. Fold change in expression was calculated using the following 
equation: 
R = 2-IACt sample - ACt control) 
= 2-MCt 
R = relative expression, !lCt: Ct difference between samples, control = wild type day 0 
sample, sample = overexpression cell line day 0 or wild type sample at day 2,5 or 7. 
Expression results are shown in Table 3.1. Variation between samples was assessed 
by calculation of the range of variation (maximum value - minimum value), and the 
coefficient of variation was also calculated. Tmem131 displayed the smallest range of 
variation between samples (0.36), and also the smallest coefficient of variation across 
experimental samples (0.18). 
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Table 3.1 Relative expression of six candidate endogenous control genes in study samples 
Relative expression 
P-tubulin nono rpl13a bola2 dynactin tmem131 
G10 0.79 1.01 1.05 0.75 0.82 0.71 
G22 0.95 1.19 1.03 1.21 1.30 1.07 
WT Day2 0.98 1.32 0.96 0.94 1.09 0.86 
WT Day5 0.67 0.83 0.84 0.64 0.81 0.74 
WT Day7 0.59 0.84 0.64 0.61 0.76 0.77 
i 
Range of variation 0.39 0.49 0.41 0.6 0.54 0.36 I 
Coefficient of variation 0.21 0.22 0.19 0.30 0.24 0.18 I 
Expression of six candidate endogenous control genes was measured in G10 and G22 overexpression cell lines, and wild type differentiating P19 cells at 
days 2, 5 and 7, measured against undifferentiated P19 cells (day 0). 
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3.2.1_2.2 Test normalisation using short-listed endogenous control genes 
Tmem131 and dynactin were used for test normalisation of a-I-fucosidase, which was 
up-regulated in microarray analysis of the two overexpression cell lines. Relative 
expression values are shown in Table 3.2. The two controls gave almost identical 
results and confirmed up-regulation of alpha-I-fucosidase. Tmem131 was selected for 
use as the endogenous control as this gene previously displayed the lowest range of 
variation and coefficient of variation across experimental samples (Table 3.1). 
Table 3.2 Relative expression of FUCA1 when normalised against candidate 
endogenous control genes tmem131 and dynactin 
Relative expression of FUCA1 
Sample Normalisation with trnem131 Normalisation with dynactin 
G10 day 0 1.627 1.625 
G22 day 0 1.131 1.094 
Expression of alpha-I-fucosidase (up-regulated in the microarray study) was 
measured in G10 and G22 overexpression cell lines against undifferentiated P19 cells 
(day 0), normalised to both tmem131 and dynactin. The two controls gave highly 
similar results. 
3.2.1.3 Analysis of target and control gene amplification efficiency 
The maximum PCR efficiency of a reaction (E) is 2, if every single template is 
replicated in each cycle [Pfaffi, 2001]. Target and control genes should ideally show 
similar amplification efficiency, but data can be corrected for differences in assay 
efficiency by prior calculation of these values. Real-time PCR efficiencies for each 
gene were calculated from the exponential phase of the slope in the SDS v1.3.1 
software, using the equation E = 10 [-1/stope1• Reactions were performed in duplicate 
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using a 5-point 10-fold dilution series of P19 wild type day 0 cDNA (1, 0.1, 0.01, 
0.001, and 0.0001). Assay properties are shown in Table 3.3. A value of -3.33 
corresponds to an assay efficiency of 100%, and generally -3.2 to -3.6 is considered 
acceptable. However, as expression quantifications will be corrected for peR 
efficiency (see section 3.2.1.4), assays with efficiency outside this range are also 
usable. Linearity values ~ 0 . 9 9 9 are desirable, and assays to all genes with the 
exception of RBMS1 met this. 
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Table 3.3 Target and endogenous control real time assay linearity and efficiency 
Gene Linearity (R2) Slope Efficiency (E) 
PETA-3 0.995 - 4.01 1.78 
RBMS1 0.986 - 3.03 1.89 
VegfB 0.992 - 3.62 1.89 
Annexin A4 0.994 - 3.37 1.98 
Tropomyosin 0.998 - 3.29 2.01 
Gamma-filamin 0.997 - 3.62 1.89 
mRbap46 0.998 - 3.53 1.92 
PMM2 0.997 - 3.42 1.96 
Neurofilament 3 0.998 -5 1.58 
Glutaredoxin 0.997 - 3.27 2.02 
HNRPDL 0.991 - 3.27 2.02 
Erp57 0.994 - 3.42 1.97 
PA2.26 0.998 -3.42 1.90 
a-I-fucosidase 0.995 - 4.22 1.72 
Fibronectin 0.997 - 3.51 1.93 
a-2-macroglobulin 0.997 - 3.78 1.84 
Calreticulin 0.998 - 3.72 1.85 
Ap4e1 0.996 - 3.34 2 
S100A10 0.996 - 3.74 1.85 
Tmem131 0.992 - 3.83 1.82 
Standard curves were constructed for all target and control genes using cDNA from 
P19 wild type undifferentiated cells. Reactions were performed in duplicate at five 
serial dilutions of P19 wild type day 0 cDNA (1, 0.1,0.01,0.001, and 0.0001). 
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3.2.1.4 Expression analysis 
Quantitative PCR reactions were performed in triplicate on cDNA reverse transcribed 
from RNA used in the initial microarray analysis. For correction of expression 
quantifications to take into account PCR efficiency (E), the equation R = 2·MCt was 
modified to the equation below: 
(E ) .aCt target (control - sample) target 
R= 
(Ereference) .aCt ref (control- sample) 
R = relative expression, E = efficiency of QPCR assay, ~ C t : : Ct difference between 
samples, target = gene of interest, reference = endogenous control gene, control = 
wild type day 0 sample, sample = overexpression cell line at day 0 I wild type sample 
at day 2,5 or7. 
Expression data is represented in Table 3.4 and Figures 3.1 and 3.2. Figure 3.1 
shows relative expression of 18 genes of interest in the two TBX5 I GATA-4 
overexpression cell lines at day 0 of differentiation, displayed as log2 fold change. A 
number of genes displayed average up-regulation of 2-fold or greater including 
S100A10, glutaredoxin, v-filamin, RBMS1, PETA-3, PA2.26, neurofilament 3, and a-
tropomyosin. 
Figure 3.2 displays expression profiles of the 18 genes of interest in wild type 
differentiating P19 cells, represented as log2 fold change. As mentioned previously, 
wild type TBX5 and GAT A-4 expression in differentiating P19 cells is switched on at 
day 2 and day 0 of differentiation respectively, and shows a massive increase over 
days 5 and 7. A number of genes followed the same pattern of expression including 
glutaredoxin, V-filamin, RBMS 1, PET A-3, a-tropomyosin, calreticulin, erp57, and 
annexin A4. 
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Table 3.4 Relative expression of candidate genes in TBX5 I GATA4 
overexpression cell lines and wild type differentiating wild type cells, measured 
by QPCR 
Fold change 
Overexpression cell lines Wild type 
Gene G10 G22 G10/G22 WT WT WT day 0 day 0 average day 2 day 5 day7 
S100A10 3.74 3.18 3.46 4.40 1.87 2.75 
Glutaredoxin 2.45 2.75 2.60 1.75 5.94 11.6 
Gamma 3.85 4.06 3.96 1.50 6.11 9.89 filamin 
RBMS1 3.22 2.71 2.97 9.29 9.66 13.2 
PETA-3 3.76 3.23 3.50 0.94 1.84 2.25 
PA2.26 3.57 2.34 2.96 0.68 0.43 0.58 
Neurofilament 2.48 3.37 2.93 5.19 0.17 2.60 
Tropomyosin 1 3.32 1.40 2.36 1.37 3.11 10.5 
AP4e1 1.65 1.47 1.56 1.65 1.12 1.57 
Fibronectin 1.64 1.61 1.63 34.7 18.9 34.2 
a-I-fucosidase 1.40 1.39 1.40 1.97 1.92 3.64 
Mrbpa46 1.84 1.61 1.73 1.39 1.60 1.49 
Calreticulin 1.26 1.47 1.37 1.08 1.59 1.99 
Erp57 1.01 1.33 1.17 0.85 0.92 1.42 
Pmm2 1.06 1.23 1.15 1.20 0.85 1.44 
Hnrpdl 0.72 0.83 0.78 0.63 0.54 1.13 
Vegfb 0.43 0.55 0.49 0.53 0.50 0.42 
Annexin A4 0.85 0.55 0.70 0.51 0.74 1.23 
QPCR analysis of candidate genes was carried out in TBX5 I GAT A-4 overexpression 
cell lines G10 and G22, and P19 wild type cells at days 2,5 and 7, measured against 
undifferentiated wild type P19 cells. Data was normalised against tmem131 and 
corrected for real time assay efficiencies. 
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Figure 3.1 Relative expression of candidate genes in TBX51 GAT A4 overexpression cell lines G10 and G20 
QPCR analysis of candidate genes was carried out in overexpression cell line G10 and G22 at day 0, measured against wild type P19 cells on day O. 
Expression is represented as log2 fold change , and error bars represent standard deviation . Data was corrected for real time assay efficiencies and 
normalised against tmem131 . 
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Figure 3.2 Relative expression of candidate genes in wild type differentiating wild type cells 
QPCR analysis of cand idate genes was carried out in P19 wild type cells at days 2, 5 and 7, measured against wild type P19 cells on day o. Expression is 
represented as log2 fold change, and error bars represent standard deviation . Data was corrected for real time assay efficiencies and normalised aga inst 
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3.2.2 Selection of genes for further study 
Genes displaying the highest fold increases in expression in the overexpression cell 
lines. and following the same pattern of expression as TBX5 and GATA-4, were 
selected for further analysis. These included TPM1, PETA-3, PA2.26, RBMS1, 
FUCA 1, and FN. y-Filamin was also of interest, but a future aim of this research was 
to study these genes further in the chick embryo, and a chick homologue of this gene 
does not exist. Thus this gene was eliminated from further study. 
3.2.2.1 Relative expression of candidate genes in TBX5 I GATA-4 
overexpression cell lines 
Of the genes selected for further validation, following the overexpression of TBX5 and 
GATA-4, a mean increase in expression ranging from 1.4-fold to 3.5 fold was 
observed. PETA-3, a member of the tetraspan superfamily of membrane proteins, 
was up-regulated 3.5-fold. The transcription factor RBMS 1, and the small 
transmembrane glycoprotein PA2.26, displayed an average increase of 3-fold in the 
two overexpression cell lines. a-tropomyosin, a coiled actin-binding protein and 
component of the sarcomere, showed an average 2.4-fold increase, and the 
exoglycosidase enzyme a-L-fucosidase displayed a 1.4-fold increase in expression. 
Fibronectin, an adhesive extracellular matrix (ECM) glycoprotein, displayed 1.6-fold 
up-regUlation of expression in both overexpression cell lines. 
3.2.2.2 Relative expression of candidate genes In wild type differentiating P19 
cells 
QPCR expression analysis of TBX5 and GAT A-4 was performed previously by 
Jonathan Ronksley, and expression of both increased during cardiomyocyte 
differentiation, with massive up-regUlation on days 5 and 7 [Ronksley, 2007]. RBMS1, 
PETA-3, a-tropomyosin and a-L-fucosidase mirrored the expression pattern of TBX5 
and GATA-4, with up to 13-fold increases in expression by day 7. The expression 
pattern of PA2.26 and fibronectin diverged slightly, and an increase from day 2 to day 
7 was not apparent. 
107 
Study of candidate genes in the embryonic chick 
3.2.3 Candidate genes 
The candidate genes TPM1, PETA-3, PA2.26, RBMS1, FUCA1, and FN were chosen 
for further study of their function during cardiac development. An additional gene 
(DES), encoding the sarcomeric filament protein desmin, was added to the study. 
This was based on a similar microarray study carried out by Dr Lynn Amy (a former 
Post-Doctoral researcher in the lab), where TBX5 and GATA-4 were transiently 
overexpressed in the P19 cell line and desmin was identified as a potential target. 
3.2.3.1 TPM1 
TPM1 belongs to the tropomyosin gene family and encodes a-tropomyosin, a dimeric 
a-helical coiled actin-binding protein. It is a contractile component of the sarcomeric 
thin filament, crucial for myocardial function [Perry, 2001]. The tropomyosins are 
expressed predominantly in skeletal, smooth, and cardiac muscle, and at lower levels 
in non-muscle cytoskeletal and actin associated cells [Pittenger et aI., 1994]. Familial 
dilated and hypertrophic cardiomyopathy have been linked to mutations in TPM1 
[Lakdawala et aI., ; Thierfelder et aI., 1994]. E40K and E54K mutations in TPM1 
cause dilated cardiomyopathy due to decreased sensitivity to Ca2+ [Mirza et aI., 2007]. 
TPM1 null mice do not survive past E11.5, whilst heterozygous mice are viable and 
fertile [Rethinasamy et aI., 1998]. 
3.2.3.2 Fibronectin 
Fibronectin (discussed in section 1.6.5) is an ECM glycoprotein expressed in the 
myocardium, endocardium, and foregut [Waterman and Balian, 1980], and also in the 
cardiac jelly, with expression highest in regions adjacent to the myocardium where 
endocardial cushion cell migration occurs [Ffrench-Constant and Hynes, 1988]. There 
is evidence of a role for fibronectin in endocardial cell migration [Icardo et aI., 1992]. 
Fibronectin null homozygous embryos display abnormalities such as a shortened 
anterior-posterior axes, and defects in the neural tube, heart, embryonic vessels and 
mesoderm derived tissues become apparent at E7.5 - E8.0, worsening as 
development proceeds and eventually leading to embryonic lethality [George et aI., 
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1993]. Heart development defects occur, with heart primordia remaining unfused. 
Less severely affected embryos have fused primordia with abnormal morphology. 
Myocardial tissue thickening, a deficiency in cardiac jelly, and abnormal endocardium 
morphology has also been observed. 
3.2.3.3 Desmin 
Desmin is a sarcomeric type III intermediate filament protein which associates with Z-
discs and connects myofibrils to one another and to the plasma membrane. It has an 
important contractile role in cardiac, skeletal and smooth muscle. Mouse knockout of 
desmin results in cardiomyopathy, and heart tissue from these animals displays 
abnormally shaped and distributed mitochondria [Thornell et aI., 1997]. Disturbances 
in cardiac conduction in desmin null mice have also been observed [Schrickel et al.]. 
A range of mutations in the desmin gene have been associated with familial cardiac 
and skeletal myopathy [Bergman et aI., 2007; Fidzianska et aI., 2005; Goldfarb et aI., 
1998; Goudeau et aI., 2001; Olive et aI., 2007; Sung et aI., ; Taylor et aI., 2007; 
Vernengo et aI., ; Vrabie et aI., 2005]. Features of this disease include atrial dilation, 
cardiac arrhythmia, conduction block, and sudden death due to conduction defects 
[Vernengo et al.]. 
3.2.3.4 PET A-3 
Platelet endothelial tetraspan antigen-3 or PET A-3 is a member of the transmembrane 
4 or tetraspan superfamily of membrane proteins, which strongly associate with 
laminin binding integrins such as a 3 ~ 1 , , and other tetraspans (e.g. CD9 or CD63). 
PETA-3 is thought to have a role in cell-cell adhesion, cell migration, platelet 
adhesion, and angiogenesis [Wright et aI., 2004]. PETA-3 expression is observed in 
the endothelium and epithelium, Schwann and dendritic cells, megakaryocytes, 
platelets, and in skeletal, smooth and cardiac muscle [Sincock et aI., 1997]. In cardiac 
muscle, PETA-3 expression is seen (at high levels) in the sarcolemma of muscle cells 
and capillary endothelium [Sincock et aI., 1997]. The phenotype of PET A-3 null mice 
has been characterised in three separate studies. The first study described PET A-3 
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null mice as viable, healthy and fertile, but displaying defects in haemostasis with 
extended bleeding times and greater blood loss [Wright et aI., 2004]. A separate 
study examining the role of PETA-3 in angiogenesis additionally revealed PETA-3 null 
mice do not display defects in vasculature during normal development [Takeda et aI., 
2007]. However, alternative in vivo and in vitro assays did show an effect as a result 
of mouse gene knockout, with changes in adhesion, spreading and invasion, all of 
which are important processes in angiogenesis [Takeda et aI., 2007]. Nonsense 
mutations in the human PET A-3 gene have been associated with kidney failure, and a 
third study of PET A-3 knockout mice revealed that with age, these mice developed a 
similar pathological state to that seen in human patients: knockout mice displayed 
proteinuria due to focal glomerulosclerosis, glomerular basement membrane 
disorganisation, and tubular cystic dilation [Sachs et aI., 2006]. 
3.2.3.5 P A2.26 
PA2.26 is a small 172 amino acid transmembrane glycoprotein originally identified as 
a cell surface antigen, that is expressed in skeletal muscle, heart, lung and placental 
tissue [Martin-Villar et aI., 2005]. Its function has been studied by transfection of 
PA2.26 into immortalised keratinocytes that do not express the protein [Scholl et aI., 
1999]. These cells displayed differences in cell-cell adhesion, and actin cytoskeletal 
reorganisation, altering the cell morphology from epithelial to fibroblastoid, indicating 
PA2.26 plays a role in cell migration. A specific role for PA2.26 in the heart has not 
yet been demonstrated. As a protein involved in the extracellular matrix, it may be 
involved in cardiac remodelling. 
3.2.3.6 FUCA1 
Alpha-L-fucosidases are exoglycosidases that are involved in fucosylated 
glycoconjugate processing (they catalyse terminal L-fucose residue removal), and 
also possess transglycosylation properties [Intra et aI., 2006]. These enzymes are 
involved in inflammation, cancer development, cystic fibrosis, and lysosomal storage 
disease [Intra et aI., 2006]. 
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3.2.3.7 RBMS1 
RBMS1 is a multifunctional gene involved in transcriptional regulation, activation of 
DNA replication, cell cycle regulation, and apoptosis. The human RBMS1 gene gives 
rise to multiple splice variants encoding proteins of approximately 400 amino acids 
[Takai et ai., 1994]. RBMS1 contains two ribonucleoprotein consensus sequences, 
each containing an RNA-binding protein consensus motif (RNP1-A and RNP1-B). 
which are essential to its function [Dreyfuss et ai., 1988]. RBMS1, via its RNP 
domains, interacts with the N-terminal region of a catalytic subunit of DNA polymerase 
a, stimulating its polymerase activity [Niki et ai., 2000a]. RBMS1, via these domains, 
also binds to the c-myc protein which has important functions in cell cycle regulation, 
cell transformation, and apoptosis [Niki et ai., 2000b]. RBMS1 transcriptionally 
regulates a number of genes including a-smooth muscle actin [Kimura et ai., 1998] 
(discussed in Chapter 5), MHC Class I and II genes [Balducci-Silano et ai., 1998], and 
the thyrotropin receptor [Shimura et aI., 1995]. RBMS 1 expression has been studied 
by northern blot analysis in the adult mouse, where expression was detected in all 
tissues examined except testis [Fujimoto et aI., 2000]. A more detailed spatial 
analysis of expression has not been performed. Expression of RBMS1 is induced by 
mitogens such as serum [Fujimoto et ai., 2001]. Rbms1-1· mice once born appear 
healthy but display an atypical Mendelian ratio i.e. disruption of this gene results in 
embryonic lethality in some homozygous mice [Fujimoto et ai., 2001]. RBMS1 
knockout embryos display growth and developmental abnormalities at E2.5 when 
cultured in vitro for 5 days, and female adult mice show a reduced progesterone 
concentration. These findings together account for the embryonic lethality observed. 
It is not clear whether cardiac defects occur in these mice. RBMS1 suppresses 
transcription of a-smooth muscle actin, which is important in myofibrillogenesis, via 
cis-elements in its promoter region [Kimura et ai., 1998]. This could indicate a 
potential regulatory role for RBMS1 in the heart. 
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3.2.4 Bioinformatic identification of conserved TBX5 and GATA·4 binding sites 
within putative targets 
In order to identify evolutionarily conserved transcription factor binding sites in genes 
of interest, multi-species sequence alignments were performed using online Mulan 
software (http://mulan.dcode.org/).This software allows detection of evolutionarily 
conserved regions (ECRs) and specific consensus sequences within them 
[Ovcharenko et aI., 2005]. Full genomic sequences of candidate genes plus 10 kb 
upstream from the first exon and 10 kb downstream from the last exon, were manually 
exported from the Ensembl database (www.ensembl.org) and input into Mulan. TBX5 
binds to the consensus sequence [AlGIT]GGTG[T/C][CITIG][AlG] [Ghosh et aI., 2001] 
and GATA-4 to the consensus sequence [A/T]GATA[AlG] [Plumb et aI., 1989]. The 
search input sequences DGGTGYBR and WGATAR were used in accordance with 
IUPAC-IUB codes for nucleic acid bases (Appendix C). 
Jonathan Ronksley previously performed similar analyses between human and mouse 
and found multiple binding sites for both TBX5 and GAT A-4 in all of the genes 
examined, with RBMS1 displaying the highest number of conserved consensus 
binding sites for TBX5 and GATA-4 [Ronksley, 2007]. In the next chapter of this 
thesis, candidate genes will be studied in the developing chick embryo, including 
assessment of their responsiveness to TBX5 and GATA4. In light of this, alignments 
have been performed between chicken and human sequences in addition to mouse 
and human sequences, for identification of regions conserved between all three 
species. 
Figure 3.3i-vii displays Mulan analysis results for the seven genes of interest. No 
multi-species conserved consensus binding sites for either TBX5 or GATA-4 were 
identified upon analYSis of the PA2.26, PETA-3 and FUCA1 genes (Figures 3.3i, 3.3ii 
and 3.3iii). Analysis of the TPM1 gene revealed two conserved binding sites for 
TBX5, and one for GATA4, all within the coding region (Figure 3.3iv). Figure 3.3v 
shows Mulan analysis of the DES gene. Two conserved TBX5 consensus binding 
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sites were identified the coding region, and no GATA-4 sites were found. Figure 3.4vi 
shows analysis of the FN gene. Three conserved sites for both GATA-4 and TBX5 
were identified, all within the coding region. RBMS1 analysis resulted in identification 
of three putative binding sites for TBX5 (all within the coding region), and four GATA-4 
sites were identified, two in the coding region, and two in the 3' UTR (Figure 3.3vii). 
Of the genes studied, RBMS1 displayed the highest number of multi-species 
conserved putative binding sites for both TBX5 and GAT A-4. 
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Figure 3.3i Mulan analysis of the PA2.26 gene in human, mouse and chicken 
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Figure 3.3iii Mulan analysis of the FUCA-1 gene in human, mouse and chicken 
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Figure 3.3iv Mulan analysis of the TPM1 gene in human, mouse and chicken 
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Figure 3.3v Mulan analysis of the desmin gene in human, mouse and chicken 
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Figure 3.3vi Mulan analysis of the fibronectin gene in human, mouse and 
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Figure 3.3vii Mulan analysis of the RBMS1 gene in human, mouse and chicken 
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Figure 3.3i-vii Mulan analysis of candidate genes in human, mouse and chicken 
Alignment of full length genes (marked by blue arrows) plus 10 kb upstream and 
downstream (marked by yellow lines) in human, mouse and chicken was performed 
for identification of consensus TBX5 and GATA-4 binding sites using the transcription 
factor binding site identification tool in Mulan software (http://mulan .dcode.org/). 
Evolutionarily conserved regions with ~ ~ 50% homology between species are plotted , 
and regions meeting the input criteria (100 nucleotide run, minimum 70% identity) are 
indicated by the red rectangles on top of each plot. The lower scales represent mouse 
I human sequence alignment, and the upper scales represent chicken I human 
sequence alignment. Consensus sites conserved between all three species are 
represented by vertical red or purple dashes for TBX5 or GATA-4 respectively, and 
have been boxed. Genes analysed are PA2.26 (i), PETA-3 (ii), FUCA1 (iii), TPM1 (iv), 
DES (v), FN (vi), and RBMS1 (vii). No conserved consensus binding sites were 
identified for either TBX5 or GATA-4 in PA2.26, PETA-3 or FUCA 1. Two conserved 
binding sites for TBX5 and one for GAT A-4 were identified within the coding region of 
TPM1 . Two conserved TBX5 consensus binding sites were identified the coding 
region, and no GAT A-4 sites were found in the DES gene. In the FN gene, three 
conserved sites for both GAT A4 and TBX5 were identified, all within the coding region. 
RBMS1 analysis resulted in identification of three putative binding sites for TBX5 (all 
within the coding region), and four GATA-4 sites were identified, two in the coding 
region , and two in the 3' UTR. 
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3.2.5 Cloning of RBMS1 fragments for functional analysis of evolutionarily 
conserved regions (ECRs) In RBMS1 
Whilst bioinformatic analysis is a useful tool for identifying conserved consensus 
transcription factor binding sites, the functional significance of these regions needs to 
be confirmed experimentally. Luciferase reporter studies are useful for measuring 
promoter response in cells. RBMS1 was selected for further study based on its high 
number of conserved putative binding sites and the fact that this is a novel gene in 
terms of a cardiac function. 
3.2.5.1 Identification of regions of the RBMS1 gene for further study 
In order to assess transcriptional activation of RBMS1 by TBX5 and GATA-4, 
luciferase reporter studies were carried out on regions of interest in the mouse 
promoter. For this purpose Mulan alignment between human and mouse sequences 
only was performed and is displayed in Figure 3.4. Conserved regions containing 
putative binding sites for both TBX5 and GATA-4 were identified across the gene. 
Three regions of particular interest are boxed. The first region of interest is the main 
promoter region of the 5' UTR, containing single conserved TBX5 and GAT A-4 sites 4 
kb - 5kb upstream from the ATG translational start site. The transcriptional start site 
of this gene has not been determined (this was attempted in the next section, see 
3.3.5.2). Another conserved region of approximately 1 kb was identified within intron 
1, found to contain single putative sites for both TBX5 and GATA-4 within 100 bp of 
one another. Both sites are conserved between the human and mouse, and the TBX5 
site is also conserved with the chick. The high degree of conservation of this non-
coding region indicates this may serve as an enhancer or repressor element. A third 3 
kb region was identified within the 3' UTR, containing one putative binding site for 
TBX5 and multiple conserved GAT A-4 sites, three of which are also present in the 
chicken sequence. 
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Figure 3.4 Mulan analysis of the RBMS1 gene in human and mouse 
Alignment of the full RBMS1 gene plus 10 kb upstream and downstream in human 
and mouse was performed for identification of consensus TBX5 and GAT A-4 binding 
sites using the online Mulan transcription factor binding site identification tool 
(http://mulan.dcode.org/). Evolutionarily conserved regions with ~ ~ 50% homology 
between species are plotted. Conserved consensus sites are represented by vertical 
red or purple dashes for TBX5 or GATA-4 respectively. Multiple conserved GATA-4 
and TBX5 sites were identified throughout the gene. Regions of interest in the 5' 
UTR, intron 1, and in the 3' UTR are boxed. 
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3.2.5.2 Primer design and peR amplification 
In order to assess the regulatory activity of regions of interest, they needed to be peR 
amplified and cloned into suitable reporter vectors. peR reactions were carried out 
using PfuU/tra II Fusion HS DNA polymerase, a proof-reading enzyme that requires 
dramatically shortened extension times and is therefore ideal for accurate 
amplification of long targets. Initially, two primer pairs were designed to each region 
(sequences in Table 2.2), and peR amplification attempted with all four primer 
combinations. The intron 1 region was successfully amplified with all primer 
combinations, and the fragment selected for cloning is displayed in Figure 3.5. peR 
of the 5' and 3' UTR regions resulted either in no amplification, or amplification of 
multiple bands. 
The large size of the 5' UTR region (4.6 kb from the GATA-4 site to the initiating ATG) 
may have contributed to the difficulties in its amplification, and could also pose 
problems in subsequent cloning. For study of this region as a promoter the 
transcriptional start site (but not the translational start site) needs to be included. Two 
strategies were employed in order to minimise the size of this region; mouse EST 
searches were carried out to identify the transcribed region, and determination of the 
transcriptional start site was attempted using a number of online prediction tools. One 
matching EST was found extending 690 bp 5' of the ATG translational start site 
(GenBank Accession 10: BP765823). Transcription start site identification tools all 
gave differing results, so this data was not taken into account. An additional two 
primer pairs were designed to the shortened region (4 kb) and multiple combinations 
tested for peR amplification under various conditions. This again resulted either in 
no amplification, or amplification of multiple bands. 
The 3' UTR region contains long runs of adenine nucleotides which can cause DNA 
polymerase slippage, resulting in difficulties in peR amplification. An additional two 
primer pairs were designed and multiple combinations tested for peR amplification, 
again without success. 
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Figure 3.5 peR amplification of the conserved region within intron 1 of RBMS1 
PCR reactions were electrophoresed on 2% agarose gels using 1 kb+ DNA ladder 
(Invitrogen) as a size marker. Negative PCR controls (where water was added in place of 
template) were included. 
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3.2.5.3 Destination vectors 
The intron 1 fragment was cloned into two destination vectors for assessment of its 
activity as a regulatory element and the individual and combined effects of TBX5 and 
GATA-4. 
3.2.5.3.1 pGL3-Basic vector with ANF minimal promoter 
The pGL3-Basic vector contains the luciferase gene but lacks upstream promoter or 
enhancer sequences, which means that luciferase expression depends on the 
insertion of a functional promoter. The human ANF minimal promoter (70 bp) was 
previously cloned into the Kpnl site of this vector by Dr Tushar Ghosh, who kindly 
provided this for use as a destination vector in this study. The ANF promoter displays 
basal promoter activity which means this is a sensitive system and allows detection of 
discrete changes in activation. The intron 1 fragment was cloned into the Sac I site of 
the multiple cloning region of this vector, and is represented in Figure 3.6. 
3.2.5.3.2 pGL3-Promoter vector 
The pGL3-Promoter vector contains an SV40 promoter upstream of the luciferase 
gene, and regions of DNA containing putative enhancer elements can be inserted 
upstream or downstream of this unit. The SV40 promoter displays strong activity and 
has advantages when quantifying large changes in activation. The intronic fragment 
was cloned into the Sacl site of the multiple cloning region of this vector, and is 
displayed in Figure 3.7. 
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Figure 3.6 pGL3-Basic Vector circle map and schematic displaying position of 
inserts 
The pGL3-8asic vector contains the luciferase gene but lacks upstream promoter or 
enhancer sequences, which means that luciferase expression depends on the 
insertion of a functional promoter. The human ANF minimal promoter (70 bp) was 
previously cloned into the Kpnl site of this vector by Dr Tushar Ghosh, and this was 
kindly provided for use as a destination vector in this study. The intron 1 fragment 
was cloned into the Sac I site of the multiple cloning region of this vector. 
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Figure 3.7 pGL3·Promoter Vector circle map and schematic displaying position 
of insert 
The pGL3-Promoter vector contains an SV40 promoter upstream of the luciferase 
gene, and regions of DNA containing putative enhancer elements can be inserted 
upstream or downstream of this unit. The intronic fragment was cloned into the Sacl 
site of the multiple cloning region of this vector. 
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3.2.5.4 Cloning of the RBM51 intron 1 fragment 
Primers incorporating Sacl restriction sites were designed and used for PCR 
amplification of insert for cloning into destination vectors. PCR products were gel-
purified and quantified prior to ligation and initial cloning into the pGEM-T vector. 
Inserts were sequenced in both directions for confirmation of sequence and 
determination of orientation. Primer sequences are given in Table 2.3 and are 
displayed below: 
Sac I restriction site: 
S' -
3' -
• GAGCTC 
CTCGAG 
• 
Original primers: 
- 3' 
- S' 
Forward: 
Reverse: 
S' - CACCTCTCTCTACCTGAAAAGATGG - 3' 
S' - AAAGCTTTGCATCACAGCATCTTAT - 3' 
Primers with restriction site: 
Forward: S' - GATCGAGCTCCACCTCTCTCTACCTGAAAAGATGG - 3' 
Reverse: S' - GATCGAGCTCAAAGCTTTGCATCACAGCATCTTAT - 3' 
Luciferase reporter assays were performed by Dr Tushar Ghosh, and results are 
displayed in Appendix D. GATA-4 had a repressive effect on promoter activity via this 
region, whilst TBX5 had no effect. 
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CHAPTER 4 
STUDY OF CANDIDATE GENES IN THE EMBRYONIC CHICK 
4.1 AIMS 
This chapter aims to investigate the expression and responsiveness of candidate 
genes to TBX5 and GATA-4 in the developing chick as follows: 
a) Confirmation of expression of candidate genes in the developing chick heart 
including investigation of temporal expression 
b) Development of an in ovo model of TBX5 and GATA-4 knockdown with 
appropriate controls 
c) Model validation by phenotypic analysis of embryos subjected to single and 
double knockdown of TBX5 and GATA-4 during key stages of cardiac 
development 
d) Development of a robust QPCR method for cardiac expression analysis, and 
study of candidate gene expression in TBX5 / GAT A-4 double knockdown 
embryonic hearts 
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4.2 RESULTS 
4.2.1 Investigation of candidate gene temporal expression profiles by RT -peR 
Expression of the candidate genes (PA2.26, PETA-3, FUCA 1, FN, TPM1, DES, and 
RBMS1) in the developing chick heart was examined at seven stages of development 
(HH12, HH14, HH16, HH19, HH22, HH24 and HH26). These developmental stages 
encompass the early stages of heart looping, chamber formation, atrial septation, and 
the start of ventricular septation. Wild type embryonic age was assessed visually 
according to Hamburger and Hamilton stages [Hamburger and Hamilton, 1992], and 
hearts removed under sterile conditions before immediate storage in RNA/ater. 
Hearts were pooled prior to RNA extraction and cDNA synthesis. PCR amplification 
was performed using HotStar Taq. Primers were designed using the online Roche 
Universal ProbeLibrary assay design centre (https:l!www.roche-applied-science.com) 
as these primers would subsequently be used for QPCR expression analysis (section 
4.3.4). Consequently, all products are 60 - 90 bp. Assays spanning exons were 
selected wherever possible. In the case of a-tropomyosin, alignments with other 
members of this gene family were performed during assay design to ensure 
specificity, and the RT-PCR product generated was cloned into the pGEM-T Easy 
vector for sequencing to confirm amplification of the correct product. Primer 
sequences and positional information is given in Table 2.4. Expression of all 
candidate genes was detected in the developing heart at all stages examined (Figure 
4.1). Negative RT controls were included and did not display amplification (Appendix 
E). In addition, amplicons were electrophoresed on the same gel in order to confirm 
relative sizes (Appendix F). 
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Figure 4.1 RT -PCR expression profiles of candidate genes in the chick heart 
RT-PCR products were electrophoresed on 2% agarose gels using Hyperladder IV as a 
size marker (500 bp and 100 bp bands are indicated along with product sizes). Expression 
was studied at HH12, HH14, HH16, HH19, HH22, HH24 and HH26. GAPDH was 
included as a housekeeper gene. Negative PCR controls (where water was added in 
place of template) are shown (-PCR). Negative RT controls (where reverse transcriptase 
enzyme was not added) were also included and did not display amplification (Appendix E). 
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4.2.2 Development of an in ovo model of TBX5 and GAT A-4 knockdown 
To investigate the functional significance of the TBX51 GATA-4 interaction, an in ovo 
model of combined knockdown was generated. This enabled phenotypic analysis of 
double knockdown embryos, and expression analysis of candidate downstream genes 
and therefore the identification of new genes for analysis. 
4.2.2.1 Morpholino position and design 
Morpholinos targeted to TBX5 (Accession 10: AF033671.1) and GATA-4 (Accession 
10: XM_ 420041.1) were previously designed by Gene-Tools in collaboration with Dr 
Elizabeth Packham. Both morpholinos are designed to the AUG translational start 
sites in order to sterically block ribosomal binding and protein translation (Table 2.7, 
Figure 4.2). Morpholinos targeted to TBX5 (and corresponding controls) were tagged 
with 3' lissamine, whilst morpholinos targeted to GAT A-4 (and corresponding controls, 
section 4.2.2.2) were tagged with 3' carboxyfluorescein. This allowed evaluation of 
individual morpholino uptake during combinatorial use. 
4.2.2.2 Selection and design of specificity controls 
The use of appropriate controls is essential for confirmation of target specificity when 
investigating genes of unknown function. A pre-designed standard control morpholino 
(with no target) is available from Gene-Tools (USA), and a number of custom 
sequence oligomers can also be used as controls of specificity. The inverse-
antisense control morpholino is an oligomer whose sequence is the inverse of the 
targeting morpholino sequence. The advantage of this control is that its length and 
base composition are identical to that of the antisense morpholino. This is not 
however widely used as a control of specificity. The sense control morpholino is an 
oligomer with the reverse complement sequence of the targeting morpholino (identical 
to the target region). In some cases these have been reported to have an up-
regulatory effect on target expression, and are not strongly recommended. The 5-
base mismatch control incorporates five mismatched bases into the sequence of the 
targeting morpholino, most effective when three of out five of these are cytosine-
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guanine substitutions or vice versa. At the time this research was carried out (2008), 
this was considered the most rigorous control of specificity, and was used in addition 
to the standard control morpholino. Sequences are given in Table 2.7, and Figures 
4.2 and 4.3 additionally display morpholino target regions. Actual bases to be mis-
paired were selected by Gene-Tools. 5-base mismatch control morpholinos were 
subsequently replaced with 7-base mismatch morpholinos (section 4.2.2.5), and 
sequences of these are also shown in Table 2.7 and Figures 4.2 and 4.3. 
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Chicken TBX5 AUG morpholino 
Actual AUG ' 7-mismatch ' MO* 
Planned AUG 7-mismatch MO* 
AUG 5 - mismatch MO 
AUG MO 
mRNA 
Protein 
3 '- ~ ~ ~ A A C G C T G ~ C C ~ T C ~ T T C ~ T C C G G - 5 ' 
3 '- C G A A A A C T G ~ C C ~ T C ~ T T C ~ T C C G G - 5 ' 
3 '- C ~ A A A C ~ T G G C C ~ T C C T T ~ C T ~ G G G - 5 ' 
3 '- CGAAACGTGGCCCTCCTTCCTCGG - 5 ' 
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5 '- CUCUCCECUUUGCACCGGGAGGAAGGAGCCFGAAUGCUCCGCGCCCGCGGACCAG UGGGGGAUUCGGCGAAGGAAGCUCGUAACAUGGCGGACACCGAGG - 3 ' 
M L R A R G P V G D S A K EAR N MAD T E 
Figure 4.2 TBX5 targeting morpholino sequence and target region 
Morpholino sequences are shown in the 3' - 5' direction, and target binding regions are boxed, with AUG start sites shaded in grey. Bases altered in 
mismatch control morpholinos are underlined. *An error was made during the design of this morpholino and an extra base (guan in e) inserted at position 19 in 
the 5' - 3' direction. 
-VJ 
VJ 
Chicken GATA-4 AUG morpholino 
AUG 7-mismatch MO 
AUG 5- mismatch MO 
j'- G C T Q T A ~ ~ T G ~ T ~ T C C A A T C C C T A C C - 5 ' 
3 ' - GCTGTAGATGCTCTCCAATCGCTAC - 5 ' 
- - - - -
3 ' - GCTCTACATGGTCTCGAATCGGTAC - 5 ' 
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AUG MO 
mRNA 
Protein 
5 ' - AUUGCGCUCGGAGACCCAUCUGGGGUUUGGGGGGCCCCGCUQFGAGAUGUACCAGAGCUUAGCCAU§GCGGCGAACCCCGGCCCCCCGUCC UACGAAGGG - 3 ' 
M Y Q S LAM A A N P G P P S Y E G 
Figure 4.3 GAT A-4 targeting morpholino sequence and target region 
Morpholino sequences are shown in the 3' - 5' direction , and target binding regions are boxed, with the AUG start site shaded in grey. Bases altered in 
mismatch control morpholinos are underl ined. 
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4.2.2.3 Selection of a developmental window for morpholino application 
One of the practical considerations in selecting a timeframe for morpholino application 
is the ease with which embryonic age can be assessed. Based on initial experiments. 
it was possible to accurately assess the developmental stage of embryos in ova from 
HH10 onwards. and this is also the stage at which the heart starts to beat. Prior to 
this a dye such as India ink (commonly used to view vasculature in chicken embryos 
[Latker et aI., 1986]), would be required for visualisation, rendering the embryo 
unusable for a knockdown study. Also, at any selected time-point, there is a large 
degree of variation in embryonic age. This means it would be extremely laborious to 
attempt knockdowns at one focused stage of development, particularly on the scale 
intended in this study. In light of these considerations, morpholinos were applied at 
HH10 - HH16, and embryos harvested for analysis at HH 19. These are key 
developmental stages which encompass looping of the heart (dextral looping occurs at 
HH10 - HH12, post dextral-looping at HH12 - HH17/18), and initiation of atrial 
septation (HH14). Since TBX5 and GATA-4 mutations have been associated with 
atrial septal defects, knockdown of these transcription factors in the early stages of 
atrial septation is ideal for elucidation of their individual and joint functions, and 
analysis of the effect on postulated downstream targets. 
4.2.2.4 Morpholino application and assessment of uptake 
Embryos were staged visually prior to morpholino application, as described in section 
2.1.6.5. In cases of dual morpholino treatment, two morpholinos each at a 
concentration of 250 ~ M M were combined (resulting in a final concentration of 500 ~ M ) . .
Standard control morpholino was applied singly at 500 ~ M M in order to match the total 
concentration of experimental morpholino. Wild type embryos were simultaneously 
opened and staged. Fo"owing incubation, extra-embryonic membranes were 
removed for assessment of morpholino uptake and photography. Fluorescence levels 
of two embryos classed as positive for morpholino uptake are shown in Figure 4.4 and 
indicate typical levels for a" embryos used in the study. 
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Figure 4.4 Assessment of morpholino uptake 
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Single morpholino treatment: 
Standard control 500 ~ M M
(fluorescein tag) 
Dual morpholino treatment: 
TBX5 5-base mismatch 
250 ~ M M (fluorescein tag) 
+ 
GATA-4 5-base mismatch 
250 ~ M M (lissamine tag) 
Bright field and fluorescent views of embryos classed as positive for morpholino 
uptake are displayed and indicate typical fluorescence levels for all embryos used in 
the study. (A) Single embryo treated with a single fluorescein tagged standard control 
morpholino at 500 ~ M M (displayed from the left and right). (B) Single embryo treated 
with two morpholinos, TBX5 5-base mismatch at 250 ~ ~ , , and GATA-4 5-base 
mismatch at 250 ~ M M (displayed from the left and right) . Scale bars represent 1000 
~ ~ . .
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4.2.2.5 Preliminary testing of targeting and control morpholinos in ovo 
Initial phenotypic analysis of embryos was carried out externally and is displayed in 
Figure 4.5. Outflow tract and ventriclular regions are labelled. Figure 4.5 A1-A2 and 
81-82 depict wild type and standard control treated embryonic hearts, which display 
normal curvature and shape. C1 and C2 represent examples of T8X5 I GATA-4 
double 5-base mismatch treated embryos, which respectively display a constricted 
outflow tract and dilated ventricle. Of the double mismatch control embryos, 3 I 10 
externally harboured a cardiac defect. Since these were similar to, but less severe 
than, the abnormalities observed in knockdown embryos (discussed later in section 
4.2.7), it was hypothesised that one or both of the control morpholinos was still able to 
bind to the target region, but with lower affinity than the targeting morpholinos. In 
order to overcome this problem, and upon recommendation by Gene-Tools, both 5-
base mismatch morpholinos were replaced with 7-base mismatch controls. Where 
possible, different bases were altered to those originally modified (Table 2.7, Figures 
4.2 and 4.3). The new controls were again tested prior to use to rule out low affinity 
binding or mis-targeting effects. 
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Figure 4.5 External phenotypic analysis of embryos treated with 5-mismatch 
morpholinos in comparison to standard control-treated and wild type embryos 
Bright field lateral embryonic views are displayed with developmental stages of 
morpholino application and embryo harvest. Standard control morpholino was applied 
at a concentration of 500 ~ M M (B1 and B2), and 5-mismatch control morpholinos each 
applied at 250 ~ M M for a final morpholino concentration of 500 ~ M M (C1 and C2). Scale 
bars represent 500 ~ ~ . . ot - outflow tract, v - ventricle 
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4.2.2.6 External phenotypic analysis of single and double knockdown embryos 
4.2.2.6.1 Whole body analysis 
Figure 4.6 shows whole embryonic views of animals subjected to various morpholino 
treatments. Wild type, standard control and double mismatch control embryos display 
a normal body shape and 'c' shaped curvature (Figure 4.6 A1, B1 and C1 
respectively). Embryos subjected to individual knockdown of TBXS and GATA-4 
(Figure 4.601 and E1) diverted only slightly from this. In contrast, double knockdown 
embryos (Figure 4.6 F1 - FS) displayed a variety of defects including growth 
retardation (F3), body kinking and/or twisting (F1, F3, F4), and severe defects in heart 
looping (F2 and FS). 
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Figure 4.6 External whole body analysis of TBX51 GAT A-4 single and double knockdown embryos 
Bright field lateral embryonic views are displayed with developmental stages of morpholino application and embryo harvest. Embryos were treated with a final 
morpholino concentration of 500 ~ ~ . . A1 , B1 and C1 show a wild type, standard control and double mismatch control embryo respectively. 01 and E1 are 
examples of TBX5 single knockdown and GATA-4 single knockdown embryos respectively. F1 - F5 are examples of double knockdown embryos. Arrows 
indicate abnormalities in body shape. Scale bars represent 1000 ~ ~ . .
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4.2.2.6.2 Cardiac analysis 
External analysis focusing on embryonic hearts was also performed and is displayed 
in Figure 4.7. Outflow tract and ventricular regions are marked where identifiable. 
Embryos in the three control groups showed no outward abnormalities (Figure 4.7 A1 
- C1). TBXS knockdown resulted in heart malformations, primarily ventricular (Figure 
4.7 D1) in 2 I 3 embryos. GATA-4 single knockdown embryos displayed a similar 
phenotype (Figure 4.7 E1), and 3 I 4 embryos were affected. A variety of heart 
defects were observed in double knockdown animals and five examples are shown 
(Figure 4.7 F1 - FS). These included severe heart-restricted growth retardation (F3), 
ventricular constriction (F4), and overall malformations with abnormal heart looping in 
all embryos shown (F1 - FS). Cardiac defects were present in 9 I 12 double 
knockdown embryos. External phenotypic analysis data is summarised in Table 4.2 
(with additional internal analysis data, see next section). These findings are 
consistent with the phenotype of Gata4+1- TbxS+I- mice [Maitra et aI., 2009], published 
during the time of this study. 
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Figure 4.7 External cardiac analysis of TBX51 GATA-4 single and double knockdown embryos 
Bright field lateral embryonic views are displayed with developmental stages of morpholino application and embryo harvest. Embryos were treated with a final 
morpholino concentration of 500 !-1M . A1, B1 and C1 show a wild type , standard control and double mismatch control embryo respectively . D1 and E1 are 
examples ofTBX5 single knockdown and GATA-4 single knockdown embryos respectively. F1 - F5 are examples of double knockdown embryos. Scale bars 
represent 500 !-1m . ot - outflow tract , v - ventricle 
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4.2.2.7 Histological analysis of embryos 
Following photography, embryos were fixed in 4% PFA then dehydrated in a graded 
ethanol series prior to being embedded in wax. Embryos were sectioned coronally at 
10 microns and sections were transferred onto slides for haemulum staining and 
mounting with DPX. Due to the high proportion of knockdown embryos with gross 
cardiac malformations (particularly in cardiac looping), consistent orientation of hearts 
for sectioning in the same plane was not possible in all cases, with resulting difficulties 
in comparative phenotypic analysis. 
Figure 4.8 shows haemulum stained sections through embryos in the three control 
groups; (A) wild type, (B) standard control, and (C) TBX5 7-base mis I GATA-4 7-base 
mis, and two example embryos from each group are displayed. Regions of atrial 
septum formation are shown at their maximum point upon viewing serial sections 
throughout the embryo, and are boxed. All embryos displayed normal sized atrial 
septa. 
Figure 4.9 shows heamulum stained sections through TBX5 and GATA-4 single and 
double knockdown embryos. Again, regions of atrial septum formation are shown at 
their maximum size. TBX5 knockdown embryos, in addition to the external cardiac 
defects seen, displayed a slight reduction in atrial septum size (Figure 4.9 A1 and A2). 
GATA-4 knockdown also resulted in a less pronounced atrial septum size in one 
embryo (Figure 4.9 B1). Unfortunately the orientation of other sectioned GATA-4 
knockdown embryos did not allow analysis of septa size (e.g. B2). 
Double knockdown of TBX5 and GATA-4 resulted in a number of internal cardiac 
defects (Figure 4.9 C1 and C2). C1 displayed an abnormal shape, and upon viewing 
sections throughout the heart, a complete lack of trabeculation was also observed. 
The beginnings of an atrial septum were visible. The second double knockdown 
embryo shown (C2) displayed a localised thickening of the cardiac jelly at the point of 
atrial septum formation, but no septum, despite the large overall size of the heart. 
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Phenotypic analysis data is summarised in Table 4.2. Approximately 75% of double 
knockdown embryos displayed a cardiac defect. 
These findings are consistent with the phenotype of Gata4+1- Tbx5+1- compound 
heterozygote mice [Maitra et al.. 2009]. published at the time of this study (2008/9). 
Due to the phenotypic characterisation of compound heterozygote embryos performed 
in this publication. analysis of phenotype was not carried out on as large a scale as 
originally planned. and was used primarily for the purposes of technique validation and 
confirmation of knockdown. 
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Wild type 
Standard control 
" 
Figure 4.8 Histological analysis of the three control groups 
Haemulum stained coronal embryonic sections through two embryos in each group 
are displayed. Three control groups were studied; (A) wild type, (8) standard control , 
and (C) T8X5 7-base mis / GATA-4 7-base mis. Developmental stages of morpholino 
application (where applicable) and embryo harvest are indicated. A final morpholino 
concentration of 500 IJM was used in cases of morpholino treatment. Regions of atrial 
septa formation are boxed, shown at their maximum size upon viewing serial sections 
throughout the embryo. Scale bars represent 500 IJm . 
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Figure 4.9 Histological analysis of TBX5 and GATA-4 knockdown embryos 
Haemulum stained coronal embryonic sections through two embryos in each group 
are displayed. Three knockdown groups are represented; (A) TBX5 single knockdown 
(+ GATA-4 7-base mis), (B) GATA-4 single knockdown (+TBX5 7-base mis), and (C) 
TBX5 I GAT A-4 double knockdown. Developmental stages of morpholino appl ication 
(where applicable) and embryo harvest are indicated. Each morpholino was applied 
at a concentration of 250 ~ ~ , , resulting in a final morpholino concentration of 500 ~ ~ . .
Regions of atrial septa formation are boxed, shown at their maximum size upon 
viewing serial sections throughout the embryo. Scale bars represent 500 ~ ~ . .
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Table 4.1 Summary of abnormalities seen in TBX51 GATA-4 single and double knockdown embryos and controls 
Naturelregion of heart Wild type Standard control Double mismatch TBX5 knockdown I GATA-4 knockdown TBX5 I GAT A-4 
abnormality control GATA-4 mismatch I TBX5 mismatch double knockdown 
Body size I shape 0/3 0/3 0/3 0/3 1/4 7/12 
--.to. ~ ~
In 
-iii Heart size I shape 0/3 0/3 0/3 2/3 2/4 8/12 >-
ro 
c: 
co Heart looping 0/3 0/3 0/3 2/3 1/4 8/12 ro 
c: 
.... 
Q) Other 0/3 0/3 0/3 1/3 1/4 2/12 x 
w 
Total 0/3 0/3 0/3 213 3/4 9/12 
In Atrial septum 0/3 0/3 0/3 2/2 1 11 1/3 
-iii 
>-
ro Trabeculae 0/3 0/3 0/3 0/3 - 2/3 c: 
co 
ro Cardiac jelly 0/3 0/3 0/3 1/3 0/3 2/3 E 
Q) 
C Total 013 0/3 0/3 213 113 313 
----
Groups represented are wild type, standard control, TBX5 I GAT A-4 double mismatch control, TBX5 single knockdown (with GAT A-4 mismatch control), 
GATA-4 single knockdown (with TBX5 mismatch control), and TBX51 GATA-4 double knockdown_ 
Study of candidate genes in the embryonic chick 
4.2.3 QPCR expression analysis of candidate genes in TBX5' GATA-4 double 
knockdown embryos 
For assessment of the responsiveness of candidate genes to TBX5 and GATA-4 in 
the developing chick heart, expression was analysed by QPCR in double knockdown 
embryos and controls. 
4.2.3.1 Sample collection and preparation 
Approximately 600 eggs were opened in total for this study. Morpholino was applied 
to around half following exclusion of embryos which were no longer viable or not within 
the desired range of development (HH12 - HH16). Morpholino uptake was confirmed 
in HH19 stage embryos prior to tissue isolation. Eight hearts were pooled per 
sample, and three biological replicates collected per group (3 groups: wild type 
(calibrator), double 7-base mismatch control, and double knockdown). Exactly 1 IJg 
RNA was used per 20 IJI reverse transcription reaction for identical loading in 
subsequent reactions. eDNA for all samples was prepared simultaneously, 
appropriately diluted (section 2.2.1.10.5), aliquoted, and stored at -80°C prior to use. 
HH24 whole embryo cDNA was used for generation of standard curves. 
4.2.3.2 QPCR assay design 
QPCR assays were designed as set out in section 2.2.1.10.1, generally spanning a 60 
- 100 bp region including an exon-exon boundary, and were suitable for use with an 
annealing temperature of 60°C. Primer sequences and assay information are given 
in Table 2.4. These primers were also used for RT -PCR expression profiling (Figure 
4.1) which additionally served to confirm products sizes and single product 
amplification prior to QPCR. Assays were designed to all seven candidate genes 
(PA2.26, PETA-3, FUCAt, FN, TPM1, DES, and RBMS1), and four potential 
endogenous control genes - GAPDH, Tap, EEF1A1, and RPLPO. The gene MYH6, a 
known target of TBX5 and GATA-4 [Ching et aI., 2005; Huang et aI., 1995; Molkentin 
et aI., 1994], was also included as a positive control. During the time of this study, 
147 
Study of candidate genes in the embryonic chick 
MYH6 was additionally shown to be down-regulated in Gata4+/' TbxS+/' compound 
heterozygote mice at E11.S and E13.5 [Maitra et al., 2009). 
4.2.3.3 Comparative CT method (MCT) versus Relative Standard Curve method 
In Chapter 3, the Comparative Cr method was used for QPCR expression analysis in 
the P19 cell line using transmembrane protein 131 (tmem131) as an endogenous 
control, generating a data set that was both accurate and reproducible. This method 
was attempted here using GAPDH as an endogenous control, but it was not possible 
to obtain reproducible results (not shown). The Comparative CT method does not 
require the use of standard curves on each reaction plate, and whilst this has 
economical and time-savings advantages (particularly for high-throughput screening) it 
also means that it is not possible to assess the efficiency or reliability of each 
individual run. An alternative method, the Relative Standard Curve method, 
overcomes this limitation and was tested and optimised for quantification of gene 
expression in the chick. This method involves the construction of standard curves 
from known quantities of DNA for both the target and endogenous control, with sample 
DNA amplified simultaneously under identical conditions. Sample target and 
endogenous reference quantities are determined using this information, and assay 
efficiency data is generated in parallel, producing highly accurate data. 
4.2.3.4 Selection of an endogenous control for relative quantification 
Selection of an appropriate endogenous control gene is a crucial step in relative 
quantification experiments. Normalisation to an endogenous control allows correction 
of any skewing of data arising from small differences in starting quantity of template. 
The endogenous control must be expressed at the same time as the target gene, and 
display uniform expression across all samples i.e. expression should not be affected 
by sample treatments. Four genes were selected as potential candidates - TBP 
(TATA box binding protein), GAPDH (glyceraldehyde-3-phosphate dehydrogenase), 
EEF1 A 1 (eukaryotic translation elongation factor 1 alpha 1) and RPLPO (large 
ribosomal protein). These are commonly used as endogenous controls in QPCR. 
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Primer sequences and assay information are given in Table 2.4. RT-PCR products 
generated using these primers were checked for size and specificity prior to QPCR 
(data not shown). 
4.2.3.4.1 Preparation of standard curves 
In order to assess QPCR assay efficiency and suitability of these four genes for use 
as endogenous controls, standard curves were constructed for each gene (using a 10 
point dilution series of 4-fold). These are shown in Figures 4.10 - 4.13, and standard 
curve linearity and assay efficiency values are summarised in Table 4.2. As 
mentioned, a linearity of ~ 0 . 9 9 9 and slope in the range -3.2 to -3.6 is desirable. All 
assays generated standard curves that met the linearity criteria. The slope (and 
therefore efficiency) of the GAPDH assay was outside the acceptable range so this 
gene was excluded. TBP, whilst meeting the criteria set out, generated a poor 
amplification plot (Figure 4.11 a) with amplification starting at the high cycle number of 
26 (EEF1A1 and RPLPO expression was observed from 18 and 16 cycles 
respectively). On this basis, TBP was also excluded, and EEF1A1 and RPLPO were 
short-listed for normalisation of data. 
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Figure 4.10 GAPDH amplification plot (A) and resulting standard curve (8) 
Two replicate reactions were performed at ten concentrations of cDNA, based on a 4-
fold dilution series . Amplification efficiency was calculated from the slope of the 
standard curve using the equation E = 10 [.1/slope]. Slope: -3.738, R2: 0.992, Efficiency 
(%): 85.132 
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Figure 4.11 T8P amplification plot (A) and resulting standard curve (8) 
Two replicate reactions were performed at ten concentrations of eDNA, based on a 4-
fold dilution series. Amplification efficiency was calculated from the slope of the 
standard curve using the equation E = 10 ['lIsI0pe] . Slope: -3.49, R2: 0.994, Efficiency 
(%): 93.427 
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Figure 4.12 EEF1A1 amplification plot (A) and resulting standard curve (8) 
Two replicate reactions were performed at ten concentrations of cDNA, based on a 4-
fold dilution series. Amplification efficiency was calculated from the slope of the 
. h t' E 10 [-1 /slope] SI 3 513 R2 0 99 Effi standard curve uSing t e equa Ion = . ope: - . , : . 5, Iciency 
(%): 92 .611 
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Figure 4.13 RPLPO amplification plot (A) and resulting standard curve (8) 
Two replicate reactions were performed at ten concentrations of cDNA, based on a 4-
fold dilution series. Amplification efficiency was calculated from the slope of the 
standard curve using the equation E = 10 [-lIsI0pe]. Slope: -3.226, R2: 0.995, Efficiency 
(%): 104.142 
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Table 4.2 Summary of endogenous control gene assay properties 
Gene Linearity (R2) Slope Efficiency (%) Starting cycle 
GAPDH 0.992 -3.738 85.1 22 
TBP 0.994 -3.490 93.4 26 
EEF1A1 0.995 -3.513 92.6 18 
RPLPO 0.995 -3.226 104.1 16 
Values are based on standard curves prepared from a 10-point 4-fold dilution series 
using HH24 whole embryo cDNA (Figures 4.10 - 4.13). 
4.2.3.4.2 Analysis of variation of endogenous control expression levels In 
study samples 
Expression of an endogenous control genes used for normalisation of data must not 
be affected by experimental treatments, so should display uniform expression levels 
across all sample groups (3 groups: wild type (calibrator), double 7-base mismatch 
control, and double knockdown). To investigate this, CT values of EEF1A1 and 
RPLPO were measured in triplicate for each sample following their identical 
preparation and dilution. ~ C T T values were calculated for each group (Table 4.3) from 
mean CT values of biological and experimental replicates using the equation: 
~ C T T (sample) = Average CT (calibrator) - Average CT (sample) 
Samples with higher template concentrations than the calibrator result in lower CT 
values and positive ~ C T T values, and vice-versa. A ~ C T T value of 1 equates to a two-
fold difference in expression, and the ~ C T T value of an ideal endogenous control will 
vary only slightly from zero indicating stable expression. Both RPLPO and EEF1A1 
displayed relatively constant expression across samples (maximum ~ C T T values of 
0.36 and 0.44 respectively) and were suitable for use. 
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RPLPO was selected for use as the endogenous control since the range of ~ C T T values 
observed across samples was narrowest, and assay linearity (0.995) and efficiency 
(104%) were closest to ideal. 
Table 4.3 Mean CT and ~ C T T values of EEF1A1 and RPLPO In study samples 
RPLPO EEF1A1 
Sample 
Mean CT ~ C T T Mean CT ~ C T T
Wild type (calibrator) 27.17389 0 26.54730 0 
7-mismatch control 26.85162 0.322276 26.71622 -0.16892 
Double knockdown 26.81002 0.363879 26.99526 -0.44797 
Three biological samples were analysed per group, each assayed in triplicate. 
Standard curves for both genes were run in parallel on the same reaction plate for 
confirmation of assay quality. 
4.2.3.5 QPCR expression analysis of candidate genes 
The calibrator sample (in this case untreated or wild type) serves as a baseline for 
comparison of target and endogenous control levels, and also allows comparison 
across reaction plates. Baseline and threshold values were set manually, and 
absolute quantities of each gene generated from the standard curves in Applied 
Biosystems 7500 v2.0.1 software. Standard curves for target and endogenous control 
genes were included on each plate, with each point measured in duplicate. All 
samples were run simultaneously on the same plate, each assayed in triplicate. 
Reaction plates were run twice. Biological and experimental replicates were grouped 
for data normalisation and standard deviation calculations. 
Results of QPCR expression analysis are displayed in Table 4.4 and Figure 4.14. 
Expression is displayed relative to expression of the endogenous control RPLPO. 
PA2.26 and FUCA 1 displayed very low expression levels which were not accurately 
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quantifiable, and it was therefore necessary to exclude these from the QPCR study. 
Expression of the other five candidate genes (PETA-3, DES, TPM1, FN, and RBMS1) 
was accurately quantified but no significant differences were observed between the 
double knockdown and control groups (measured by the student's t test using p<0.05 
as the threshold value). MYH6 was used as a positive control in this study as it known 
to be regulated by TBX5 and GATA-4 [Ching et aI., 2005; Huang et aI., 1995; 
Molkentin et aI., 1994]. This gene did not however display any change in expression. 
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Table 4.4 QPCR expression analysis of candidate genes In TBX5 I GATA·4 
knockdown animals and controls 
Relative expression 
Gene Double Double mismatch Wild type knockdown control (untreated control) 
PETA-3 1.80 ± 0.64 1.69 ± 0.47 1.50 ± 0.31 
Desmin 9.79 ± 2.66 10.1 ± 2.58 10.9 ± 2.26 
a-tropomyosin 2.34 ± 0.75 2.45 ± 0.67 2.86 ± 0.44 
Fibronectin 4.31 ± 1.38 3.43 ± 1.14 4.53 ± 0.81 
RBMS1 2.10 ± 0.49 1.81 ± 0.49 1.84 ± 0.41 
MYH6 31.0 ± 10.9 25.3 ± 7.1 26.9 ± 7.2 
QPCR expression analysis was performed on cardiac tissues from TBX5 / GATA-4 
double knockdown embryos, TBX5 7-mis I GATA-4 7-mis control embryos, and wild 
type embryos (3 biological replicates per group). Each reaction plate was run in 
duplicate. Data was normalised to RPLPO. No significant differences in expression 
were observed for any gene (measured between the knockdown group and both 
control groups by the student's t test using p<O.05 as the threshold value). 
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Figure 4.14 Relative expression of candidate genes in TBX51 GAT A·4 knockdown animals and controls 
QPCR expression analysis was performed on TBX5 I GATA-4 double knockdown embryos, TBX5 7-mis I GATA-4 7-mis controls, and wild type embryos (3 
biolog ical replicates per group). Each reaction plate was run in duplicate. Data was normalised to RPLPO. Error bars represent standard deviation. No 
significant differences in expression were observed for any gene (measured between the knockdown group and both control groups by the student's t test , 
using p<O.05 as the threshold value). 
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CHAPTER 5 
INVESTIGATION OF THE ROLE OF RBMS1 IN CARDIAC 
DEVELOPMENT 
5.1 INTRODUCTION 
5.1.2 a-Smooth muscle actin, a transcriptional target of RBMS1 
As mentioned, a-smooth muscle actin (a-SM) is a known downstream target of 
RBMS1. a-SM is the major actin isoform present in vascular tissue. A detailed 
analysis of the expression pattern of a-smooth muscle actin (and the two striated a-
actin genes) in the developing chick heart was performed by Ruzicka and co-workers 
[Ruzicka and Schwartz, 1988]. a-SM actin is the earliest expressed actin isoform in 
the developing heart, and the only actin expressed at HH8/9. It is the predominant 
actin at HH10, where it is expressed along the length of the tubular heart, in anterior 
structures which give rise to the presumptive conus arteriosus and ventral aorta, and 
in cardiogenic cells contributing to formation of atrial and sinus venosus regions. At 
HH11, expression is found in sarcomeres in the myocardium, alongside a-skeletal and 
a-cardiac actin, suggesting a role for a-SM actin in myofibrillogenesis [Sugi and 
Lough, 1992]. By HH12, expression of a-SM actin is selectively down-regulated and 
becomes restricted to the most anterior regions of the heart, namely the conus 
arteriosus and ventral aorta [Ruzicka and Schwartz, 1988]. This pattern of expression 
is maintained in subsequent developmental stages. The two striated a-actin genes 
become the predominantly expressed actin isoforms from HH12 in the heart. The 
developmental expression of a-SM actin in skeletal and myocardial cells (studied in 
the rat) is also transient and ceases after birth, again indicating a role for a-SM actin in 
sarcomeric development and cardiac muscle cell differentiation [Woodcock-Mitchell et 
ai., 1988]. Differentiation of outflow tract and atrioventricular endothelial cells into 
mesenchymal cells occurs during cardiac development, forming endocardial cushions 
157 
Investigation of the role of RBMS 1 in cardiac development 
which are essential for heart valve and septa formation. a-SM actin plays an 
important role in this crucial process of endothelial-mesenchymal transformation 
[Nakajima et aI., 1997], indicating an additional role in cardiogenesis. 
Mouse knockout of the a-SM actin gene (ACTA2) results in impaired vascular 
contractility and blood flow, with no reported effects on development of the heart 
[Schildmeyer et aI., 2000; Tomasek et aI., 2006]. However, these findings were based 
upon gross examination of embryos and cross-sectional analysis of cardiac muscle. 
Internal heart structures were not examined for abnormalities. Mutations in ACTA2 in 
humans are associated with a variety of vascular diseases such as coronary artery 
disease (CAD), ischemic strokes, Moyamoya disease (MMD), and thoracic aortic 
aneurysms and dissections (TAAD) [Guo et aI., 2009). In addition, ACTA2 mutations 
are also associated with the CHD patent ductus arteriosus [Guo et aI., 2007]. 
5.1.3 Transcriptional regulation of a-smooth muscle actin 
Expression of a-SM actin is mediated by positive and negative cis-elements and their 
corresponding trans-acting factors. A number of positive regulators have been 
identified e.g. serum response factor (SRF) which acts via the CArg box [Hautmann et 
aI., 1997; Shimizu et aI., 1995; Simonson et aI., 1995), and essential transcriptional 
enhancer factor-1 (TEF-1) which acts via the purine rich motif [Cogan et aI., 1995). 
Less is known about the negative regulation of this gene. Until recently, only two 
negative regulators of a-SM actin, vascular a-SM actin single-strand binding factors 1 
and 2 (VACssBF1 and VACssBF2), were identified, both acting via the TEF-1 binding 
domain in single stranded DNA [Cogan et aI., 1995]. A novel negative regulatory 
element has since been identified in the a-SM actin promoter region, ranging from -
238 to -219. Mutation and deletion analyses revealed the sequence TATCTTA (-228 
to -222) is essential for negative regulation [Kimura et aI., 1998]. Gel shift assays 
(using smooth muscle cell nuclear extracts) were designed to identify protein factors 
specifically interacting with this sequence, and resulted in identification of the nuclear 
protein RBMS1. RBMS1 was found to interact with both single and double stranded 
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DNA containing this sequence. Furthermore, RBMS 1 overexpression resulted in 
suppression of a-SM actin promoter activity. This provided evidence of a novel role 
for RBMS1 in the negative transcriptional regulation of a-SM actin. 
5.1.4 a-cardiac and a-skeletal actin 
The striated actins, a-skeletal and a-cardiac actin, are the major actin isoforms in 
skeletal and cardiac muscle respectively. Due to the common ancestry and high level 
of homology between these and a-smooth muscle actin, it is possible these genes 
may have retained some common regulatory elements, and the regulatory effect of 
RBMS1 on a" three actins will be assessed in this chapter. Both a-cardiac and a-
skeletal actin are expressed in the heart where they each have an important function. 
Expression of a-cardiac actin begins at HH9 (at lower levels than a-smooth muscle 
actin) in the ventricular myocardium, subsequently spreading in a spatial pattern 
corresponding with the progression of myofibrillogenesis [Ruzicka and Schwartz, 
1988]. Mutations in alpha cardiac actin produce atrial and ventricular septal defects 
[Matsson et aI., 2008]. Expression of a-skeletal actin is detectable from HH12, with 
the pattern of expression largely following that of a-cardiac actin, with greater 
expression in the conus region [Ruzicka and Schwartz, 1988] 
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5.2 AIMS 
This chapter aims to study RBMS1 in the developing chick embryo as follows: 
a) Bioinformatic characterisation of the chicken RBMS1 gene and transcripts 
b) Determination of the expression pattern of RBMS 1 in the developing chick 
c) Morpholino knockdown of RBMS1 for phenotypic analysis 
d) Characterisation of the effect of morpholinos on RBMS1 mRNA splicing and I 
or mRNA levels 
e) Bioinformatic characterisation of a-smooth muscle actin and related genes, 
and QPCR expression analysis of these in RBMS1 knockdown embryos 
versus controls 
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5.3 RESULTS 
5.3.1 Bioinformatic Identification and characterisation of the chicken RBMS1 
gene 
The human RBMS1 gene was identified at chromosome 2: 161,101,000-161,378,000 
using NCBI. The corresponding chicken gene was identified at chromosome 7: 
23,214,270-23,352,271 (method described in section 2.2.6.1). Synteny of the chick 
genomic location with the known human genomic region of RBMS1 was confirmed, 
establishing identification of the true orthologue (Figure 5.1). Gene sequence 
alignments were performed in the online ECR browser (http://ecrbrowser.dcode.org) 
for ten species against the human (base) genome (Figure 5.2), showing this gene is 
conserved across a multitude of species. Two chicken RBMS 1 protein transcripts 
were identified and multispecies alignment of RBMS1 protein sequences again 
showed this gene is highly conserved between the chicken, human, chimpanzee, 
mouse and rat (Figure 5.3). Sequence alignment of the two corresponding chicken 
mRNA transcripts is shown in Figure 5.4. ESTs matching the RBMS1 transcripts were 
identified and aligned with the theoretical mRNA sequences for sequence 
confirmation, represented in Figure 5.5. Transcript ENSGALT00000018146 contains 
a 9 bp insertion in exon 7, likely to have been introduced through an a l ~ e r n a t i v e e
splicing mechanism. Each transcript has been assigned a different AUG translational 
start site based on the postulated protein sequences. It is unclear which (if either) is 
the predominant transcript. 
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Figure 5.1 Synteny of the chicken and human RBMS1 genes 
Synteny between the chromosomal location of the chicken RBMS 1 gene and the 
known chromosomal location of the human RBMS 1 gene was confirmed in Ensembl 
(http://www.ensembl.org ). The centre block represents the species and region of 
interest (chicken. chromosome 7:23214240-23352391 ). and the smaller chromosomes 
represent syntenic regions with the second species (human). Chromosome 
2:161128662-161350305 is of interest. Blocks are coloured according to the 
chromosome of the second species. Black lines connect syntenic blocks with the 
same orientation. and brown lines connect syntenic blocks with opposite orientation. 
The RBMS1 gene is marked with the small red box. 
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Figure 5.2 Multispecies conservation of the RBMS1 gene 
Sequence alignments were performed in the online ECR browser (http://ecrbrowser.dcode .org) for ten species against the human (base) genome. The y-axis 
represents the percentage identity between the base and aligned genomes, and regions meeting the input criteria (100 nucleotide run , minimum 70% identity) 
are indicated by the pink rectangles on top of each plot. Blue lines indicate coding exons and salmon regions indicate intronic regions. Untranslated regions 
are shown in yellow, and red areas indicate intergenic regions. Green regions represent transposable elements and simple repeats . 
Mus_musculus 
Rattus_norvegicus 
Pan_troglodytes 
Homo_sapiens 
Chicken ENSGALP00000032479 
Chicken=ENSGALP00000018124 
Mus_musculus 
Rattus norvegicus 
Pan_troglodytes 
Homo sapiens 
Chicken ENSGALP00000032479 
Chicken=ENSGALP00000018124 
Mus_musculus 
Rattus_norvegicus 
Pan_troglodytes 
Homo_sapiens 
Chicken ENSGALP00000032479 
Chicken=ENSGALP00000018124 
Mus_musculus 
Rattus_norvegicus 
Pan_troglodytes 
Homo sapiens 
Chicken ENSGALP00000032479 
Chicken=ENSGALP00000018124 
Mus_musculus 
Rattus_norvegicus 
Pan_troglodytes 
Homo_sapiens 
Chicken ENSGALP00000032479 
Chicken=ENSGALP00000018124 
Mus_musculus 
Rattus norve gicus 
Pan_troglodytes 
Homo_sapiens 
Ch i cken ENSGALP00000032479 
Chicken=ENSGALP00000018l24 
Mus_musculus 
Rattus_norvegicus 
Pan_troglodytes 
Homo_sapiens 
Chicken ENSGALP00000032479 
Chicken=ENSGALP00000018124 
Mus_musculus 
Rattus_nor vegicus 
Pan_troglodytes 
Homo_sapiens 
Chi cken ENSGALP00000032 479 
Chicken=ENSGALP00000018l2 4 
Mus musculus 
Rattus_nor vegicus 
Pan_troglodytes 
Homo sapiens 
Chicken_ENSGALP00000032479 
Chicken_ENSGALP00000018124 
Investigation of the role of RBMS1 in cardiac development 
- ------------- - - -- - -- - -----------MAPPSPSTTSSNNNSS 
MGKVWKQQMYPQYATYYYPQYLQAKQSLVPAHPMAPPSPSTTSSNNNSSS 
--MIFPSSSGNPGGSSNCRTPYRKQQSLVPAHPMAPPSPSTTSSNNN SS 
MGKVWKQQMYPQYATYYYPQYLQAKQSLVPAHPMAPPSPSTTSSNNNSSS 
- --- - -- -MYPQYTTYYYPQYLLAKQSIVPAHPMAPPSPSTTSSNNNSSS 
----- - --- - ---------------- -------MAPPSPSTTSSNNNSSS 
SSNSGWDQLSKTNLYIRGLPPNTTDQDLVKLCQPYGKIVSTKAILDKATN 
SSNSGWDQLSKTNLYIRGLPPNTTDQDLVKLCQPYGKIVSTKAILDKATN 
SSNSGWDQLSKTNLYIRGLPPHTTD DLVKLCQPYGKIVSTKAILDKTTN 
SSNSGWDQLSKTNLYIRGLPPHTTDQDLVKLCQPYGKIVSTKAILDKTTN 
SSNSGWDQLSKTNLYlRALPPNTTDQDLVKLCQPYGKIVSTKAILDKTTN 
SSNSGWDQLSKTNLYlRALPPNTTDQDLVKLCQPYGKIVSTKAILDKTTN 
K KGYGFVD'DSPAAAQKAVSALKANGVQAQMAK QEQDPTNLYISNLPL 
K KGYGFVD DSPAAAQKAVSALKASGV AQMAKQQEQDPTNLYISNLPL 
K KGYGFVD DSPAAAQKAVSALKASGVQAQMAKQQEQDPTNLYISNLPL 
K KGYGFVD DSPAAAQKAVSALKASGVQAQMAKQQEQDPTNLYISNLPL 
K KGYGFVD DSPAAAQKAVSALKASGVQAQMAKQQEQDPTNLYISNLPL 
K KGYGFVD DSPAAAQKAVSALKASGVQAQMAKQQEQDPTNLYISNLPL 
SMDEQELENMLKPFGQVISTRVLRDSSG 
SMDEQELENMLKPFGQVISTRVLRDSSGT 
SMDEQELENMLKPFGQVISTRILRDSSGT 
SMDEQELENMLKPFGQVISTRILRDSSGT 
SMDEQELENMLKPFGQVISTRILRDSSGT 
SMDEQELENMLKPFGQVISTRILRDSSGT 
* * * * * * * * * * * * * * * * * * * * * : ' * * * * * : ~ ~ ~ ~ ~
ESTEKCEAVIAH 
FNGKFIKTPPGVSAPTEPLLCKFADGGQKKRQNPNKYIPNGRPWPRDG--
FNGKFIKTPPGVSAPTEPLLCKFADGGQKKRQNPNKYIPNGRPWPREG--
FNGKFIKTPPGVSAPTEPLLCKFADGGQKKRQNPNKYIPNGRPWHREG--
FNGKFIKTPPGVSAPTEPLLCKFADGGQKKRQNPNKYIPNGRPWHREGEV 
FNGKFIKTPAGVSVPAEPLLCKFADGGQKKRQNQNKYIQNGRAWHREG--
FNGKFIKTPAGVSVPAEPLLCKFADGGQKKRQNQNKYIQNGRAWHREGEV 
* ~ * * * * * * * . * * * . * : * . * * * * * * * * * * * * * + * * **** •• * . ' * : * 
- EAGMTLTYDPTTAALHNGFYPSPYSIATNRMITQTSLTPYIASPVSAYQ 
- EAGMTLTYDPTTAALHNGFYPSPYSIATNRMITQTSLTPYIASPVSAYQ 
- EAGMTLTYDPTTAAIQNGFYPSPYSIATNRMITQTSITPYIASPVSAYQ 
RLAGMTLTYDPTTAAIQNGFYPSPYSIATNRMITQTSITPYIASPVSAYQ 
-EAGMTLTYDPTTAALQNGFYPSPYSITANRMITQTSITPYIASPVSTYQ 
RLAGMTLTYDPTTAALQNGFYPSPYSITANRMITQTSITPYIASPVSTYQ 
.** * ** * ** ** * * :: 1r .** .. *. *** : : _* • • • •• • : ..... ..... . : * * 
VQSPSWMQPQPYILQHPGAVLTPSMEHTMSLQPASMISPLAQQMSHLSLG 
VQSPSWMQPQPYILQHPGAVLTPSMEHTMSLQPASMISPLAQQMSHLSLG 
VQSPSWMQPQPYILQHPGAVLTPSMEHTMSLQPASMISPLAQQMSHLSLG 
VQSPSWMQPQPYILQHPGAVLTPSMEHTMSLQPASMISPLAQQMSHLSLG 
VQSPSWMQPQPYIMQHPGAVLTPSMDHTMSLQPASMISPLTQQMSHLSLG 
VQSPSWMQPQPYIMQHPGAVLTPSMDHTMSLQPASMISPLTQQMSHLSLG 
* * * **** **** * * : ** *** *** * ** : ** ** **** * * ** * * : * ** *** * ** 
STGTYMPATSAMQGAYLPQYTHMQTAAVPVEEASGQQQVAVETSNDHSPY 
STGTYMPATSAMQGAYLPQYTHMQTATVPVEEASGQQQVTVETSNDHSPY 
STGTYMPATSAMQGAYLPQYAHMQTTAVPVEEASGQQQVAVETSNDHSPY 
STGTYMPATSAMQGAYLPQYAHMQTTAVPVEEASGQQQVAVETSNDHSPY 
STGTYMPATTAMQGAYIPQYTHVQTAAVPVEEASGQQQVTVETSSDHSPY 
STGTYMPATTAMQGAYIPQYTHVQTAAVPVEEASGQQQVTVETSSDHSPY 
. * * * * * * ** : **** * * : *** : * : * * : : * * ********** : * * ** . * * ** * 
TFPPNK 
TFPPNK 
TFQPNK 
TFQPNK 
TYQQNK 
TYQQNK 
Figure 5.3 Multispecies alignment of RBM51 protein sequences 
Alignments were performed between human, chimpanzee, mouse, rat, and both chicken 
transcripts . Standard one letter abbreviations for amino acids have been used (see Appendix 
8). Identical amino acids are marked with asterisks, and RNP1 motifs are boxed. 
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ENSGALT00000033119 
ENSGALT00000018146 
ENSGALT00000033119 
ENSGALT00000018146 
ENSGALT00000033119 
ENSGALT00000018146 
ENSGALT00000033119 
ENSGALT00000018146 
ENSGALT00000033119 
ENSGALT00000018146 
ENSGALT00000033119 
ENSGALT00000018146 
ENSGALT00000033119 
ENSGALT00000018146 
ENSGALT00000033119 
ENSGALT00000018146 
ENSGALT00000033119 
ENSGALT00000018146 
ENSGALT00000033119 
ENSGALT00000018146 
ENSGALT00000033119 
ENSGALT00000018146 
ENSGALT00000033119 
ENSGALT00000018146 
ENSGALT00000033119 
ENSGALT00000018146 
ENSGALT00000033119 
ENSGALTOOOOOOIB146 
ENSGALT00000033119 
ENSGALT00000018146 
ENSGALT00000033119 
ENSGALT00000018146 
ENSGALT00000033119 
ENSGALT00000018146 
ENSGALT00000033119 
ENSGALT00000018146 
ENSGALT00000033119 
ENSGALT00000018146 
ENSGALT00000033119 
ENSGALT00000018146 
CCCCAACCCTGCACTGCAGGCTACATTTCCAGCTTCNTGGGCATAGTGTGGAAACAGCAG 
---------------------- - ------ -AGCTTCNTGGGCATAGTGTGGAAACAGCAG 
TACCCCCAGTACACCACCTACTACTACCCCCAGTATCTGCTGGCGAAGCAGTCCATT 
ATGTACCCCCAGTACACCACCTACTACTACCCCCAGTATCTGCTGGCGAAGCAGTCCATT 
************************************************************ 
GTACCAGCCCACCCAATGGCTCCTCCTAGTCCCAGCACCACCAGCAGTAATAACAACAGT 
GTACCAGCCCACC CTCCTCCTAGTCCCAGCACCACCAGCAGTAATAACAACAGT 
AGTAGCAGCAGCAACTCAGGATGGGATCAATTAAGTAAAACAAACCTTTACATCAGAGCA 
AGTAGCAGCAGCAACTCAGGATGGGATCAATTAAGTAAAACAAACCTTTACATCAGAGCA 
************************************************************ 
CTGCCTCCAAACACCACTGATCAGGACCTGGTAAAATTATGCCAACCGTATGGGAAAATT 
CTGCCTCCAAACACCACTGATCAGGACCTGGTAAAATTATGCCAACCGTATGGGAAAATT 
************************************************************ 
GTATCCACAAAGGCTATTTTGGATAAGACAACAAACAAGTG AAAGGTTATGGTTTTGTG 
GTATCCACAAAGGCTATTTTGGATAAGACAACAAACAAGTG AAAGGTTATGGTTTTGTG 
***************************************** ****************** 
TCGACAGCCCAGCAGCTGCTCAGAAGGCAGTTTCTGCTCTAAAGGCTAGTGGAGTC 
TCGACAGCCCAGCAGCTGCTCAGAAGGCAGTTTCTGCTCTAAAGGCTAGTGGAGTC 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ~ * * * * * * * * * * * * * * * * * * * *
CAGGCACAAATGGCAAAGCAACAAGAACAGGATCCAACAAATTTATACATTTCCAATTTG 
CAGGCACAAATGGCAAAGCAACAAGAACAGGATCCAACAAATTTATACATTTCCAATTTG 
************************************************************ 
CCACTTTCAATGGATGAGCAGGAGCTTGAGAACATGCTTAAGCCTTTTGGGCAGGTTATC 
CCACTTTCAATGGATGAGCAGGAGCTTGAGAACATGCTTAAGCCTTTTGGGCAGGTTATC 
************************************************************ 
TCTACGAGGATATTGCGTGACTCGAGTGGAACAAG CGTGGTGTTGGCTTTGCCAGG TG 
TCTACGAGGATATTGCGTGACTCGAGTGGAACAAG CGTGGTGTTGGCTTTGCCAGG TG 
*********************************** ********************* ** 
GAATCAACAGAAAAATGTGAAGCAGTGATTGCTCATTTTAACGGAAAATTCATAAAGACA 
GAATCAACAGAAAAATGTGAAGCAGTGATTGCTCATTTTAACGGAAAATTCATAAAGACA 
***************************************-*********.*********. 
CCAGCAGGAGTTTCTGTTCCTGCAGAACCTTTATTGTGCAAGTTTGCTGATGGAGGACAG 
CCAGCAGGAGTTTCTGTTCCTGCAGAACCTTTATTGTGCAAGTTTGCTGATGGAGGACAG 
************************************************************ 
AAAAAGAGACAGAATCAGAATAAATACATACAGAATGGAAGAGCATGGCACAGAGAAGGC 
AAAAAGAGACAGAATCAGAATAAATACATACAGAATGGAAGAGCATGGCACAGAGAAGGC 
************************************************************ 
GAGG - --- - - ---CTGGAATGACACTCACTTATGATCCAACCACAGCTGCTTTACAAAAT 
GAGGTGAGACTTGCTGGAATGACACTCACTTATGATCCAACCACAGCTGCTTTACAAAAT 
GGATTTTATCCATCACCCTACAGTATTACAGCAAACAGAATGATCACTCAAACATCTATT 
GGATTTTATCCATCACCCTACAGTATTACAGCAAACAGAATGATCACTCAAACATCTATT 
**************.*****************.*****.* •• * ~ * * * * * * * * * * * * * * * * *
ACGCCATATATTGCTTCTCCGGTTTCCACATACCAGGTTCAGAGTCCTTCTTGGATGCAG 
ACGCCATATATTGCTTCTCCGGTTTCCACATACCAGGTTCAGAGTCCTTCTTGGATGCAG 
************************************************************ 
CCTCAACCATATATAATGCAGCACCCAGGTGCTGTACTGACTCCCTCCATGGACCACACC 
CCTCAACCATATATAATGCAGCACCCAGGTGCTGTACTGACTCCCTCCATGGACCACACC 
ATGTCACTACAGCCTGCATCAATGATAAGCCCTTTGACGCAGCAGATGAGTCATCTTTCA 
ATGTCACTACAGCCTGCATCAATGATAAGCCCTTTGACGCAGCAGATGAGTCATCTTTCA 
TTAGGCAGTACTGGAACATACATGCCAGCCACAACAGCTATGCAAGGAGCCTACATACCC 
TTAGGCAGTACTGGAACATACATGCCAGCCACAACAGCTATGCAAGGAGCCTACATACCC 
CAATACACACATGTCCAGACAGCAGCGGTTCCTGTTGAGGAAGCCAGTGGTCAACAGCAG 
CAATACACACATGTCCAGACAGCAGCGGTTCCTGTTGAGGAAGCCAGTGGTCAACAGCAG 
************************************************************ 
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GTTACAGTAGAGACGTCCAGTGACCATTCTCCGTATACGTATCAACAAAATAAGI CTG 
GTTACAGTAGAGACGTCCAGTGACCATTCTCCGTATACGTATCAACAAAATAAG CTG 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ~ * * * ~ ~ * * * * * * * * * * * *
TGAGATGCCCGGTGTTGACCCGGCCTGGAGAAGGGTGCAAAGGCTGAAACAATCATGGAT 
TGAGATGCCCGGTGTTGACCCGGCCTGGAGAAGGGTGCAAAGGCTGAAACAATCATGGAT 
TTTACTGATCAATTGTGCTTTAGGAATTATTGACAGTTTTGCACAGGTTCTTGAAAATGT 
TTTACTGATCAATTGTGCTTTAGGAATTATTGACAGTTTTGCACAGGTTCTTGAAAATGT 
TATTTATAATGAAATCAACTAAAACTATTTTTGCTATAAGTTCTATAAGGTGCATAAGAA 
TATTTATAATGAAATCAAC - -------------- - ---------- - - --- - ------- --
AAACCTTAAAT TCATCTAGTAGCTGTTCCCATGAACAGGTTTATTTTAGTAAAAAAAAAA 
ATTTTTATCAAGTGTTACG 
Figure 5.4 ClustalW alignment of the two chicken RBMS1 mRNA transcripts 
Identical bases are marked with asterisks. ATG translation start sites are shown in 
green. and stop codons in red. RNP1 motif encoding regions are boxed. Sequences 
are from Ensembl (www.ensembl.org ). April 2010. 
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.. 603508858F I • 
.. 603954254F1 • 
l........ ur--r=! ENSGALT00000018146 (1369 bp, 373 residues) 
.. 603541128F1 ~ ~
.. 603215963F1 
! : = - ~ - - - - ~ ~ ~ - - - - ~ ~ - - ~ ~ ~ ~ - - ~ - - ~ ~ ~ i .• _._-_. __ --! ENSGALT00000033119 (1510 bp, 393 residues) 
RNP1 RNP1 
100 bp 
Untranslated reg ion 
:- - - - -: Non-identical exon 
Figure 5.5 Representation of the two chicken RBMS1 mRNA transcripts and EST coverage 
Diagrams are drawn to scale based on the transcripts ENSGAL T00000018146 and ENSGAL T0000003311 9 (Ensembl, April 2010). Exons that differ between 
transcripts are shown with dashed lines, and untranslated reg ions are shown in grey. Regions encoding the two RNP1 motifs are marked . Matching ESTs 
and reg ions of sequence identity are ind icated . 
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5.3.2 Investigation of RBMS1 expression in the developing chick 
5.3.2.1 RT ·peR 
RBMS1 expression was initially examined by RT -PCR in chick embryonic segments at 
three stages of development (HH16, HH19 and HH24) as a preliminary means of 
temporal I spatial characterisation of expression. Primers were designed to bind to 
both RBMS1 transcripts resulting in amplification of a 488 bp fragment (sequences in 
Table 2.5, primer positions are represented in Figure 5.7, A). Figure 5.6 shows results 
of RT-PCR expression analysis. Expression was detected in all segments (head, 
heart, body I limbs) at all three developmental stages examined (Figure 5.6, A). 
Negative RT controls were included and did not display amplification (Figure 5.6, B). 
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A 
RBMS1 
(SF 110R) 
RPLPO 
B 
RBMS1 
(SF 1 10R) 
RPLPO 
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~ ~ ~ ~
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Figure 5.6 RT·PCR expression analysis of RBMS1 
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Products were electrophoresed on 2% agarose gels using Hyperladder IV (Bioline) as 
a size marker (500 bp and 100 bp bands are indicated along with product sizes). (A) 
Expression was examined in wild type chick embryonic body segments at HH16, 
HH19 and HH24. RPLPO was used as a housekeeping gene. (B) Negative RT 
controls where reverse transcriptase enzyme was not added were included for both 
genes and did not result in amplification. 
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5.3.2.2 Whole mount in situ hybridisation 
RT-PCR expression analyses show that RBMS1 is expressed in the developing chick 
heart at HH12 - HH26 (Chapter 4), and throughout the embryo at HH16, HH19 and 
HH24 (Figure 5.6). These did not however allow identification of specific regions or 
structures of the heart giving rise to these signals. In order to obtain a more detailed 
picture of the localisation of RBMS1 transcripts, whole mount in situ hybridisation was 
performed. Two non-overlapping probes were generated against RBMS1 using the 
RT-PCR products shown in Figure 5.7, designed to bind to both RBMS1 transcripts. 
RT -PCR products were gel purified, cloned into the pGEM-T Easy vector, and 
sequenced in both directions for confirmation of sequence and determination of 
orientation. Clones selected contained insert in the forward orientation. Plasmid 
linearisation was carried out using an appropriate enzyme whose restriction site was 
not present within the insert, in this case Spel for antisense probes, and Sacll for 
sense probes (Appendix F). Single stranded DIG-labelled RNA probes were 
synthesised using a DIG RNA labelling mix by in vitro transcription with T7 RNA 
polymerase (antisense) or SP6 RNA polymerase (sense). Expression was examined 
at HH16, HH19 and HH24. For colour development, samples were incubated in fresh 
colour reagent at room temperature for 20 minutes in the dark, and longer as 
appropriate up to a maximum of 90 minutes due to the high strength of the signal. 
Background was reduced by washing in KTBT and a graded methanol series. 
Samples were stored in PBS and photographed in 70% glycerol. 
RBMS1 expression was detected in the heart and throughout the embryo at all three 
stages of development, and represented in Figures 5.8 - 5.10. In situ hybridisation 
results for HH16 and HH19 early stage embryos (using the 5F/10R probe) are 
displayed in Figure 5.8. At HH16, staining to the heart was very weak, and other 
regions of the embryo including the somites displayed strong expression. The HH19 
embryo displayed general expression, and staining to the heart was stronger at this 
stage. HH24 stage embryos are displayed in Figure 5.9 (probe 1F/5R) and Figure 
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5.10 (probe 5F/10R). RBMS1 displays expression in all areas of the heart, and is 
highly expressed in the developing forelimb and hind limb buds, somites, and brain. 
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Figure 5.7 Amplicons used for RNA probe synthesis 
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ENSGALT00000018146 (1369 bp, 373 residues) 
ENSGALT00000033119 (1510 bp, 393 residues) 
100 bp 
Untranslated region 
.-----1 
Non-identical exon 
(A) Representation of the two chicken R8MS1 mRNA transcripts, ENSGALT00000018146 and ENSGALT00000033119 are shown, and primer positions are 
indicated by the arrows. (8) RT-PCR products were amplified from HH19 chick heart eDNA and are displayed in the gel image, and product sizes are 
indicated 
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Figure 5.8 In situ hybridisation expression analysis of RBM51 in the HH16 and HH19 
chick embryo using the 5F/10R probe 
Lateral embryonic views of embryos are displayed, and embryonic age is indicated . Expression 
was detected with the 1 F/5R antisense probe, using the corresponding sense probe as a control 
(shown in Figure 5.11). Scales bars represent 500 ~ ~ . . h - heart, som - somites 
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II 
som 
Figure 5.9 In situ hybridisation expression analysis of RBMS1 in the HH24 chick embryo 
using the 1F/5R probe 
Lateral embryonic views of embryos are displayed . Expression was detected with the 1 F/5R 
antisense probe, using the corresponding sense probe as a control. Scales bars represent 500 
~ ~ . . tel - telencephalon, mes - mesencephalon, h - heart, ot - outflow tract, a - atrium, v -
ventricle, hlb - hind limb bud, fib - forelimb bud, som - somite 
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Figure 5.10 In situ hybridisation expression analysis of RBMS1 in the HH24 chick embryo 
using the 5F/10R probe 
Lateral embryonic views of embryos are displayed. Expression was detected with the 5F/10R 
antisense probe, using the corresponding sense probe as a control. Scales bars represent 500 
IJm. tel - telencephalon, mes - mesencephalon, h - heart, ot - outflow tract, a - atrium, v -
ventricle, hlb - hind limb bud, fib - forelimb bud, som - somite 
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5.3.3 RBMS1 morpholino knockdown studies 
In order to investigate the role of RBMS 1 in cardiac development, morpholino loss of 
function studies were carried out. Morpholinos were applied at HH10 - HH16, and 
embryos harvested for analysis at HH19. At HH10 - HH12, dextral looping of the heart 
occurs, and looping continues until HH17/HH18. Endocardial cushion formation in the 
AV canal has begun by HH12, and development of the interatrial septum begins at 
HH14. These are crucial stages in cardiac development, and gene knockdown at this 
time will provide information into the role of RBMS1 in these processes. 
5.3.3.1 Design of splice-junction targeting morpholinos and controls 
Due to the presence of two RBMS1 mRNA transcripts, each potentially with a distinct 
ATG translational start site (Figure 5.4), morpholinos were designed to common splice 
junctions in order to modify gene splicing in both transcripts. Splice-blocking 
morpholinos can either be targeted to splice donor sites (exon-intron) or splice 
acceptor sites (intron-exon), and most commonly result in exon skipping, or 
alternatively in intron retention [Morcos, 2007]. Activation of cryptic splice sites may 
also occur, which can result in partial insertions or deletions [Morcos, 2007]. The 
design of splice-junction targeting morpholinos requires additional pre-mRNA 
sequence information, with well defined exon-intron and intron-exon junctions. This 
sequence information was obtained through the combinatorial use of genomic 
sequence information (extracted from Ensembf) and cDNA sequence information 
(verified with EST evidence, as outlined in section 5.3.1). The RBMS1 E212 
morpholino was designed to bind to the exon 2 - intron 2 splice junction. This 
morpholino was predicted to cause deletion of ex on 2 (176 bp), a resulting frameshift 
and premature termination. Alternatively, retention of intron 2 (25676 bp) may occur, 
also resulting in a premature termination. Morpholino sequence, target region and 
possible effects are displayed in Figure 5.11. A corresponding 5-base mismatch 
morpholino was also designed as a control of specificity and is displayed. Morpholino 
sequences are displayed in Table 2.8. 
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Chicken RBMS1 E212 morpholino 
E212 5 - mismatch morpholino 
E212 morpholino 
3 '- ATACCGTTGCCATTGATGCTATCAA - 5 ' 
3 ' - ATACGGTTGGCATTCATGCTATGAA - 5 ' 
Pre - mRNA 
mRNA 
5 ' - GCACUGCCUCCAAACACCACUGA UCAGGACCUGGUAAAAU[U-AUGCC AACCG-UAAG UACGA UACUu)AAAUACGGAUUACGGAAUCGUACC UUAUAAG UUU G - 3 ' 
5 '- GCACUGCC UCCAAACACCACUGAUCAGGACCUGG UAAAAUUAUGCCAACC - 3 ' 
Protein ALP P N T T D Q D L V K L C Q 
& ~ ~ ~ 3 R R Exon 5R 
Pre-mRNA 
Wild type mRNA I I II · ·1 111 I IV I V I VI VII IVIIII IX I X I XI I XII I XIII I XIV 
Possible E212 effect on spl icing: Exon 2 skipping (176 bp exclusion) [ rlliT iv [- V VI r VII IVlIII - lx- I x r XI XII [ XIII XIV 
Intron 2 retention (25 676 bp inclusion) II Hili I IV I _. V-T vir VII [Villi IX I X I XI XII I XIII I XIV 
c=J100bp 
Figure 5.11 RBMS1 E212 and control morpholino sequences and predicted effects on mRNA splicing 
The shorter of the two mRNA transcripts (ENSGAL T00000018146) is represented for simplicity; all morpholinos, primers etc have been designed to bind to common regions of 
both transcripts . Exons are drawn to scale, and intron sizes have been standardised. Morpholino sequences are shown in the 3' - 5' direction, and target binding reg ions are 
boxed . Bases altered in mismatch control morpholinos are underl ined. 
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5.3.3.2 Preliminary testing of morpholinos in ovo 
Initial phenotypic analysis of embryos was carried out externally and is displayed in 
Figure 5.12. The degree of abnormality was determined by gross examination of 
embryo size and shape, followed by visual assessment of heart shape and structure. 
Figure 5.12 A1 and B1 depict wild type and standard control treated embryonic hearts, 
which display normal size, curvature and shape. Figure 5.12 C1 and C2 are examples 
of embryos treated with the E212 5-mismatch morpholino at 250 IJM and 500 IJM 
respectively, both displaying an abnormal heart shape and constriction to the ventricle. 
In total, 2 I 8 embryos treated with the mismatch control at 250 IJM, and 5 I 18 
embryos treated at 500 IJM harboured a cardiac defect. Since these were similar to 
the abnormalities observed in knockdown embryos (discussed later in section 5.3.3.4), 
it was thought that the 5-base mismatch morpholino was still able to bind to the target 
region (as in Chapter 4), and a new control of specificity was required. 
5.3.3.3 Selection and design of an alternative control of specificity 
At the time of this research, it emerged that the use of mismatch morpholinos was no 
longer considered the best control of specificity (personal communication with Dr Jon 
Moulton, Gene-Tools). This was based on the frequency with which mismatch 
morpholinos were able to generate an effect due to retained binding capability to 
target sites, or off-target effects, as demonstrated in this thesis. Instead of moving to 
a 7-base mismatch control (as previously in Chapter 4), the use of a second non-
overlapping targeting morpholino to the same gene was recommended in order to look 
for morpholino specificity upon generation of a common phenotype, since it was 
deemed unlikely the same off-target effect would be created by separate morpholinos. 
Morpholino specificity and effect on target mRNA or protein could then be determined 
by other means. Consequently, a second splice site morpholino was designed; the 
RBMS1 E818 morpholino was designed to bind to the exon 8 - intron 8 splice junction, 
and predicted to cause deletion of exon 8 (50 bp) and a resulting frameshift, or 
retention of intron 8 (92 bp) which would result in a premature stop. This is 
represented in Figure 5.13, and morpholino sequences are given in Table 2.8. 
178 
Investigation of the role of RBMS1 in cardiac development 
Standard control 
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Figure 5.12 External phenotypic analysis of embryos treated with RBMS1 E2125-
base mismatch morpholinos in comparison to standard control-treated and wild 
type embryos 
Bright field lateral embryonic views of wild type (A 1). standard control (81). and E212 
5-mismatch control (C1-C2) are displayed with developmental stages of morpholino 
application and embryo harvest. Standard control morpholino was applied at a 
concentration of 500 ~ M . . and mismatch control morpholinos applied at both 250 ~ M M
and 500 ~ M M as indicated. Scale bars represent 500 ~ ~ . . ot - outflow tract, v -
ventricle 
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Chicken RBMS1 ESIS morpholino 
3 '- TACCCATACAATTCACGACCATGTG - 5 ' ESlS morpholino 
Pre-mRNA 
mRNA 
5 ' - G C U G G A A U G G C A C U C A C U U A U G G U C C A A C C A C A A C U G C U U U A C A A N N U G G G U A U G U U A A A U G C U G G U A C A ~ A A G A A A A A A A U G U U U G C A U U A U G A A A A U U U - 3 ' 
5 ' - GCUGGAAUGACACUCACUUAUGAUCCAACCACAGCUGCUUU ACAAAAUGG - 3 ' 
Protein A GMT L T Y D P T T A A L Q N 
Exon SF Exon 10R 
Pre-mRNA 
Wild type mRNA I I II I III I IV I V VI I VII IVI IiI IX I X I XI I XII I XII I I XIV 
Possible E818 effect on spl icing: Exon 8 skipping (50 bp exclusion) [ I r-II - . I-III I 1"-r - - v - ~ V V T T VII IX I X I XI I XII I XIII I XIV ~ ~
Intron 8 retention (92 bp inclusion) I I II I III I IV - I V I VI VII M IH IX I X I XI I XI I I XIII I XIV 
c=J100 bp 
Figure 5.13 RBMS1 ESIS morpholino sequence and predicted effect on splicing 
The shorter of the two mRNA transcripts (ENSGAL T00000018146) is represented for simplicity; all morpholinos, primers etc have been designed to bind to common reg ions of 
both transcripts. Exons are drawn to scale, and intron sizes have been standardised. Morpholino sequences are shown in the 3' - 5' direction, and target binding reg ions are 
boxed . Bases altered in mismatch control morpholinos are underlined . 
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5.3.3.4 External phenotypic analysis of RBMS1 knockdown embryos 
External analysis focusing on embryonic hearts was performed on animals subjected 
to various morpholino treatments (Figure 5.14). Wild type and standard control 
treated embryos displayed no outward abnormalities (Figure 5.14 A 1 and B 1 
respectively) whilst treatment with RBMS1 targeting morpholinos resulted in a range of 
cardiac abnormalities (Figure 5.14 C1-C4, 01-04). 
Treatment with the RBMS 1 E212 targeting morpholino resulted in heart malformations 
at both concentrations of application (Figure 5.14 C1 - C4). Morpholino was applied 
to the embryos depicted in Figure 5.14 C1 and C2 at 250 ~ M , , and these respectively 
display an abnormal heart shape and defect in heart looping. Embryos shown in 
Figure 5.14 C3 and C4 were treated at 500 ~ M M and display a bulbous heart and 
irregular heart shape respectively. In total, cardiac abnormalities were seen in 2 / 11 
embryos treated with the E212 morpholino at 250 ~ M M and 5/16 embryos treated at 
500 ~ M . .
E818 treated embryos also displayed abnormalities in heart shape and looping (Figure 
5.1401 - 04). Embryos treated at 250 ~ M M are displayed in Figure 5.14 01 and 02, 
and respectively show abnormal cardiac looping and a thin almost tubular ventricle. 
Treatment at 500 ~ M M resulted in abnormal cardiac looping and heart shape (Figure 
5.14 03 and 04 respectively). In total, abnormalities were seen in 2/15 embryos 
treated with the E818 morpholino at 250 ~ M , , and 8 / 17 embryos treated at 500 ~ M . .
Phenotypic analysis data is summarised in Table 5.2. 
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Figure 5.14 Altered cardiac morphology of RBMS1 knockdown embryos 
Bright field lateral embryonic views of wild type (A 1), standard control (B 1), RBMS 1 E212 applied at 250 11M (C 1-C2) and 500 11M (C3 and C4) , and RBMS 1 
E818 applied at 250 11M (01-02) and 500 11M (03-04) are displayed . Developmental stages of morphol ino application and embryo harvest are indicated. Two 
examples of embryos subjected to each treatment are displayed. Scale bars represent 500 11m . at - outflow tract , v - ventricle 
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5.3.3.5 Histological analysis of RBMS1 knockdown embryos 
Embryos were fixed in 4% PFA and dehydrated in a graded ethanol series prior to wax 
embedding. Embryos were sectioned coronally at a thickness of 10 microns, and 
sections transferred onto slides for haemulum staining and mounting with OPX. The 
high frequency of looping abnormalities did not always allow sectioning in the correct 
plane, resulting in difficulties in assessment of septum size in some cases. Figure 
5.15 shows haemulum stained sections through control and knockdown embryos at 
points where the atrial septum is visible at its maximal size. Wild type and standard 
control embryos displayed a normal overall heart shape and structure including atrial 
septum size (Figure 5.15 A 1 and B 1 respectively). Treatment with the splice targeting 
morpholinos resulted in a reduction in the size of the atrial septum. Figure 5.15 C1 
and C2 are two examples of embryos treated with the E212 morpholino at 250 IJM; C1 
displayed a complete lack of septum, and C2 was normal. In total, 1 17 embryos in 
this treatment group displayed an internal cardiac defect. A larger proportion of 
embryos treated at 500 IJM displayed cardiac abnormalities (5/11), primarily in septal 
size, with secondary defects also present in some cases. Both examples shown 
(Figure 5.15 C3 and C4) are abnormal, with an atrial septum absent in C3. C4 shows 
septal growth but the heart is under-developed. Treatment with the E818 morpholino 
at 250 IJM (Figure 5.15 01 and D2) did not have an effect on the internal structure of 
the heart (based on 8 embryos). However, treatment with this morpholino at 500 IJM 
resulted in a reduction in the size of the atrial septum in 6 I 13 cases. The two 
morpholinos produced overlapping but distinct abnormalities, which may be explained 
by the fact that each was targeted to a different region of the RBMS 1 gene, resulting 
in different functional domains being affected in surviving proteins. This is observed 
with genes such as TBX5 in HOS, where mutations in the 5' end of the T-box most 
significantly affect the heart, whilst mutations in the 3' end of the T -box have a more 
predominant effect on the limbs [Basson et aI., 1999] (although there are exceptions 
[Boogerd et al.]). Overall, knockdown of RBMS1 resulted in refinement of the original 
phenotype observed in TBX5 / GATA-4 double knockdown embryos, with 
abnormalities restricted to the heart. This was surprising in view of the widespread 
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expression pattern of RBMS 1, particularly when compared to the more restricted 
expression patterns of both TBX5 and GAT A-4. 
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Figure 5.15 Histological analysis of altered cardiac morphology of RBMS1 
knockdown embryos at HH19 
Haemulum stained coronal embryonic sections through two embryos in each group 
are displayed. Groups represented are; (A) wild type, (B) standard control (500 JJM), 
(e) RBMS1 E212 (250 JJM and 500 JJM), and (D) RBMS1 E818 (250 JJM and 500 JJM). 
Developmental stages of morpholino application (where applicable) and embryo 
harvest are indicated. Regions of atrial septa formation (or expected septation) are 
boxed, shown at their maximum size upon viewing serial sections throughout embryo. 
Scale bars represent 500 JJm. 
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Table 5.1 Summary of heart abnormalities seen in RBMS1 knockdown embryos in comparison to controls 
Embryos with heart abnormality 
Naturelregion of heart Untreated (wild Standard RBMS1 E212 5- RBMS1 E2125- RBMS1 E212 RBMS1 E212 RBMS1 E818 RBMS1 E818 
abnormality type) control 500 IJM mis250 IJM mis 500 IJM 250 IJM 500 IJM 250 IJM 500 IJM I 
II) Heart size I shape 1/30 0/10 2/8 2/18 1/11 3/16 2/11 6/17 
-iii 
>-iii Heart looping 1/30 0/10 2/8 3/18 1 111 2/16 0/11 2/17 c: 
III 
iii Ventricle formation 0/30 0/10 0/8 0/18 0/11 0/16 0/11 0/17 E 
Q) 
x Total 2/30 0/10 2/8 5/18 2/11 5/16 2/15 8/17 w 
II) Atrial septation 1 110 0/10 1 11 2/3 117 5/11 0/8 6/13 
-iii 
z.. 
Trabeculation 0/10 0/10 1 11 1/3 117 3/8 0/8 III 0/6 c: 
<11 
iii Cardiac jelly 0/10 0/10 0/1 0/3 017 0/8 0/8 0/13 E 
2 
.£ Total 1/10 0/10 1/1 2/3 1/7 5/11 0/8 6/13 
----- -- --
Groups represented are wild type, standard control (500 ~ M ) , , RBMS1 E212 (250 ~ M M and 500 ~ M ) , , and RBMS1 E818 (250 ~ M M and 500 J-lM)-
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5.3.4 Characterisation of morpholino effects on splicing 
For characterisation of morpholino effects on splicing, RT-PCR was carried out using 
strategically placed primers for detection of alternatively spliced products. 
5.3.4.1 RBMS1 E212 morpholino 
5.3.4.1.1 Sample collection and preparation 
RBMS1 E212 morpholino was applied to approximately 100 eggs following exclusion 
of embryos which were no longer viable or not within the desired range of 
development (HH12 - HH16). Morpholino-treated embryos were excised from the egg 
at HH19, placed in sterile chilled PBS, and membranes quickly removed. Morpholino 
uptake was assessed under fluorescent light and positive hearts isolated and stored in 
RNA/ater at -20°C. Eight hearts were pooled per sample, and three biological 
replicates collected per group (2 groups: knockdown and wild type). RNA was 
column-extracted and concentration assessed by spectrophotometry. Exactly 1 ~ g g
RNA was used per 20 ~ I I reverse transcription reaction, and samples made up to 100 
IJI prior to use. 
5.3.4.1.2 Primer placement for detection of alternatively spliced transcripts 
As previously mentioned, the E212 morpholino would be expected to result either in 
exon 2 skipping, or intron 2 retention (Figure 5.12). Morpholino binding to splice 
junctions can also result in activation of cryptic splice sites, leading to partial insertions 
or deletions. Primers were therefore designed to flank the entire region which may be 
affected, in order to determine the nature of the morpholino effect through 
amplification of alternatively spliced transcripts and assessment of their size. Thus, 
the initial set of primers was placed in exon 1 and exon 5. An additional set of primers 
was also designed to exon 2 and exon 3; these could amplify any products with partial 
intronic retention (dependent on the size of the intronic region retained). Due to the 
large size of intron 2 (25676 bp), it would not be possible to amplify this whole region 
by PCR in the event of full intronic retention. Instead, a third set of primers was 
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designed within intron 2 in order to attempt peR amplification of a small portion of this 
region (243 bp) for comparison between knockdown animals and untreated controls. 
Primer sequences are given in Table 2.5. RPLPO was used as an internal control and 
amplified in parallel. 
5.3.4.1.3 RT -peR amplification and sequencing of mRNA transcripts 
peR products generated using the above primers are shown in Figure 5.16. peR 
using exon 1 F and exon 5R primers resulted in sale amplification of the wild type 
transcript (354 bp) in all samples. Amplification using a second set of primers, exon 
2F and exon 3R, also generated a single wild type product (213 bp) in all samples. 
Amplification using the above primer pairs was performed using extension times 
ranging from 30 seconds to 5 minutes, all yielding the same result. Products were 
also sequenced (one knockdown and one wild type from each group) to assess 
whether alternative splicing events (which may not have altered product sizes) had 
occurred, and all transcripts detected were normal. A third set of primers designed to 
detect retention of intron 2 produced an intronic band of the expected size (243 bp) in 
all samples. This was thought to be a pre-mRNA transcript, as amplification did not 
occur in negative RT controls (where no reverse transcriptase enzyme was added). 
RPLPO was also assayed as an internal control. 
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Figure 5.16 Characterisation of the effect of the RBMS1 E212 morphollno on 
mRNA splicing 
PCR was performed at an annealing temperature of 60 °C with 35 cycles of 
amplification, and samples electrophoresed on 2% agarose gels. Three biological 
replicates were assayed for morpholino-treated and wild type groups. Three sets of 
primers were used for amplification of RBMS1 transcripts, and RPLPO was assayed in 
parallel as an endogenous control. 
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5.3.4.2 RBMS1 ESIS morpholino 
5.3.4.2.1 Sample collection and preparation 
Embryos were treated with morpholino as previously (section 5.3.4.1.1). Three wild 
type and three morpholino positive whole embryos were harvested at HH19, and RNA 
column extracted and quantified for cDNA synthesis using 1 ~ g g RNA in a 20 ~ I I
volume. Samples were made up to 100 ~ I I prior to use. 
5.3.4.2.2 Primer placement for detection of alternatively spliced transcripts 
The E818 morpholino would be expected to result in exon 8 skipping (50 bp), or intron 
8 retention (92 bp) (Figure 5.13). Flanking primers were designed to exon 5 and exon 
10 for detection of alternatively spliced transcripts. An additional set of primers was 
also designed to exon 8 I exon 9, which would result in amplification of products 
harbouring partial/full intron retention. Primer sequences are given in Table 2.5. 
RPLPO was included as an endogenous control. 
5.3.4.2.3 RT-PCR amplification and sequencing of mRNA transcripts 
Figure 5.17 shows results of RT -PCR amplification using the above primers. Both 
sets of primers resulted in amplification of a single wild type transcript in all samples 
i.e. alternatively spliced products were not found. The product generated from the 
KD1 sample appeared to be fainter than the others in both RT-PCR assays, and 
QPCR was used to quantify any changes (see next section, 5.3.5). RT -PCR products 
from a single wild type and knockdown sample were also sequenced to assess any 
changes, but only wild type sequences were detected. 
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Figure 5.17 Characterisation of the effect of the RBMS1 E818 morpholino on 
mRNA splicing 
PCR was performed at an annealing temperature of 60°C with 35 cycles of 
amplification, and samples electrophoresed on 2% agarose gels. Three biological 
replicates were assayed per group. Two sets of primers were used for amplification of 
RBMS 1 transcripts, and RPLPO was assayed in parallel as an endogenous control. 
The arrow indicates bands generated from low level genomic contamination in -RT 
samples KD2 and KD3 (152 bp product). 
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5.3.5 QPCR analysis of morpholino effects on mRNA levels 
RT-PCR did not result in detection of alternatively spliced products as a result of 
treatment with either morpholino. Nonsense-mediated decay (NMD) is a cellular 
mechanism in which aberrant mRNAs are detected (through recognition of premature 
termination codons (PTCs», and degraded [Hentze and Kulozik, 1999]. It was 
possible that NMD was eliminating alternatively spliced transcripts in morpholino-
treated embryos, which would result in a corresponding decrease in wild type RBMS1 
mRNA transcripts. QPCR expression analysis was performed in order to quantify any 
morpholino-induced change in RBMS1 mRNA levels. RNA isolated previously for 
splicing characterisation was used, and new reverse transcriptase reactions were 
performed. Dilutions of cDNA were carried out immediately upon synthesis, as 
described in 2.2.1.10.5. 
5.3.5.1 Validation of RPLPO as an appropriate endogenous control 
RPLPO was used in Chapter 4 as an endogenous control for normalisation of data, 
where its suitability was assessed by study of assay properties and analysis of 
variation of expression levels in study samples. In order to confirm that RPLPO 
expression was not affected by samples treatments here, CT values of RPLPO were 
measured in triplicate for each sample following their identical preparation and dilution, 
and are displayed in Table 5.2. RPLPO displayed constant expression across 
samples for both experimental groups ( ~ C T T values of -0.24 (E212 treatment) and 0.16 
(E818 treatment», and was used as an endogenous control gene. 
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Table 5.2 Mean CT and 6CT values of RPLPO in study samples 
Morpholino Sample Mean CT 6CT 
Wild type (calibrator) 25.42368 0 
RBMS1 E212 
Morpholino treated 25.66415 -0.24048 
Wild type (calibrator) 18.03443 0 
RBMS1 E818 
Morpholino treated 17.87218 0.162246 
Three biological samples were analysed per group. each assayed in triplicate. A 
standard curve was run in parallel on the same reaction plate for confirmation of assay 
quality. 
194 
Investigation of the role of RBMS 1 in cardiac development 
5.3.5.2 QPCR analysis of RBMS1 in morpholino treated embryos 
Baseline and threshold values were set manually, and absolute quantities of each 
gene generated from the standard curves in Applied Biosystems 7500 v2.0.1 software. 
Standard curves for target and endogenous control genes were included on each 
plate, with each point measured in duplicate. All samples were run simultaneously on 
the same plate, each assayed in triplicate. Biological and experimental replicates 
were grouped for data normalisation and standard deviation calculations. Results of 
QPCR analysis are shown in Table 5.3 and Figures 5.18 and 5.19. No difference in 
mRNA levels of RBMS1 was observed between morpholino treated and wild type 
animals (data non-significant by student's t test). It is not clear why these approaches 
(both RT -PCR and QPCR) did not show any change at the mRNA level, given the 
identical and specific phenotype generated by the two morpholinos. 
Table 5.3 QPCR expression analysis of RBMS1 In E212 and E81S morpholino 
treated animals and controls 
RBMS1 relative expression 
Morpholino Morpholino treated Wild type 
RBMS1 E212 1.01 ± 0.44 1.04± 0.19 
RBMS1 E818 0.39 ± 0.11 0.41 ± 0.12 
QPCR expression analysis was performed on RBMS1 E212 morpholino treated 
embryonic hearts (8 per sample), and E818 treated whole embryos (1 per sample), 
each with corresponding wild type controls. 3 biological replicates were assayed per 
group. Expression is measured relative to the endogenous control RPLPO. Data was 
not significant (student's t test, p<0.05). 
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Wild Type 
Figure 5.18 QPCR expression analysis of RBMS1 in E212 morpholino treated 
animals and controls 
QPCR expression analysis was performed on RBMS1 E212 morpholino treated 
embryonic hearts (8 per sample), with corresponding wild type controls. 3 biological 
replicates were assayed per group. Expression is measured relative to RPLPO. Error 
bars represent standard deviation. Data was not significant by student's t test. 
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Figure 5.19 QPCR expression analysis of RBMS1 in ESIS morpholino treated 
animals and controls 
QPCR expression analysis was performed on E818 morpholino treated whole embryos 
(1 per sample), with corresponding wild type controls. 3 biological replicates were 
assayed per group. Expression is measured relative to RPLPO. Error bars represent 
standard deviation. Data was not significant by student's t test. 
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5.3.6 Bioinformatic promoter analysis of the a-actin genes 
The a-actins are likely to have arisen from a common ancestral gene and show a high 
level of sequence similarity. Work by others has shown that RBMS1 negatively 
regulates expression of a-smooth muscle actin via a TATCTTA sequence found in the 
promoter region at position -228 to -222 [Kimura et aI., 1998]. Due to the high degree 
of conservation between a-smooth muscle actin and other a-actins (a-skeletal and a-
cardiac actin), it was postulated that RBMS1 may also playa role in the transcriptional 
regulation of these genes. The T ATCTT A motif in a-smooth muscle actin displays 
only partial conservation (57%) with other species such as human, rat and mouse 
[Kimura et aI., 1998]. This means that multi-species alignment for promoter analysis 
(as performed in Chapter 3) would not be an appropriate tool for identification of this 
motif. Promoter analysis was instead performed to examine the presence of the 
T ATCTT A regulatory sequence solely in chicken striated a-actin genes, using the 
'fuzznuc' search function (http://emboss.bioinformatics.nl/) which searches for patterns 
in nucleotide sequences. The TATCTTA motif was identified in both striated actin 
genes, located approximately 7 kb and 4.5 kb upstream of the first exon of a-cardiac 
and a-skeletal actin respectively. The position of these in relation to transcriptional 
start sites has not been determined. Additional motifs were identified within the coding 
regions and further 3'. 
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5.3.7 QPCR expression analysis of the actin genes in RBMS1 E212 morpholino 
treated animals and controls 
RBMS1 negatively regulates transcription of a-smooth muscle actin, which means this 
gene can act as a positive control for knockdown. QPCR expression analysis was 
performed to assess whether a-smooth muscle actin and other a-actin genes were up-
regulated in RBMS1 E212 morpholino treated embryonic hearts. The effect of the E818 
morpholino on expression of these genes would also have been performed, but time 
restrictions did not allow this. 
5.3.7.1 QPCR assay design 
As previously, QPCR assays were designed using the online Roche Universal 
ProbeLibrary assay design centre (https://www.roche-applied-science.com) following 
the same general guidelines. Sequence alignments between the three a-actins were 
performed for design of assays to regions of maximal diversity for gene-specificity. 
The relevant regions including primer and probe binding sequences and RT -PCR 
products generated are shown in Figure 5.20. Amplicons were cloned into the pGEM-
T Easy vector for sequencing to confirm assay specificity. Primer sequences and 
positional information are given in Table 2.6. 
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a-smooth muscle actin 
a-skeletal muscle actin 
a-cardiac muscle actin 
a-smooth muscle actin 
a-skeletal muscle actin 
a-cardiac muscle actin 
a-smooth muscle acUn 
a-skeletal muscle actin 
a-cardiac muscle actin 
G C A C C T G A G G A C A T T G A C A T A G A A G A T G T G T G A G G A G G ~ G A C A G C ~ T G C C C T T G T T T G T G A C A A T G G C T C A G G G C T C T G T A A A
--- - -----------ATCAGCCAAGATGTGTGACGACGAGGAGACCACCGCGCTGGTGTGCGACAACGGCTCGGGGCTGGTCAA 
AGCATATTACTGTGAATGTATTCAGGAAAATACATTCTTAAAATTTCATTCCATAAATCTTTCATCGTAATGGCTGGTTAATTGGATACGGTGTA 
TGCCAACCAC---------ACTCAGGATGACA- ATCTTGTAGGTT[CAGGCTqcTGAGGACC---TGCACCAGCCATGCAACTT- - -- - - - --TC 
TTCCCACTCAG---- -- - - GATGACGACAGTATGCTTCTTGGAGTCT--TCTGGCAGCCCTTC--CTGAACTCCTCCGTCATTGTACAGTTTGTT 
TGAAAACGAGATGGCCACTGCTGCCTCTTCCTCCTCTCTGGAAAAAAGCTATGAGCTTCCTGATGGC 
TGAGAACGAGATGGCCACCGCTGCCTCCTCCTCCTCCCTGGAGAAGAGCTATGAGCTGCCTGATGGG 
TGAGAATGAAATGGCCACAGCTGCTTCGTCAT[CTCCCTGGAGNAGAGCTACGAATTGCCTGATGGT 
Figure 5_20 QPCR assays used for expression analysis of the three actin genes 
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Primer binding sites are underlined, and probe binding sites are boxed. Sequences have been aligned with the corresponding region of the other two a-actin 
genes (shown in grey). 2% agarose gel images displaying the RT-PCR products generated are shown on the right. Specificity of each assay was confirmed 
by sequencing of RT-PCR products following cloning into the pGEM-T Easy vector. 
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5.3.7.2 Expression analysis 
QPCR expression analysis was performed using the same samples as previously, on 
RBMS1 E212 morpholino treated embryonic hearts (8 per sample) and corresponding 
wild type controls. Three biological replicates were assayed per group. Data was 
normalised to RPLPO. Table 5.5 and Figure 5.21 show results obtained from QPCR 
analysis of the a-actins in E212 treated embryos and controls. Expression was 
measured relative to RPLPO. In wild type HH19 embryonic hearts, a-cardiac actin 
was the most highly expressed actin, followed by a-skeletal actin, with a-smooth 
muscle actin displaying the lowest level of expression. Expression of a-smooth 
muscle actin was found to be greater in the E212 treatment group than in wild type 
embryos (significant by the student t test, p<0.05). No significant differences in 
expression of the striated actins were observed between the treated and untreated 
groups. 
Table 5.5 QPCR expression analysis of actin genes in RBMS1 E212 morpholino 
treated animals and controls 
Relative expression 
Gene RBMS1 E212 treatment Wild Type 
a-smooth muscle actin 3.87 ± 1.13* 2.25 ± 0.95 
a-skeletal muscle actin 30.3 ± 8.28 23.4 ± 8.48 
a-cardiac muscle actin 29.3 ± 11.6 33.1 ± 4.31 
QPCR expression analysis was performed on RBMS1 E212 treated animals and wild 
type controls (3 biological replicates per group). Expression is measured relative to 
the endogenous control RPLPO. *Significant difference between E212 treated sample 
and wild type control (p<0.05, student's t test). 
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Figure 5.21 QPCR expression analysis of the three actin genes in RBMS1 E212 
morpholino treated animals and controls 
QPCR expression analysis was performed on RBMS 1 E212 treated animals and wild 
type controls (3 biological replicates per group). Expression is measured relative to 
the endogenous control RPLPO. Error bars represent standard deviation. ·Significant 
difference between E212 treated sample and wild type control (p<O.05, student's t 
test). 
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CHAPTER 6 
MICROARRAY EXPRESSION ANALYSIS OF TBX51 GATA-4 
DOUBLE KNOCKDOWN EMBRYOS 
6.1 AIMS 
This chapter aims to identify new downstream targets of TBX5 and GAT A-4 in the 
developing chick heart by performing microarray analysis of double knockdown 
embryos as follows: 
a) Morpholino knockdown and collection of tissue. Extraction of RNA and 
assessment of concentration and purity 
b) Microarray expression analysis of TBX5 I GATA-4 double and single 
knockdown embryos and controls 
c) Review of literature and selection of candidate genes for further study 
d) Preliminary expression analyses in the chick embryo 
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6.2 RESULTS 
6.2.1 Morpholino knockdown and tissue collection 
Morpholinos were applied as described previously (Chapter 4) to create five sample 
groups: 
1) TBX5 and GATA-4 double knockdown 
2) TBX5 single knockdown (with GATA-4 7-mismatch control) 
3) GATA-4 single knockdown (with TBX5 7-mismatch control) 
4) TBX5 7-mismatch control and GATA-4 7-mismatch control 
5) Wild type 
Approximately 300 eggs were opened in total for this study. Morpholino was applied 
to around half following exclusion of embryos which were no longer viable or not at the 
required stage of development. Morpholinos were applied at HH15 for harvest at 
HH19 at a concentration of 250 ~ M M each, and uptake was assessed by fluorescent 
microscopy. Morpholino positive embryonic hearts were isolated and stored in 
RNA/ater prior to appropriate pooling of samples for column extraction of RNA. One 
sample was collected per experimental group, each comprising eight hearts (this was 
found to be the minimum number of HH19 stage hearts required for successful 
isolation of RNA). It would have been preferable to include three samples per 
experimental group; however resource did not allow this. As a result, this approach 
does not provide enough statistical power, and data will require further validation 
either by subsequent addition of a further two samples per group for microarray 
analysis, or by QPCR validation using a mimumum of three samples per group. 
6.2.2 Assessment of RNA quality 
High RNA purity and quality is of paramount importance in applications such as 
microarray expression analysis. Impurities can affect RNA labelling efficiency and the 
stability of the fluorescent label. RNA concentration and purity was initially measured 
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by spectrophotometry, and is displayed in Table 6.1. All samples displayed 260/280 
ratios of approximately 2, and 260/230 ratios equal to or greater than 1.8, indicating 
high RNA purity. Samples were sent to the Nottingham Arabidopsis Stock Centre 
(NASC) for further QC analysis of RNA using the Agilent bioanalyser, and subsequent 
microarray expression profiling. Traditionally, RNA integrity is assessed by agarose 
gel electrophoresis, but this method requires large amounts of sample RNA (0.5 - 2.0 
I-'g) and is not very sensitive in detecting degradation. The bioanalyser allows 
capillary based electrophoretic sample separation according to molecular weight, and 
subsequent fluorescent detection to generate electropherogram and in gel-like 
images. It requires far smaller quantities of RNA (as low as 200 pg) and is a more 
sensitive and reliable method [Imbeaud et aI., 2005]. Figure 6.1 shows bioanalyser 
RNA profiles and in gel-like images generated using the five samples purified for 
microarray analysis. The two peaks represent the 18S and 28S ribosomal RNA 
subunits, and the absence of smaller degradation products indicates high quality RNA. 
RNA integrity numbers (RIN) are a means of numerically categorising sample integrity 
from electrophoretic traces, and range from 1 (fully degraded RNA) to 10 (intact RNA) 
[Schroeder et aI., 2006]. RIN values generated are displayed in Table 6.1 and ranged 
from 9.3 to 10, indicating intact RNA. 
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Table 6.1: RNA concentration, purity, and integrity of samples used for 
microarray expression analysis 
Spectrophotometry Bioanalysis 
Sample 260/280 260/230 Concentration RIN value (ng IIJI) 
TBX51 GATA-4 double 2.11 1.79 240.8 9.3 knockdown 
TBX5 knockdown (+ GATA-4 2.09 2.07 157.2 9.4 7-mis) 
GATA-4 knockdown (+ TBX5 2.05 2.04 339.3 10 7-mis) 
TBX5 7-mis I GATA-4 7-mis 2.09 1.99 315.8 9.9 
Wild Type 2.09 2.16 282.0 9.8 
RNA concentration and purity was measured by spectrophotometry, and RNA integrity 
numbers (RIN) assessed using a bioanalyser. All samples displayed 260/280 ratios of 
approximately 2, and 260/230 ratios greater than or equal to 1.8, indicating high RNA 
purity. RIN numbers ranged from 9.2 to 10, indicating RNA was intact. 
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Figure 6.1 Bioanalyser analysis of RNA samples prior to microarray analysis 
Bioanalyser QC analysis of RNA was performed by NASC. Electropherograms are 
displayed with in gel-like images to the right. The two peaks represent the 18S and 
28S ribosomal RNA subunits, and the absence of smaller degradation products 
indicates high quality RNA. RIN values ranged from 9.3 - 10 and are displayed in 
Table 6.1. 
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6.2.3 Microarray expression study 
Microarray expression profiling analysis was performed by the NASC using the 
Affymetrix GeneChip® Chicken Genome Array. Probe sets on this array are designed 
with 11 oligonucleotide pairs for specific detection of transcripts. Each array contains 
coverage of over 28000 chicken genes and 32773 transcripts. 
6.2.3.1 Analysis of data 
Data was analysed in GeneSpring software (Agilent). Genes displaying changes of 2-
fold or greater in comparison to wild type embryos were selected. Genes differentially 
regulated in TBX5 I GATA-4 double knockdown, TBX5 single knockdown, GATA-4 
single knockdown embryos, and overlapping categories are represented in Figure 6.2. 
In total, 56 genes displayed altered expression in TBX5 I GATA-4 knockdown 
embryos, 28 of which were unique to this group. Single knockdown of TBX5 and 
GATA-4 resulted identification of 109 and 67 genes respectively. A number of genes 
displayed differential regulation both in response to double knockdown of TBX5 and 
GATA-4, and in response to single knockdown of one or both of these transcription 
factors. These genes were also of relevance, particularly those displaying a greater 
fold change in expression in the double knockdown group compared to single 
knockdowns (Le. potential synergistic activation). All gene lists assembled were 
subsequently cross-referenced with genes differentially regulated in TBX5 7-mis I 
GATA-4 7-mis control embryos, and any common genes removed. Genes within each 
of the seven groups and fold changes observed are displayed in Tables 6.2 - 6.8. All 
categories shown directly relate to sections of the venn diagram shown in Figure 6.2, 
and are therefore mutually exclusive. 
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Figure 6.2 Genes differentially regulated in microarray analysis of TBX5 and 
GATA-4 single and double knockdown 
Venn diagram displaying genes which show a ~ ~ . 0 0 fold change in TBX5 I GATA-4 
double knockdown, TBX5 single knockdown and GATA-4 single knockdown embryos 
in comparison to wild type animals . Gene lists created were subsequently cross-
referenced genes differentially regulated in TBX5 7-mis I GATA-4 7-mis control 
embryos and common genes removed. 
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Table 6.2 Genes differentially regulated in microarray analysis of TBX51 GATA-4 
double knockdown chick embryos 
Probe Set 10 Gene Title Gene Fold change Symbol 
Gga.3795.1.S1_at SRY (sex determining region SOX3 2.0196466 i Y)-box 3 
Gga.153.1.S 1_at Zic family member 1 (odd- ZIC1 2.5582569 i paired homolog, Drosophila) 
Gga.153.1.S2_at Zic family member 1 (odd- ZIC1 26.636639 i paired homolog, Drosophila) 
transcription factor AP-2 beta 
Gga.9289.1.S1_at (activating enhancer binding TFAP28 2.2718828 t 
protein 2 beta) 
protein tyrosine 
Gga.2977.1.S1_at phosphatase, receptor-type, PTPRZ1 6.1341915t 
Z polypeptide 1 
c-fos induced growth factor 
Gga.3219.1.S1_at (vascular endothelial growth FIGF 2.2266912 t 
factor D) 
Gga.556.1.S1_at paired box gene 6 PAX6 2.6883574 t 
Gga.657.1.S1_at forkhead box G1 FOXG1 2.8416626 i 
Gga.3535.1.S 1_at nuclear receptor subfamily 2, NR2E1 2.7937800 t group E, member 1 
Gga.952.1.S1_at NK2 homeobox 1 NKX2-1 11.427207 t 
Gga.10.1.S1_at orthodenticle homeobox 2 OTX2 16.048748 i 
GgaAffx.20141.1.S1_at orthodenticle homeobox 2 OTX2 2.7658422 t 
GgaAffx.20545.1.S1_s_at Finished cDNA, clone 2.0427935 t ChEST1 015n20 
Gga.1862.1.S1_at hypothetical gene supported LOC420770 2.6278262 t byCR390114 
Gga.9574.1.S1_at similar to enhancer of split LOC419390 2.6523864 t related protein-7 
Gga.11969.1.S1_at cytokine-like 1 CYTL1 2.2584643 t 
Gga.14235.1.S1_at Finished cDNA, clone 2.6366910 t ChEST125m3 
Gga.2646.1.S1_at Phospholipase C, eta 1 PLCH1 2.7627573 t 
Gga.16236.1.S 1_s_at Finished cDNA, clone 2.5964615 t ChEST928e1 
Gga.14703.1.S1_at SP8 2.0750513 t 
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Gga.19600.1.S1 _at Finished eDNA, clone 3.6129053 i ChEST963kS 
Gga.19626.1.S1 _s_at suppressor of zeste 12 SUZ12 2.0030265 i homolog (Drosophila) 
Gga.4S46.1.S1 _at cellular retinoie aeid binding CRABP1 4.9209270 i protein 1 
GgaAffx.2384S.1.S1_at golgi autoantigen, golgin GOLGA4 2.0230920 i subfamily a, 4 
GgaAffx.379S.1.S1_at glypiean 3 GPC3 2.3861866 i 
GgaAffx.24879.4.S1_at 2.2617579 l 
Genes displaying fold changes of 2-fold or greater in comparison to wild type embryos 
were selected, and fold changes observed are indicated . Genes displaying up-
regulation are displayed in black, and down-regulated genes are displayed in red. 
Gene lists were cross-referenced with genes differentially regulated in TBX5 7-mis / 
GATA-4 7-mis control embryos, and common genes removed . 
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Table 6.3 Genes differentially regulated in microarray analysis of TBX5 single 
knockdown chick embryos 
Probe Set 10 Gene title Gene Fold 
symbol change 
Gga.919.1.S1_at distal-less homeobox 5 DLX5 2.356541 t 
Gga.S334.1.S1_a_at regulator of G-protein RGS4 2.195912t 
signaling 4 
Gga.32.1.S1_at mab-21-like 1 (C. elegans) MAB21L1 2.133591 t 
Gga.8359.1.S 1_at glutathione S-transferase A3 GSTA3 4.219509 t 
Gga.9334.1.S1_at serum/glucocorticoid SGK1 2.062817 t regulated kinase 1 
Gga.635.1.S1_at Spindling SPIN 2.516693 t 
Gga.827.1.S1_at erythroid-specific transcription LOC396450 2.594897 t factor eryf1 
Gga.580.1.S2_at growth factor independent 1 B GFI1B 2.200138 i transcription repressor 
GgaAffx.20420.1.S1_at NEDD4 binding protein 2-like N4BP2L1 2.208199 t 1 
GgaAffx.21102.1.S1_s_at aldolase B, fructose- ALOOB 3.452897 t bisphosphate 
GgaAffx.21598.1.S1_s_at Similar to trans-Golgi protein LOC425502 2.764642 t GMx33 
GgaAffx.20558.1.S 1_at Chromodomain helicase DNA CHD1 3.355640 t binding protein 1 
Gga.4981.1.S1_s_at hemoglobin, gamma G 11/ HBG1111 5.235574 t hemoglobin, gamma A HBG2 
GgaAffx.20789.1.S1_at hemoglobin, alpha 1 HBA1 2.144276 t 
Gga.2909.1.S1_at hemoglobin, alpha 2 HBA2 2.369730 t 
Gga.3078.1.S1_at similar to general transcription LOC430910 2.022142 i factor 
Gga.5205.1.S 1_at benzodiazapine receptor BZRPL1 2.122973 t (peripheral)-like 1 
Gga.17132.1.S1_at Finished cDNA, clone 2.293467 t ChEST120n19 
Gga.7809.1.S1_at Hypothetical protein LOC771 069 3.389699 t LOC771 069 
Gga.8915.1.S1_s_at chromosome 20 open reading C200rf108 2.639697 t frame 108 
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Gga.5139.1.S1_at fructose-1,6-bisphosphatase FBP1 2.028548 t 1 
Gga.9054.1.S1_s_at adenosine deaminase ADA 2.316033 t 
Gga.11474.1.S1_a_at Rieske (Fe-S) domain RFESD 2.534035 t 
containing 
Gga.20049.1.S1_at hypothetical gene supported LOC421241 2.146337 t by CR406891 
Gga.14585.1.S 1_at Finished cDNA, clone 3.843172 t ChEST488016 
Gga.16155.1.S1_at Finished cDNA, clone 2.132346 t ChEST38i14 
Gga.1 0658.1.5 1_at Finished cDNA, clone 2.608275 t ChEST1 007e1 0 
Gga.8463.1.S1_s_at chromodomain helicase DNA CHD1 2.508791 t binding protein 1 
Gga.10138.1.S1_at Finished cDNA, clone 2.291931 t ChEST12613 
Gga.12484.1.S 1_at Myelin oligodendrocyte MOG 2.693002 t glycoprotein 
Gga.16904.1.S 1_at Finished cDNA, clone 2.043179 t ChEST749023 
Gga.13093.1.S 1_at Finished cDNA, clone 2.143198 t ChEST900p6 
Gga.11630.2.S1_a_at HypotheticallOC426615 lOC426615 2.957734 i 
Gga.11630.2.S1_at Hypothetical LOC426615 LOC426615 2.785122 t 
Gga.14069.1.S 1_s_al erythrocyte membrane protein EPB42 2.005124 t band 4.2 
Gga.20011.1.S1_at coiled-coil domain containing CCDC84 2.052319 t 84 
Gga.9566.2.S1_s_at solute carrier family 25, SlC25A37 2.479893 t 
member 37 
Gga.11848.1.S1_at Finished cDNA, clone 2.073347 t ChEST394j22 
Gga.19575.1.A 1_at Finished cDNA, clone 2.270295 t ChEST445p2 
Gga.10138.3.S1_at Finished cDNA, clone 2.569093 t ChEST12613 
GgaAffx.11738.1.S 1_s_at early growth response 1 EGR1 2.099442 t 
GgaAffx.12834.1.S1_at cyclin D3 CCND3 2.027003 t 
GgaAffx.23623.2.S1_at AHNAK nucleoprotein 2 AHNAK2 2.430334 t 
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GgaAffx.23789 .1.S 1_at STEAP fam ily member 3 STEAP3 2.233264 i 
GgaAffx.24779.1 .S1 _s_at Finished cDNA, clone 2.307856 i ChEST556p11 
Gga.6201 .1.S1 _at putative ISG12-2 protein ISG12-2 2.257 i 
Gga.7505.1.S1 _at Acyl-CoA synthetase short- ACSS1 2.126091 i chain family member 1 
Gga.6481 .1.S1 _at Transcribed locus 3.182043 i 
Gga.6758.1 .S1_at Transcribed locus 2.482223 i 
Gga.6836.1.S1 _at Transcribed locus 2.606474 i 
Transcribed locus, moderately 
Gga.6590.1.S1 _at similar to NP _446096.1 2.269154 i 
cadherin 23 (otocadherin) 
[Rattus norveqicus] 
Gga.6209.1 .A1_at 2.011379 1 
Gga.2087.1.S1_s_at casein kinase 1, epsilon CSNK1E 2.123844 t 
GgaAffx.20789.1.S1 _at Ribosomal protein, large, P1 RPLP1 2.076906 ! 
Gga.13093.1.S1_at Finished cDNA, clone 2.134106 t ChEST430n10 
Gga.19320.1.S1_at hypothetical gene supported LOC426510 2.192061 t by CR406681 
Genes displaying fold changes of 2-fold or greater in comparison to wild type embryos 
were selected , and fold changes observed are indicated . Genes displaying up-
regulation are displayed in black, and down-regulated genes are displayed in red . 
Gene lists were cross-referenced with genes differentially regulated in TBX5 7 -mis / 
GATA-4 7-mis control embryos, and common genes removed . 
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Table 6.4 Genes differentially regulated in microarray analysis of GATA-4 single 
knockdown chick embryos 
Probe set 10 Gene Title Gene Fold change Symbol 
Gga.2551.2.S1_s_at lactotransferrin LTF 2.918124 i 
Gga.3641.1.S1_at annexin A2 ANXA2 2.408555 i 
Gga.3133.1.S1_a_at collapsin response mediator CRMP1 2.367408 i protein 1 
Gga.16863.1.S1_s_at Gal 10 GAL10 5.975876 i 
Gga.3381.1.S2_at homeoboxA3 HOXA3 2.480355 i 
Gga.2648.1.S2_at homeobox 83 HOX83 2.833412 i 
GgaAffx.20083.1.S 1_at homeoboxA6 HOXA6 3.819832 i 
GgaAffx.21240.1.S 1_at Finished cDNA, clone 2.303639 i ChEST875h18 
Gga.1546.1.S1_at paired related homeobox 1 PRRX1 2.023035 i 
Gga.1546.1.S2_a_at Paired related homeobox 1 PRRX1 2.171399 i 
Gga.8241.1.S1_at transcription factor 21 TCF21 3.786901 i 
Gga.4112.1.S1_at apolipoprotein 8 (including AP08 3.427132 i Ag(x) antigen) 
Gga.12649.1.S1_at galanin prepropeptide GAL 2.365781 t 
GgaAffx.22999.1.S 1_s_at collagen, type I, alpha 2 COL1A2 2.244431 t 
Gga.496.1.S 1_at reelin RELN 2.224683 t 
Gga.18984.1.S1_at Finished cDNA, clone 2.356632 i ChEST608b15 
Gga.3676.1.S1_at N-acetylgalactosamine 4- LOC423952 2.042442 i sulfate 6-0-sulfotransferase 
Gga.18151.1.S1_at 8asonuclin 1 8NC1 3.634063 i 
Gga.12185.1.S1_at matrix metallopeptidase 238 MMP238 2.182316 t 
Gga.12849.1.S 1_at SPARC related modular SMOC2 2.460695 t calcium binding 2 
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Gga.13425.1 .S1_at Finished eDNA, clone 2.062347 T ChEST130f3 
Gga.14858.1.S1_at nuclear autoantigenic sperm NASP 2.072035 T protein (histone-binding) 
propionyl Coenzyme A 
GgaAffx.25098.1.S1_at carboxylase, alpha PCCA 2.053286 T 
polypeptide 
GgaAffx.5758.1.S1_at carbonic anhydrase X CA10 2.506326 T 
GgaAffx.1913.1.S1_at homeobox 85 HOX85 2.937861 T 
Gga.5598.1 .S1_at Transcribed locus 2.189897 ! 
Gga.6873.1.S1_at Transcribed locus 2.017625 ! 
Gga.17020.1.S1_at Titin TIN 2.514681 ! 
Gga.13915.1.S1_at Titin TIN 2.158793 ! 
Gga.12775.1 .A 1_at titin TIN 3.282518 1 
Gga.4777.5.A1 _at Finished cDNA, clone 2.097747 ! ChEST145d21 
Gga.17680.1.S1_at Clone cDNA3F microsatellite 2.054327 ! MCW108 sequence 
Genes displaying fold changes of 2-fold or greater in comparison to wild type embryos 
were selected, and fold changes observed are indicated. Genes displaying up-
regulation are displayed in black, and down-regulated genes are displayed in red . 
Gene lists were cross-referenced with genes differentially regulated in TBX5 7 -mis / 
GATA-4 7-mis control embryos, and common genes removed . 
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Table 6.5 Genes differentially regulated in microarray analysis of TBX51 GATA-4 
double knockdown, TBX5 single knockdown, and GATA-4 single knockdown 
chick embryos 
Fold change 
Probe Set ID Gene Title Gene Symbol 
TBX5& TBX5 GATA-4 GATM knockdown knockdown knockdown 
GgaAffx.2111 oxidative stress induced growth 05GIN1 2.695851 i 4.087098 i 2.051297 T 6.1.51_s_at inhibitor 1 
Gga.16169.1. Finished cDNA, 
51_at clone 2.7834854 T 4.3942741 2.0139991 ChE5T45e16 
Gga.19101.1. Finished cDNA, 
clone 3.49822241 5.769498 T 2.2297451 51_at ChE5T926n8 
Gga.10138.2. Finished cDNA, 
51_a_at clone 2.37024021 2.630745 T 2.0226641 ChE5T12613 
Gga.5092.1.5 
annexin A2 ANXA2 2.12961821 2.098631 T 2.4085551 1_s_al 
Gga.9032.1.5 RNA binding 
1_5_al motif protein RBM35B 2.97302 i 4.49394 i 2.480706 i 35B 
GgaAffx.1152 
claudin 1 RCJMB04_2c8 3.8028853 i 4.62055 t 2.624394 t 5.1.51_5_al 
solute carrier 
GgaAffx.7796. family 39 (zinc 5LC39A8 3.7550573 t 5.402943 T 2.87964 T 1.51_5_at transporter), 
member 8 
Genes displaying fold changes of 2-fold or greater in comparison to wild type embryos 
were selected, and fold changes observed are indicated. Gene lists were cross-
referenced with genes differentially regulated in TBX5 7-mis I GATA-4 7-mis control 
embryos, and common genes removed. 
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Table 6_6 Genes differentially regulated in microarray analysis of TBX5 I GAT A·4 
double knockdown and TBX5 single knockdown and chick embryos 
Fold change 
Probe Set 10 Gene Title Gene Symbol 
TBX5 &GATA· TBX5 
4 knockdown knockdown 
solute carrier 
Gga.4842.2. family 4. anion SLC4A1 2.0272145 t 3.647175 t 51_a_at exchanger. 
member 1 
GgaAffx.216 Finished cDNA. 2.58259 t clone 2.0174587 t 96.1.S1 at ChEST747k12 
GgaAffx.208 Finished cDNA. 4.631784 t clone 2.6281042 t 24.1.S1 at ChEST722f15 
GgaAffx.212 Finished cDNA. 3.366277 t clone 2.0515776 t 20.1.S1 s at ChEST881 h18 
Gga.4156.1. Finished cDNA. 2.235081 t clone 2.0187516 t S1 at ChEST79b1 
Gga.8098.1. Finished cDNA. 4.168608 t clone 3.2116323 t S1 at ChEST811h18 
Gga.8089.1. Kruppel-like 2.1141534 t 3.243578 i factor 1 KLF1 S1 at ( erythroid) 
Gga.7581.1. Finished cDNA. 18.489647 t 2.456972 t clone 51 at ChEST88511 
Gga.10042.1 CD200 receptor CD200R1111 RCJMB04_2511 2.0964477 t 2.639697 i 
.S1 a at 1 6 
Gga.11763.2 similar to 2.2741299 t 3.876498 i RIKEN cDNA LOC423277 
.S1 a at 1110067D22 
Gga.17183.1 Finished cDNA. 3.013425 t clone 2.011654 t 
.S1 at ChEST39708 
Gga.13903.1 paired-like PITX1 2.1853464 t 4.573031 t 
.51 at homeodomain 1 
erythrocyte 
GgaAffx.299 membrane EPB42 2.5261283 i 2.005124 t 3.1.S1_at protein band 
4.2 
solute carrier 
GgaAffx.779 family 39 (zinc SLC39A8 2.1189318 i 4.271026 t 6.1.S1_at transporter). 
member 8 
Gga.5243.1. Transcribed 2.2414985 i 2.84958 t S1 at locus 
Gga.7750.1. hypothetical LOC422459 2.2732491 t 3.474953 t S1 at LOC422459 
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Gga.8578.1. Transcribed 
S1_at locus 2.2378054 i 4.381073 i 
Genes displaying fold changes of 2-fold or greater in comparison to wild type embryos 
were selected, and fold changes observed are indicated. Gene lists were cross-
referenced with genes differentially regulated in TBX5 7-mis I GATA-4 7-mis control 
embryos, and common genes removed. 
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Table 6.7 Genes differentially regulated in microarray analysis of TBX51 GATA-4 
double knockdown and GATA-4 single knockdown and chick embryos 
Fold change 
Probe Set 10 Gene Title Gene Symbol 
TBX5 & GATA- GATA-4 
4 knockdown knockdown 
Gga.2558.1.5 collagen, type XIV, alpha 1 COL14A1 2.3760216 T 3.037223 T 1_a_at (undulin) 
Gga.2354.1 .5 Transcribed 2.1046243 T 2.661268 T 1_at locus 
GgaAffx. 1165 
sorcin RCJMB04_3f15 2.0217292 ! 4.004279 ! 9.1.S1 _at 
Genes displaying fold changes of 2-fold or greater in comparison to wild type embryos 
were selected, and fold changes observed are indicated. Genes displaying up-
regulation are displayed in black, and down-regulated genes are displayed in red. 
Gene lists were cross-referenced with genes differentially regulated in TBX5 7-mis / 
GATA-4 7-mis control embryos, and common genes removed. 
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Table 6.8 Genes differentially regulated in microarray analysis of TBX5 single 
knockdown and GATA-4 single knockdown chick embryos 
Fold change 
Probe Set 10 Gene Title Gene Symbol 
TBX5 GATA-4 
knockdown knockdown 
Gga.2551.2 . lactotransferrin LTF 2.283916 t 2.9181 24 t S1 a at 
Gga.2620.1. transthyretin DR 2.76807 i 4.394575 i S1 at 
Gga.1165.1. fibrinogen FGG 2.900268 i 2.899903 i S1 at gamma chain 
GgaAffx.215 chemokine (C-
81.1 .S1 _s_a X-C motif) CXCL 14 2.399975 t 2.832924 t 
t ligand 14 
Gga.9481 .1. 
otokeratin LOC395772 2.136159 t 2.0311 68 t S1 s at 
succinate-CoA 
Gga.9087.1. ligase, GOP- SUCLG2 3.021066 t 2.887826 t S1 _at forming , beta 
subunit 
cadherin 1, 
GgaAffx.203 type 1, E- COH1 2.103267 t 2.213427 t 74.1.S1 _at cadherin 
( ~ t h e l i a l l l
Gga.4557.1. fibrinogen beta FGB 3.862611 t 7.627894 i S1 at chain 
GgaAffx.264 hypothetical LOC424460 12.39564 t 3.578772 t 41 .1.S1 at LOC424460 
Gga.6860.1. 2.082896 ! 2.786701 ! A1 at 
Gga.14594. Finished cDNA, 
clone 2.196702 ! 2.082312 ! 1.A1_at ChEST240e14 
Gga.3690.1 . Zinc finger ZNF207 2.009688 ! 2.287068 ! A1 at protein 207 
Gga.9087.1. transcription LOC395160 2.93964 ! 2.535343 ! S1 at factor Crx 
Gga.285.1 .A 
myomesin LOC395524 2.096654 ! 2.205535 ! 1 at 
GgaAffx.111 cyclic AMP RCJMB04_ 4f1 33.1.A1 
_s_a phosphoprotein 2 2.789666 ! 2.607948 ! t ,19 kD 
Genes displaying fold changes of 2-fold or greater in comparison to wild type embryos 
were selected, and fold changes observed are indicated. Genes displaying up-
regulation are displayed in black, and down-regulated genes are displayed in red. 
Gene lists were cross-referenced with genes differentially regulated in TBX5 7 -mis I 
GATA-4 7-mis control embryos, and common genes removed. 
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6.2.4 Genes identified in microarray analysis of TBX5 and GAT A·4 knockdown 
The purpose of this genome-wide microarray study was to identify genes co-ordinately 
regulated by TBX5 and GATA-4. Five sample groups were analysed, generating 
seven categories of genes differentially regulated in response to TBX5 / GATA-4 
double knockdown, TBX5 single knockdown, GATA-4 single knockdown, and 
overlapping groups (represented in Figure 6.2). Of these seven categories, genes 
identified in the TBX5 / GAT A-4 knockdown group but not other groups were of 
greatest interest. Secondary to this group, genes appearing in the TBX5 / GAT A-4 
knockdown group and one or both of the single knockdown groups were also of 
interest, particularly those genes which showed a greater fold change in expression in 
the double knockdown group compared to single knockdowns. However, time did not 
allow study of all of these groups, and the TBX5 / GATA-4 knockdown group were 
given primary focus. In total, 26 transcribed loci were identified displaying differential 
regulation in TBX5/ GATA-4 double-knockdown embryos (by ~ 2 2 fold in comparison to 
wild type animals) but not in single knockdown embryos or controls. Not all loci 
identified corresponded to known or hypothesised genes. Eighteen of the genes of 
interest are 'known' genes and a full description of these is given in Appendix I. 
6.2.4.1 Reliability of data and general considerations 
There is always a false-discovery rate (FOR) associated with microarray gene 
expression profiling, which means it is unlikely that all of the genes identified by this 
technique are genuine targets. The FOR increases as the number of arrays per group 
decreases [Pawitan et ai., 2005] I.e. biological replicates are very important in 
microarray expression profiling, exemplified in a number of studies [Kerr et ai., 2000; 
Lee et ai., 2000; Manduchi et ai., 2000]. In this study one biological replicate was 
assayed per group which means the likelihood of obtaining false positives is very high. 
However, as only 18 genes of interest were identified (due to the high threshold set 
and large number of control groups), post-analysis elimination of false positives is not 
a lengthy procedure in this case. 
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It is surprising that knockdown of two cardiac transcription factors seems to result in 
misexpression of so many neurological genes and so few heart genes, particularly 
given that this is a heart tissue specific study. A high false positive rate due to limited 
biological replicates could be one contributing factor (as discussed above). There is 
also evidence that certain transcripts cannot be accurately detected by any technique 
(microarray expression analysis or QPCR) due to sequence specific effects [larkin et 
aI., 2005]. Also, any small levels of contaminating tissue from non-cardiac regions of 
the embryo may have resulted in anomalous results. 
This study has resulted in the identification of a number of strong candidate genes, in 
particular CRABP1, GPC3, and TFAP2B. TFAP2B is arguably the most interesting as 
mutations in this gene are already associated with the heart-hand disorder Char 
syndrome [Satoda et aI., 1999; Satoda et aI., 2000], whose anomalies include patent 
ductus arteriosus (PDA), facial dysmorphism, strabismus, hearing abnormalities, and 
an abnormal fifth digit of the hand [Char, 1978]. The ductus arteriosus is the arterial 
connection between the pulmonary artery and aorta, and serves to shunt blood from 
the right ventricle away from the lungs, allowing blood to bypass the lungs during 
foetal development. The ductus normally constricts and closes shortly after birth, and 
failure to do so results in PDA. Structures affected in Char syndrome are all 
contributed to by neural crest cells [Moser et aI., 1997] and fate mapping studies have 
shown that the medial layer of the ductus, but not the pulmonary artery and 
descending aorta, arises from cardiac neural crest (CNC) cells [Waldo et aI., 1999]. It 
is likely that TFAP2B has a role in the migration or differentiation of neural crest cells, 
which results in a specific effect on the ductus but not surrounding arterial structures. 
It is interesting that this heart-hand gene may be transcriptionally regulated by another 
heart-hand gene, TBX5, in conjunction with GATA-4. 
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6.2.5 Gene expression analysis using GEISHA 
Assessment of the anatomical expression pattern of genes is a useful starting point for 
candidate gene selection. Embryonic expression of genes was initially researched 
using the online GEISHA (gallus expression in situ hybridisation analysis) resource 
(http://geisha.arizona.edu/geisha/index.jsp).This is a database containing in situ 
hybridisation information for genes expressed at 0.5 - 6 days of development in 
chicken embryos, input via in house in situ hybridisation screening, review of literature, 
and unpublished expression information from laboratories. 
The whole body expression pattern of a number of genes was described in GEISHA 
including SOX3, ZIC1, FOXG1, NKX2-1, PAX6, and OTX2, and is described in Table 
6.9. Developmental stages HH12 - HH19 have been included where possible as 
these are of interest to this study. All six genes researched in GEISHA did not display 
obvious expression in the heart so were not considered further. 
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Table 6.9 Gene expression data from GEISHA 
Gene Developmental stage and region of expression 
HH7 - HH12: Ectoderm, neural plate/tube [Abu-Elmagd et aI., 2001] 
SOX3 HH13 - HH18: Ectoderm, neural plate/tube, pharyngeal arches and 
clefts, placcode [Abu-Elmagd et aI., 2001] 
HH13 - HH18: Dermatome, myotome, neural plate/tube, sclerotome, 
ZIC1 
somites, spinal cord [Sun Rhodes and Merzdorf, 2006] 
HH19 - HH21: Dermatome, face mesenchyme, myotome, sclerotome, 
somites [Sun Rhodes and Merzdorf, 2006] 
HH7 - HH12: Forebrain, telenchephalon [8ell et aI., 2001] 
FOXG1 
HH13 - HH15: Ear/otic placcode, forebrain, pharyngeal arches and 
clefts (Chapman SC, 2008, unpublished) 
HH13 - HH19: Telencephalon [8ell et aI., 2001] 
HH7 - HH12: Diencephalon, neural plate/tube (Chapman SC, 2008, 
NKX2-1 
unpublished) 
HH13 - HH17: Diencephalon, pharyngeal arches and clefts (Chapman 
SC, 2008, unpublished) 
HH7 - HH12: Diencephalon, eye, forebrain, neural plate/tube, spinal 
PAX6 
cord [Ohuchi et aI., 2007] 
HH13 - HH24: Diencephalon, hindbrain, telencephalon [Garcia-Calero 
et aI., 2006] 
HH7 - HH12: Forebrain, midbrain, neural plate/tube (Chapman SC, 
OTX2 
2008, unpublished) 
HH13 - HH18: Eye, forebrain, midbrain, pharyngeal arches [Plouhinec 
et aI., 2005] 
Chicken whole embryo developmental expression profiles of the genes SOX3, ZIC1, 
FOXG1, NKX2-1, PAX6 and OTX2 have been previously characterised by in situ 
hybridisation and were found in the GEISHA database 
(http://geisha.arizona.edu/geishalindex.jsp). Expression patterns are summarised and 
include developmental stages HH12 - HH19 (of interest in this study) where possible. 
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6.2.6 RT-PCR expression analysis 
In order to assess expression of other identified genes, nine of the twelve remaining 
genes were selected for RT-PCR expression analysis (TFAP2B, PTPRZ1, FIGF, 
NR2E1, LOC420770, SUZ12, CRABP1, GOLGA4, and GPC3). CYTL 1, PLCH1 and 
LOC419390 were not studied due to limited resources and time restrictions. 
RT-PCR expression analysis was performed once in chick embryonic segments at 
three stages of development (HH16, HH19 and HH24) as a preliminary means of 
temporal/spatial characterisation. Primers sequences are given in Table 2.7. Equal 
amounts of template were used in all reactions. PCR reactions were performed with 
HotStar Taq using an annealing temperature of 60°C, extension time of 30 seconds, 
and 30 PCR cycles. Negative RT controls were included for each gene and did not 
display amplification (Appendix J). Results of expression analyses are displayed in 
Figure 6.3 and are described below. RT -PCR was not performed in a quantitative 
manner and descriptions are subjective. 
SUZ12, GOLGA4 and GPC3 were expressed in all embryonic segments (head, heart, 
body / limbs) at all three stages of development indicating ubiquitous expression. 
Further studies would have to be performed to determine the exact spatial expression 
patterns of these genes. 
Expression of TFAP2B was detected in all embryonic segments at HH16. Heart 
expression appeared to be lower at HH19, and was not detectable at HH24. 
Consistent expression was observed in other regions throughout all three stages. 
CRABP1 was also expressed in all regions at the stages examined. Heart expression 
appeared to be strongest at HH16, becoming reduced at HH19 and HH24. PTPRZ1 
expression was detected in all embryonic segments at all three stages of 
development. Heart expression appeared to be fainter at HH24. TFAP2B, CRABP1, 
and PTPRZ1 follow a similar pattern, displaying expression throughout the embryo 
with heart expression appearing to be strongest early in development, and decreasing 
225 
Microarray expression analysis of TBX5 I GATA-4 double knockdown embryos 
in later stages. This could be indicative of a specific function in early heart 
development. 
LOC420770 expression was detectable in the heart and body (but not head) at all 
three stages. Interestingly, expression at HH24 was more prominent in the limbs than 
body indicating a hearVlimb expression profile, potentially similar to that of TBX5. 
FIGF was expressed in all embryonic segments, with highest expression in the head 
and body and fainter expression in the heart. NR2E1 was expressed almost 
exclusively in the head region, with faint expression in the body (at all three stages). 
Heart expression could not be detected at any of the stages examined. 
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Figure 6.3 RT·PCR expression analysis of nine candidate genes 
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RT-PCR products were electrophoresed on 2% agarose gels using Hyperladder IV as a size 
marker (500 bp and 100 bp bands are indicated along with product sizes). Expression was 
studied in chick embryonic segments at HH16, HH19, and HH24. RPLPO was included as a 
housekeeper gene. Negative PCR controls (-PCR) are shown. Negative RT controls did not 
show amplification for any of the genes and are displayed in Appendix J . 
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CHAPTER 7 
DISCUSSION 
7.1 TBX5 and GATA-4In cardiac development 
Development of the heart is a highly complex and dynamic process involving a vast 
network of genes. These genes are diverse in function, encoding growth factors, 
signalling molecules, transcription factors and their co-factors and regulators, 
components of the extracellular matrix, and structural proteins. Defects in cardiac 
genes can lead to congenital heart defects, and understanding the molecular 
pathways involved in normal cardiogenesis will allow elucidation of the pathogenesis 
of disease. This in turn is the first step toward improved diagnoses and potentially 
novel therapies. 
Heart development is a highly regulated process involving complex interplay between 
numerous transcription factors, which can also regulate transcription of one another. 
In addition, a number of transcription factors physically interact to co-ordinately 
regulate key genes and developmental pathways. Members of the NK2, MEF2, 
GATA, Tbx and Hand gene families make up a core cardiac regulatory network whose 
expression is initiated by inductive signals and upstream activators [Olson, 2006]. 
Mutations in a number of key cardiac transcription factors in this core group, including 
Nkx2.5, TBX5, and GATA-4, have been associated with CHDs [Garg et aI., 2003; Li et 
aI., 1997; Schott et aI., 1998]. In addition, these transcription factors also interact with 
one another for joint regulation of targets [Garg et aI., 2003; Hiroi et aI., 2001; Lee et 
aI., 1998]. TBX5 and GATA-4 are considered master regulators of cardiac 
development, and these two genes, in combination with Baf60c, can induce a full 
cardiac transcriptional programme [Takeuchi and Bruneau, 2009]. Additionally, the 
specific combination of TBX5, GATA-4 and MEF2C has recently been found to be 
able to reprogramme mouse postnatal fibroblasts into functional cardiomyocytes that 
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display cardiomyocyte-like global gene expression and beat spontaneously [Ieda et 
al.]. TBX5 is aT-box transcription factor and a so called 'heart-hand' gene as it has 
an important role in heart development and specification of forelimb identity [Isaac et 
aI., 1998]. Mutations in TBX5 are associated with Holt-Oram syndrome [Bass on et aI., 
1997; Fan et aI., 2003; li et aI., 1997], a congenital disorder characterised by upper 
limb and heart abnormalities. These are usually atrial or ventricular septal defects, but 
can include mitral valve defects, cardiac conduction defects, tetralogy of Fallot, and 
hypoplastic left heart syndrome [Basson et aI., 1994; Bruneau et aI., 1999]. GAT A-4 is 
a member of the GATA family of transcription factors and has a crucial role in 
cardiogenesis [Molkentin and Olson, 1997; Rivera-Feliciano et aI., 2006; Zeisberg et 
aI., 2005]. Mutations in GATA-4 are associated with atrial and ventricular septal 
defects [Garg et aI., 2003] and tetralogy of Fallot [Nemer et aI., 2006]. TBX5 and 
GATA-4 display distinct but overlapping expression patterns [Bruneau et aI., 1999; 
Kelley et aI., 1993] and form a complex that is thought to direct and synergistically 
regulate common cardiac pathways [Garg et aI., 2003]. A number of TBX5 mutations 
that are associated with cardiac septal defects abolish this biochemical interaction 
[Garg et aI., 2003], and the GATA-4 mutation G296S that is linked to ASDs also has 
this effect [Garg et aI., 2003]. These data indicate the TBX51 GATA-4 complex has a 
critical regulatory role in cardiac septation, and provide insight into why similar 
phenotypes are so often seen as a result of mutations in these genes. The 
downstream targets of TBX5 and GAT A-4 are largely unknown, and a major aim of 
this thesis has been to identify and analyse these genes. This is crucial in 
understanding the mechanism via which mutations in these transcription factors lead 
to congenital heart defects. 
7.2 Identification oftargets ofTBX5 and GATA-4 in the mouse P19 cell line 
The research carried out in this thesis was based on a previous study that aimed to 
identify downstream targets of TBX5 and GATA-4 using the mouse P19 cell line, 
which provides an excellent model of cardiomyocyte differentiation [McBurney, 1993]. 
Microarray expression analysis of two cell lines stably transfected with TBX51 GATA-4 
229 
Discussion 
overexpression vectors was carried out allowing identification of a number of genes 
which displayed differential regulation. This was supplemented with temporal gene 
expression data, quantified at selected time-points of wild type cardiomyocyte 
differentiation. Sixteen up-regulated genes displaying wild type expression profiles 
mirroring wild type TBX5 and GAT A-4 expression, and two down-regulated genes, 
were selected for further study. 
7.2.1 Validation of gene expression and preliminary bioinformatic analysis 
In Chapter 3 of this thesis, expression of genes of interest was validated by QPCR 
using the Comparative CT method for confirmation and more accurate quantification of 
expression data. Genes displaying the highest fold increases in expression in the 
overexpression cell lines, and following the same pattern of expression as TBX5 and 
GATA-4 (a general increase from day 2 - day 7 of differentiation), were selected for 
further analysis. These included TPM1, PETA-3, PA2.2B, RBMS1, FUCA1, and FN, 
which displayed 1.4 - 3.5 fold increases in expression in the overexpression cell lines. 
An additional gene (DES) encoding the intermediate filament protein desmin was 
added to the study based on a similar study where this gene showed up-regulation in 
response to transient overexpression of TBX5 and GATA-4 in the P19 cell line. 
Bioinfomatic analysis of gene promoter regions was performed in Mulan software by 
alignment between chicken, mouse and human sequences for identification of 
evolutionarily conserved regions (ECRs) and consensus transcription factor binding 
sites within them. Putative binding site analysis analysis revealed RBMS1 as the best 
target; three potential consensus binding sites for TBX5 were identified (all within the 
coding region), and four GATA-4 sites were identified (two in the coding region, and 
two in the 3' UTR). This gene was selected for further study of its activation by TBX5 
and GAT A-4. Reporter assays were designed to test activation of an intronic fragment 
of the mouse RBMS1 gene containing both a TBX5 and a GATA-4 site. This was 
thought to be a downstream enhancer or repressor element, and data showed that 
GATA-4 had a repressive effect on promoter activity via this region, whilst TBX5 had 
no effect. Attempts to study the effect of TBX5 and GAT A-4 on the 5' promoter region 
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are ongoing. Further in depth study of RBMS1 in the developing chick was carried out 
and is discussed in 7.4. 
7.2.2 Candidate genes 
The identified genes are diverse in function, encoding muscle proteins, extracellular 
matrix molecules, a transcription factor and an enzyme, and this is a reflection of the 
role of TBX5 and GAT A-4 as master regulators in the heart. The importance of 
sarcomeric proteins in muscle contractility is well established, and many of these 
genes are now also known to be important developmentally in processes such as 
septation. Thus, mutations in a number of genes encoding sarcomeric proteins are 
associated with both cardiomyopathies and congenital heart defects. MYH6 is a well 
known example of such a gene whose mutations are associated with hypertrophic and 
dilated cardiomyopathy [Morita et aI., 2005], and atrial septal defects [Ching et aI., 
2005]. This gene is also a known synergistic target of TBX5 and GAT A-4 [Huang et 
aI., 1995; Molkentin et aI., 1994]. Other sarcomeric protein encoding genes that are 
associated with ASDs include MYH7 (f3-myosin heavy chain) [Budde et aI., 2007] and 
ACTC (a-cardiac actin) [Matsson et aI., 2008; Monserrat et aI., 2007]. Mutations in 
ACTA2 (a-smooth muscle actin) and MYH11 (myosin heavy chain 11) are associated 
with patent ductus arteriosus [Guo et aI., 2007; Zhu et aI., 2006]. Initial studies by Dr 
Lynn Amy and Jonathan Ronksley led respectively to the identification of the muscle 
proteins desmin and a-tropomyosin as potential cardiac targets of TBX5 and GATA-4 
[Ronksley, 2007]. Desmin is a type III intermediate filament protein with an important 
contractile role in muscle. In humans, numerous mutations in the desmin gene have 
been associated with familial cardiac and skeletal myopathy [Bergman et aI., 2007; 
Fidzianska et aI., 2005; Goldfarb et aI., 1998; Goudeau et aI., 2001; Olive et aI., 2007; 
Sung et aI., ; Taylor et aI., 2007; Vernengo et aI., ; Vrabie et aI., 2005]. The TPM1 
gene encodes a-tropomyosin, which is an important contractile component of the 
sarcomere [Perry, 2001]. Missense mutations in TPM1 have previously been linked 
with familial hypertrophic cardiomyopathy and dilated cardiomyopathy [Lakdawala et 
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aI., ; Thierfelder et aI., 1994]. To date, neither of these genes has been associated 
with atrial septal defects. 
The extracellular matrix (ECM) consists of collagens, glycoproteins, growth factors, 
and proteases that form a macromolecular complex which interacts and 
communicates with various cardiac cell types to undergo changes in composition 
(remodelling) for determination of its function. The ECM plays an important role in 
cardiac development and growth. The ECM component fibronectin was identified in 
Jonathan Ronksley's study [Ronksley, 2007]. Fibronectin is an adhesive ECM 
glycoprotein involved in cytoskeletal organisation, cell adhesion, cell migration, and 
cell spreading [Waterman and Balian, 1980], and is thought to playa role in the 
migration of precardiac cells [Linask and Lash, 1986]. Mouse knockout of fibronectin 
has a pronounced effect on the heart, with heart primordia often remaining unfused 
[George et aI., 1993]. Embryos that are not as severely affected have fused primordia 
with abnormal morphology. Cardiac defects such as thickening of the myocardial 
tissue, cardiac jelly deficiency, and abnormal endocardium morphology also occur, 
demonstrating the importance of fibronectin in cardiac development [George et aI., 
1993]. PETA-3 is a tetraspan membrane protein involved in cell-cell adhesion, cell 
migration, platelet adhesion, and angiogenesis [Wright et aI., 2004]. PA2.26 is a small 
transmembrane glycoprotein and also plays a role in cell-cell adhesion and cell 
migration [Scholl et aI., 1999]. The process of cell migration is important in formation 
of endocardial cushions in the heart which are essential for septa and valve formation, 
suggesting possible roles for fibronectin, PETA-3 and PA2.26 here. 
Cardiac transcription factors play a key regulatory role in cardiac growth and 
patterning, and mutations in a number of cardiac transcription factors are associated 
with CHDs. The multifunctional gene RBMS1, which acts as both a cell cycle 
regulator (via binding to c-myc) and a transcription factor, was identified in the original 
P19 study [Ronksley, 2007]. RBMS1 has been shown to suppress transcription of a-
smooth muscle actin [Kimura et aI., 1998], which has important functions in the 
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developing heart (section 7.4), suggesting a potential mode of action here. Other 
downstream targets of RBMS1 are largely unknown. 
This microarray study led to the identification of an interesting and diverse group of 
genes which may be regulated by TBX5 and GAT A-4. Some of these genes are 
already linked to the heart, including desmin, a-tropomyosin, and fibronectin. Other 
genes such as PA2.26 and PETA-3 are involved in processes such as cell migration 
which are important in cardiac septation and valvulogenesis. RBMS1 is cell cycle 
regulator and transcription factor, and has not previously been implicated in cardiac 
development. FUCA 1 encodes the exoglycosidase enzyme a-L-fucosidase, and a 
role for this enzyme in cardiac development has not been postulated. 
7.3 Development of a model system for assessment of the responsiveness of 
candidate genes to TBX5 and GAT A·4 
At the time this part of the research was initiated (2008), there were no known in vivo 
studies looking at the effects of combined haploinsufficiency of TBX5 and GAT A-4. In 
Chapter 4 of this thesis, the developing chick was selected as a model organism for 
study of candidate gene expression and responsiveness to TBX5 and GATA-4. The 
chick allows easy and rapid manipulation at selected time points since development 
occurs in ovo (as opposed to in utero), and morpholino antisense technology allows 
knockdown of up to two genes simultaneously. Seven genes were previously 
identified in the mouse P19 cell line as potential targets of TBX5 and GATA-4 and 
selected for further study in the developing chick embryo; PA2.26, PETA-3, FUCA1, 
FN, TPM1, DES, and RBMS1. As a starting point, expression of these genes was 
confirmed in the embryonic chick heart at HH12 • HH26. 
7.3.1 Development of an in ovo model of TBX5 and GAT A·4 knockdown 
In order to assess candidate gene responsiveness to TBX5 and GATA-4 in the 
developing chick heart, an embryonic model of TBX5 I GATA-4 double knockdown 
was generated using AUG targeting morpholino antisense oligonucleotides. Five-
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base mismatch morpholinos were originally tested as controls of specificity, but these 
were found to have an effect most likely due to retained target binding capability and 
were therefore subsequently replaced with 7-base mismatch controls. Morpholinos 
were applied at HH10 - HH16, encompassing key events such as dextral looping 
(HH10 - HH12), the early phase of s-Iooping (HH12 - HH17/18), and the initiation of 
atrial septation (HH14) [Anderson et al., 2003; Manner, 2000]. Previous studies have 
shown that complete mouse knockout of TBX5 results in embryonic lethality by E10.5, 
and hearts fail to undergo looping and display hypoplasia of the sinuatria and left 
ventricle [Bruneau et aI., 2001]. Study of TBX5 heterozygous mice has demonstrated 
a regulatory role for TBX5 in chamber morphogenesis and cardiac septation [Bruneau 
et aI., 2001]. In this study, in ovo knockdown of TBX5 resulted in abnormalities in 
heart shape, and a reduction in the size of the atrial septum, corresponding with the 
cardiac defects present in TBX5 heterozygote mice [Bruneau et aI., 2001]. Mouse 
knockout of GATA-4 results in embryonic lethality at E7.0 - E9.S due to defects in 
ventral morphogenesis and linear heart tube formation [Molkentin and Olson, 1997]. 
Early myocyte restricted deletion of GAT A-4 by N k x 2 _ ~ r e e results in cardiac 
malformations including a single predominant ventricular chamber, myocardial 
hypoplasia, and small atrioventricular and OFT endocardial cushions due to defects in 
EMT [Rivera-Feliciano et aI., 2006; Zeisberg et aI., 2005]. Here, chick embryonic 
treatment with GAT A-4 targeting morpholinos resulted in heart malformations and 
embryos displayed indications of a reduction in the size of the atrial septum, as would 
be expected based on the ASDs observed in humans with GATA-4 mutation [Garg et 
aI., 2003; Nemer et aI., 2006]. In parallel with this research, Gata4+1• Tbx5+1• 
compound heterozygote mice were generated by another research group and full 
phenotypic characterisation was performed [Maitra et aI., 2009]. Almost 100% of 
embryos suffered postnatal lethality by day 7. Embryos displayed intrauterine growth 
retardation, a complete lack of AV septation due to defects in endocardial cushion 
maturation and modelling (not EMT), and myocardial thinning affecting both ventricles 
at E13.5, leading to subsequent heart failure and death [Maitra et aI., 2009]. In this 
study, although it was not possible to quantify morpholino effect on protein levels upon 
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chick embryonic treatment with TBX5 and GATA-4 targeting morpholinos, these 
embryos displayed the expected phenotypes. Combined knockdown of TBX5 
together with GAT A-4 resulted in more severe cardiac defects than treatment with 
either alone, and a wider range of defects was observed. Double knockdown embryos 
displayed growth retardation, severe body kinking I twisting, and general 
malformations in comparison to control animals. A variety of heart defects including a 
reduction in heart size, constriction of the ventricle, high outflow tract, and most 
commonly abnormal looping of the heart were also observed. These observations 
correlate with the phenotype of Gata4+1• Tbx5+1- mice, and interestingly there are also 
some distinct features such as the defects in cardiac looping that were observed in the 
chick but not mouse [Maitra et aI., 2009]. This may have been for a number of 
reasons including differences between species such as varying physiology and 
response to gene dosage (discussed further in section 7.7), the level of knockdown 
achieved, and the developmental stage of knockdown. Overall, morpholino 
knockdown of TBX5 and GATA-4 individually and in combination generated the 
expected phenotypes based on mouse knockouts performed by others. 
7.3.2 Candidate gene responsiveness to combined knockdown of TBX5 and 
GATA-4 
In order to examine the responsiveness of candidate genes to TBX5 and GATA-4, 
QPCR expression analysis of these genes in double knockdown embryos was carried 
out using the Relative Standard Curve method. This method is ideal for the detection 
of small changes in expression as would be expected in an in ovo system, and was 
successfully developed and optimised for use. QPCR expression analysis showed 
knockdown of TBX5 and GATA-4 had no effect on expression of PETA-3, fibronectin, 
a-tropomyosin, desmin, and RBMS 1. It was not possible to accurately quantify 
expression of PA2.26 and a-L-fucosidase due to low level expression. However, the 
level or presence of knockdown of TBX5 and GATA-4 at the protein level remains 
unknown. In addition, expression of MYH6 in these embryos was unaltered whilst this 
gene is down-regulated in Gata4+1• Tbx5+1• compound heterozygote mice [Maitra et aI., 
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2009]. If knockdown was occurring, this could be for a number of reasons; it is 
possible there are differences in the transcriptional regulation of MYH6 between the 
mouse and chick. The level of knockdown of TBX5 and GATA-4 in this system, whilst 
generating the expected cardiac phenotype, may not have been sufficient for down-
regulation of MYH6. A low level of knockdown of TBX5 and GATA-4 may have 
resulted in very discrete changes in MYH6 expression which were not detected. The 
QPCR technique itself has limitations in its sensitivity, particularly since this study is 
attempting to quantify small reductions in gene expression. If this was the case, it 
could mean that the model generated may not have been sensitive enough to show 
differential regulation of candidate genes suggesting they may still be downstream 
targets of TBX5 and GAT A-4. Establishment of knockdown and quantification of 
knockdown levels of TBX5 and GAT A-4 knockdown achieved with these morpholinos 
has not been achieved and is an important factor when considering genome-wide 
effects. Despite the numerous technical difficulties associated with this, it is absolutely 
crucial for accurate interpretation of the data presented here. The research in this 
thesis took a two-pronged approach from this stage. One gene from the original 
study, RBMS1, was selected for further analysis (Chapter 5), and the in ovo model 
generated was used for identification of new synergistic targets of TBX5 and GAT A-4 
(Chapter 6). 
7.4 Investigation of the role of RBMS1 In cardiac development 
Both TBX5 and GATA-4 are involved in embryonic cardiac cell cycle progression, 
indicating a mechanism by which they can control cardiomyocyte proliferation [Rojas 
et aI., 2008; Xiao et aI., 2001]. RBMS1 is a cell cycle gene and transcription factor 
that was identified in the mouse P19 cell line as a potential downstream target of 
TBX5 and GAT A-4. Little is currently know about the regulation of this gene other 
than the presence of a positive regulatory element that is necessary for transcriptional 
activation of RBMS1 [Fujimoto et aI., 1998]. RBMS1 binds to DNA polymerase a for 
activation of DNA replication [Niki et aI., 2000a], and can induce apoptosis, mediated 
at least in part by positive transcriptional regulation of the Fas gene, which has an 
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important apoptotic role [lida et aI., 1997; Nomura et aI., 2005]. RBMS1 also 
suppresses transcription of a-smooth muscle actin [Kimura et aI., 1998], which is 
important in myofibrillogenesis [Sugi and Lough, 1992; Woodcock-Mitchell et aI., 
1988], EMT [Nakajima et aI., 1997], and vascular contractility [Schildmeyer et aI., 
2000; Tomasek et aI., 2006] which are all important in the heart. Mutations in a-
smooth muscle actin are associated with patent ductus arteriosus, which is thought to 
arise due to impaired SMC contractility [Guo et aI., 2007]. In ovo attempts to assess 
the transcriptional regulation of RBMS1 in the chick embryo left the link between this 
gene and TBX5 I GAT A-4 unclear due to the limitations of the study. As RBMS 1 was 
considered to be potentially important in cardiogenesis based on the P19 study and 
previous work by others, investigation of this gene in the chick embryo was continued 
in Chapter 5. The chromosomal location of the chicken RBMS1 gene was identified, 
and this gene was found to give rise to two highly similar splice variants (confirmed by 
EST evidence). Multispecies sequence alignments demonstrated that this gene is 
highly conserved. 
7.4.1 RBMS1 expression 
RBMS1 expression has been studied by northern blot analysis in the adult mouse, 
where expression was detected in all tissues except testis [Fujimoto et aI., 2000]. 
However, a more detailed spatial analysis of expression has not been performed, and 
the developmental expression of this gene is unknown. In order to determine the 
spatial and temporal expression pattern of RBMS1 during chick embryonic 
development, in situ hybridisation was performed using two individual probes 
designed to detect both RBMS1 transcripts. At HH16, heart expression was weak, 
and other regions of the embryo including the somites displayed strong expression. 
The HH19 embryo displayed widespread expression, and staining to the heart was 
stronger at this stage. At HH24, RBMS1 displayed expression to the heart, and was 
highly expressed in the developing forelimb and hind limb buds, somites, and brain. 
As mentioned, RBMS1 transcriptionally regulates expression of a-smooth muscle actin 
[Kimura et aI., 1998]. It is possible the a-actin genes share common regulatory 
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elements, and it was hypothesised that RBMS1 may also transcriptionally regulate 
expression of a-skeletal and/or a-cardiac actin. 
7.4.2 Morpholino knockdown of RBMS1 
Mouse knockout of RBMS 1 results in growth and developmental defects which can 
lead to embryonic lethality [Fujimoto et aI., 2001]. Deficiency of the hormone 
progesterone occurs in adult female mice, and this is thought to contribute to the delay 
in development [Fujimoto et aI., 2001]. However, the effect RBMS1 knockout has on 
the development of the heart has not specifically been studied. In order to assess the 
function of RBMS1 in the developing heart, morpholino knockdown studies in the chick 
were performed. Due to the possibility of individual translational start sites on each 
RBMS1 transcript, splice-blocking morpholinos were used to allow simultaneous 
knockdown of both. The first morpholino was deSigned to bind to the exon 2-intron 2 
junction (E212). A corresponding 5-base mismatch morpholino was also designed as 
a specificity control, but experimental data indicated that this morpholino may still have 
been able to bind to the target region, which meant it could not be used. Consultation 
with Gene-Tools revealed that the use of mismatch morpholinos was no longer 
recommended due to a high likelihood of retained target binding capability or off-target 
effects (as observed in this thesis). Therefore, a second experimental morpholino to 
the same gene was recommended, for determination of specificity upon generation of 
a common phenotype by both. A second experimental morpholino was designed to 
bind to the exon8-intron 8 boundary (E818). Both morpholinos would most likely result 
in exon skipping, or alternatively intron retention, and all outcomes were expected to 
cause in a premature stop and produce a truncated protein. Morpholinos were applied 
at HH10 - HH16. Morpholino treated embryos were examined at HH19 and displayed 
normal body shape and size, and cardiac malformations particularly in heart looping 
were apparent upon external viewing of the heart. Histological analysis of internal 
heart structures showed defects in atrial septation, and in some cases, a complete 
absence of septum formation. Similar defects are seen as a result of knockdown of 
TBX5 and GATA-4. This data may indicate that RBMS1 is a transcriptional regulator 
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of genes involved in correct septation of the heart, possibly as a downstream target of 
TBX5 and GATA-4. This is a novel finding and if corroborated with further evidence, 
will contribute to our current knowledge of the genes and transcriptional pathways 
regulating heart development, opening up many possibilities for future research. 
7.4.3 Characterisation of morpholino effects 
The effect of RBMS1 knockdown on heart development is an interesting and novel 
finding. The two morpholinos used for knockdown of RBMS 1 gave very similar 
phenotypes, implying morpholino specificity. However, it was not possible to identify 
an effect on mRNA splicing as alternatively spliced products were not detected by RT-
PCR. Splice-modified mRNA transcripts are often undetectable by RT -peR as 
nonsense mediated decay (NMD) can eliminate them from the cell (personal 
communication with Jon Moulton, Gene-Tools). Splicing of mRNA occurs in the 
nucleus, and NMD is a cytosolic process, which means that pre-mRNA transcripts 
persist for a shorter period than transcripts undergoing NMD. Additionally, there was 
no reduction in the quantity of the wild type transcript (measured by QPCR) as would 
be expected if NMD was causing degradation of aberrant transcripts. The sensitivity 
of the assay was not a contributing factor since pre-mRNA transcripts, which persist 
for a shorter period than transcripts undergoing NMD, were detectable. Western 
blotting was also attempted to quantify RBMS1 protein levels in knockdown embryos, 
but this was not successful. However, expression of a-smooth muscle actin (a 
negatively regulated target of RBMS1) was up-regulated in RBMS1 E212 morpholino 
treated embryos, supporting the theory that RBMS1 knockdown was occurring. Time 
restrictions did not allow analysis of a-smooth muscle actin expression in embryos 
treated with the RBMS1 E818 targeting morpholino. These conflicting data raise 
questions as to whether the phenotypes observed could be due to non-specific 
effects, and whether morpholinos were in fact inducing knockdown. Morpholino 
antisense technology is a relatively new advance, and is a highly useful tool for 
studying gene function by knockdown. However, the issue of controls is extremely 
important and it is not clear which serves as the best control of specificity. Mismatch 
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morpholinos may continue to display capability to bind to target sites, but if this issue 
can be resolved with 7-base mismatch morpholinos (Le. if target binding does not 
occur and off-targets effects are also not seen), these may be suitable when 
attempting to re-create an already known and characterised effect, as in Chapter 4. 
However, when attempting to investigate novel gene function by knockdown, 
specificity controls are arguably of greater importance since the expected phenotype 
is unknown and thus there is no reference point (from an anatomical perspective). 
The use of two non-overlapping targeting morpholinos is now the recommended 
method and has advantages over mismatch controls, but is still an indirect means of 
demonstrating specificity. Whilst it is unlikely in this case that an identical cardiac 
effect was generated by two individual morpholinos through off-target RNA binding, 
and the known RBMS1 target a-smooth muscle actin was up-regulated through such 
an interaction, the effect of morpholinos on RBMS1 needs to be investigated from new 
angles before a direct cause-effect relationship can be established. The mRNA 
rescue experiment, where mRNA coding for the protein being knocked down is co-
injected with the morpholino, determines proof of specificity by restoration of the wild 
type phenotype. If this can be put into practice, this experiment provides good proof of 
principle. Alternatively, RBMS1 knockdown or knockout using an alternative model 
may be warranted. If the cardiac phenotype observed in this study can be confirmed 
to be an effect of RBMS1 knockdown, this opens up a range of possibilities for further 
research. Future directions may involve mutational analysis for investigation of 
RBMS1 as a causative gene of CHD, identification of upstream regulators and 
downstream targets, and functional study to determine the mechanisms by which a 
reduction in RBMS1 can lead to cardiac abnormalities. 
7.5 Identification of new synergistic targets of TBX5 and GATA·4 
Known synergistic targets of TBX5 and GATA-4 include MYH6 [Ching et aL, 2005; 
Huang et aL, 1995; Maitra et aL, 2009; Molkentin et aL, 1994], ANF [Plageman and 
Yutzey, 2004], and connexin 40 [Linhares et aL, 2004]. All three of these genes have 
been linked to cardiac defects; mutations in MYH6 are linked to atrial septal defects 
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[Ching et aI., 2005], and mutations in connexin 40 and ANF are associated with atrial 
fibrillation [Gollob et aI., 2006; Hodgson-Zingman et aI., 2008]. In Chapter 6, the 
previously developed in ovo model of TBX5 and GAT A-4 double knockdown was used 
for identification of new synergistic targets via microarray technology, allowing gene 
expression profiling on a genome-wide scale. Eighteen genes were identified 
displaying differential regulation in TBX5 I GATA-4 knockdown embryos but not in 
single knockdown embryos or controls (all were up-regulated by ~ 2 2 fold). The majority 
of genes identified in the TBX51 GATA-4 double knockdown group have known roles 
in embryonic development. Expression patterns of six identified genes were detailed 
in the online GEISHA resource (SOX3, ZIC1, FOXG1, NKX2-1, PAX6, and OTX2), 
and these did not display obvious expression to the heart so were not considered 
further. Based on current literature, some of the remaining twelve genes have been 
reported to display heart expression, such as the novel cytokine CYTL 1 [Kim et aI., 
2007], and the growth factor FIGF (also called VEGFD) [Avantaggiato et aI., 1998]. 
FIGF, in addition to displaying expression in the limb buds, ganglion, teeth, anterior 
pituitary, lung, kidney, derma, and vertebral column, is expressed in the presumptive 
endocardial cushions of the heart, potentially indicating a specific cardiac function 
here [Avantaggiato et aI., 1998]. In addition, FIGF signalling is also important in 
angiogenesis [Marconcini et aI., 1999; Veikkola et aI., 2001]. However, the expression 
pattern of these twelve genes had not previously been characterised fully, and nine 
prioritised genes were selected for study including TFAP2B, PTPRZ1, FIGF, NR2E1, 
LOC420770, SUZ12, CRABP1, GOLGA4, and GPC3. Expression was examined by 
RT-PCR in the embryonic chick as a preliminary means of temporal and spatial 
characterisation of expression. With the exception of NR2E1, expression of all genes 
was detectable in the heart during development. LOC420nO displayed the most 
heart-restricted expression pattern and interestingly, once it was possible to 
differentiate between body and limb expression (at HH24), expression was observed 
to be more prominent in the limbs than body. This is suggestive of a heart/limb 
expression profile, similar to that of TBX5. Other genes such as TFAP2B, CRABP1 
and PTPRZ1 displayed heart expression that appeared to be strongest during early 
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cardiac development. TFAP2B in particular was only detectable in the heart at HH16. 
Genes such as SUZ12, GOLGA4, GPC3, and FIGF displayed almost ubiquitous 
expression. It was not possible to study the expression patterns of CYTL 1, PLCH1 
and LOC419390 due to limited resources and time restrictions. Further studies need 
to be performed to determine the exact localisation of expression of genes of interest. 
A number of the identified genes have established roles in cardiac development and 
disease. The small cytoplasmic protein CRABP1 is important in the modulation of 
retinoic acid levels: this is very important developmentally and an excess of retinoic 
acid is associated with retinoic acid embryopathy (RAE), which is characterised by 
malformation of neural crest derived regions including conotruncal heart structures 
[Lammer et aI., 1985). Mutations in CRABP1 are associated with the cerebrovascular 
condition Moyamoya disease [Suzuki and Takaku, 1969). Mutations in GPC3, a cell 
surface heparan sulphate proteoglycan and component of the ECM, are linked to the 
overgrowth syndrome Simpson-Golabi-Behmel syndrome (SGBS) [Pilia et aI., 1996). 
SGBS is characterised by multiple congenital abnormalities including cardiovascular 
malformation such as VSDs, common AV canal, and DORV, cardiomyopathy, and 
conduction defects in the heart [Behmel et aI., 1984; Golabi and Rosen, 1984; Lin et 
aI., 1999: Neri et aI., 1988]. CRABP1 and GPC3 are previously unknown targets of 
TBX5 and GATA-4, and this is a novel finding. Mutations in the transcription factor 
TFAP2B are associated with Char syndrome, an autosomal dominant 'heart-hand' 
disorder whose anomalies arise in neural crest cell derived regions and include patent 
ductus arteriosus (PDA), facial dysmorphism and hand anomalies [Char, 1978]. It is 
likely that TFAP2B has a role in the migration or differentiation of neural crest cells. 
Little is currently known about the regulation of TFAP2B, and is interesting that this 
heart-hand gene may be transcriptionally co-regulated by another heart-hand gene, 
TBX5. This potentially provides a new link between cardiac transcription factors which 
have not previously been associated. 
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TBX5 and GATA-4 are known as master regulators of cardiac development, and the 
diverse nature of the identified genes in addition to the known roles of some of these 
in the heart is a demonstration of this. Further study is required to validate the link 
between these genes and the TBX51 GATA-4 complex. Insight into the regulation of 
these genes may contribute to our current understanding of the transcriptional 
networks and pathways governing cardiac development, and the genetic basis of 
CHD. Study of identified genes was halted at this stage as a starting point for future 
PhD projects. 
7.6 Summary of findings and Implications of this research 
This thesis aimed to identify and investigate genes important in cardiac development, 
with focus on the synergistic targets of TBX5 and GATA-4. The results of two 
independent microarray studies were used as a basis for this research, and a diverse 
group of candidate genes was identified as a result, many of which have not 
previously been associated with a cardiac function. 
Microarray expression analysis of TBX5 I GATA-4 double overexpression P19 cell 
lines led to the identification of a large number of candidate genes, of which seven 
were selected for further study - PA2.26, PETA-3, FUCA 1, FN, TPM1, DES, and 
RBMS1. In silico promoter analysis identified the cell cycle gene and transcription 
factor RBMS1 as the gene with most putative TBX5 and GATA-4 binding sites, and 
this gene has not previously been associated with a cardiac function. RBMS1 was 
therefore selected for further study of its role in cardiac development. Chick 
embryonic treatment with RBMS1 targeting morpholinos for knockdown of expression 
resulted in defects in cardiac looping and atrial septation. This was an interesting and 
novel finding as this gene has not previously been implicated in cardiac development, 
and opened up a range of possibilities for future research into cardiac transcriptional 
networks. However further investigation is required to confirm the effect observed was 
a direct result of RBMS1 knockdown. Based on the P19 study, the roles of fibronectin 
and a-tropomyosin in heart development were also investigated by Dr Christopher 
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Moore. Morpholino knockdown of fibronectin in the chick resulted in body twisting, 
growth retardation, abnormal looping of the heart, and a thickening of the cardiac jelly 
layer (unpublished data). Morpholino knockdown of a-tropomyosin caused kinking of 
the body, abnormal heart looping, and upon internal analysis hearts showed defects in 
trabeculation and atrial septum formation (unpublished data). Other genes such as 
PETA-3 and PA2.26 remain to be investigated and this may be a basis for future 
research projects. 
Microarray expression analysis using the in ovo model of TBX5 and GAT A-4 double 
knockdown led to the identification of a number of interesting putative targets, 
including TFAP2B, GPC3, and CRABP1, which have established roles in cardiac 
development. TFAP28 is arguably the most interesting as mutations in this gene are 
associated with the heart-hand disorder Char syndrome [Satoda et aI., 1999; Satoda 
et aI., 2000]. Research into validating the link between genes of interest and TBX51 
GATA-4 may provide new insights into regulatory networks in the heart. LOC420770, 
a novel gene of unknown function, was also identified and displayed expression 
potentially indicative of a heart-limb profile. Further studies to attempt elucidation of 
the function of this gene may provide a novel candidate gene for CHD. Investigation 
of these genes will form the basis of future research, adding to our current knowledge 
of the complex network of genes involved in heart development. 
7.7 Limitations of this approach 
The work in this thesis has been largely based on the chick. The many advantages of 
using the chick as a model of cardiac development, in terms of the structural similarity 
to the human heart, and ease of access and manipulation, have been discussed 
throughout this thesis. However, as with any model, this organism also has a number 
of limitations. As discussed, atrial septation in the chick differs from mammals; in the 
chick a single atrial septum is formed, whereas in higher vertebrates an additional 
septum (the septum secundum) also forms and contributes to atrial septation [Morse 
et aI., 1984]. This means that atrial septal defects that arise from disrupted septum 
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secundum formation cannot be modelled in the chick. Since this study has focused on 
defects of the septum primum, this has not been a major concern here. Another 
limitation of this model is that due to the evolutionary diversity between the chick and 
human, homologues of candidate genes may not be present. An example of this is 
the gene encoding gamma filamin, which was of interest in this thesis but could not be 
studied in the chick. The differing physiology of organisms, and how this can manifest 
itself in many ways including a varied sensitivity to gene dosage, is of importance. 
Even within mammalian species, vast differences in the effect of equivalent levels of 
gene knockdown can be observed. For example, human mutations in NKX2.5 
(including those generating hypomorphic alleles) are associated with an array of 
congenital heart defects [Benson et aI., 1999; Elliott et aI., 2003; McElhinney et aI., 
2003; Pashmforoush et aI., 2004; Schott et aI., 1998]. In comparison, mouse 
heterozygotes of NKX2.5 display only a mild cardiac phenotype [Biben et aI., 2000]. A 
similar effect is seen with TBX20; hypomorphic mutations in this gene in humans lead 
to a diverse range of cardiac defects [Kirk et aI., 2007], whilst in the mouse only a 
greater than 50% reduction will lead to heart defects [Stennard et aI., 2005; Takeuchi 
et aI., 2005]. This differing sensitivity and response to gene dosage is likely to be 
multi-factorial. Species-specific physiology is likely to be one contributing factor, and 
the genetic background, which is important in the manifestation of CHDs [Rajagopal et 
aI., 2007], may be another. It is possible these differences are greater in the chick 
than mouse since the chick is more physiologically and evolutionary diverse from the 
human. In this thesis, knockdown of TBX5 and GAT A-4 in the chick embryo had no 
effect on expression of MYH6. This may have been due to experimental factors, but a 
species-specific effect cannot be ruled out without further study. Unfortunately it is not 
possible to predict or quantify these effects, which means the use of any model 
organism has its limitations and these need to be considered when interpreting data. 
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APPENDIX 
APPENDIX A: An overview of cardiac development In the chick 
Chick development is described from a cardiological perspective from HH 1 - HH 36. 
The HH 1 chick embryo is at the pre-primitive streak stage [Hamburger and Hamilton, 
1992], with cardiac precursor cells identifiable in the epiblast cell layer [Yutzey and 
Kirby, 2002]. At HH 2 (6 - 7 hrs) cardiac progenitor cells exist in the postero-Iateral 
epiblast and primitive streak formation begins. An intermediate primitive streak is 
visible at HH 3 (12 - 13 hrs). The HH 4 embryo (18 - 19 hours) displays a definitive 
primitive streak and precardiac cells are found either side of Hensen's node and in the 
anterior mesoderm. Gastrulation takes place at HH 5. At HH 516 (19 - 25 hrs) the 
cells that will form the heart move into two bilateral regions in the anterolateral region 
of the embryo, the primary heart field. Cardiac precursor cells are at a higher level of 
commitment at HH 6, and expression of cardiac genes is initiated at this stage [van 
den Hoff et aI., 2004]. At HH 7 (23 - 26 hrs, 1 somite), markers of terminal myocardial 
differentiation can be detected in the primary heart fields [Han et aI., 1992]. At HH 8 
(26 - 29 hrs, 4 somites), endocardial tube formation begins. Embryonic folding leads 
to formation the primary heart tube at the embryonic ventral midline [Moorman et aI., 
2003]. Prior to looping, the heart is centrally positioned and undergoes rapid 
elongation by addition of myocardial cells to both ends of the heart tube along the 
craniocaudal axis of the embryo to form a long nearly symmetrical tube at HH9. At 
HH 9 (29 - 33 hrs, 7 somites), cardiac neural crest (CNC) cells undergo epithelial-to-
mesenchymal transition (EMT) and migrate away from the neural tube towards the 
mesenchyme, outflow tract aorticopulmonary septum, and pharyngeal arch arteries 
[Boot et aI., 2003]. The primitive tubular heart begins to beat at HH 10. Dextral 
looping, where the linear heart tube loops to the right to become c-shaped and 
asymmetric, begins at this stage and is completed at HH 12 (45 - 49 hrs, 16 somites) 
[Manner, 2000]. The early phase of s-Iooping begins at HH 13 (48 - 52 hours, 19 
somites), and this phase is characterised by transformation of the heart from a c-
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shape to an immature s-shaped structure. Development of the interatrial septum 
begins at HH 14 (50 - 53 hours, 22 somites), and the septum primum grows from the 
dorsal cranial wall of the common atrium into the atrial lumen, towards the endocardial 
cushions in the AV canal [Anderson et aI., 2003]. The early phase of s-Iooping is 
completed at HH 17 - HH 18 (52 - 72 hrs, 29 - 36 somites). The late phase of s-
looping occurs at HH 19 - HH 24, and ballooning of the chambers also occurs at this 
stage [Christoffels et aI., 2000]. At HH 21 - 23 (3.5 - 4 days, 43 - 44 somites) two 
pairs of endocardial cushions, one proximal and one distal, are found in the outflow 
tract [Qayyum et aI., 2001]. At HH 24 (4 days), the atrial septum becomes fused with 
dorsal and ventral endocardial cushions in the AV canal, and small perforations 
(foramina secunda) form in the septum [Morse and Hendrix, 1980]. The foramina 
secunda increase in size and number during days 5 and 6, creating cords of 
endocardium covered tissue [Morse and Hendrix, 1980]. This cord tissue thickens 
during days 8 to 15, reducing the size of the foramina secunda, will close to complete 
atrial septation by day 2 post hatching. At HH 25 - HH 26 (4.5 - 5 days), a third distal 
endocardial cushion (required for AV canal septation) has formed in the outflow tract. 
The aorticopulmonary septum, which divides the truncus into aortic and pulmonary 
channels, forms as a result of fusion of the left and right superior truncus swellings. 
Mitral and tricuspid valve primordia are present and the muscular interventricular 
septum, which septates the left and right ventricles, begins to grow at this stage. At 
HH 28 (5.5 days) division of the semilunar valve region results from formation of the 
aorticopulmonary septum, and AV valve development begins. At HH 34 (8.0 days), 
ventricular and outflow tract septation is completed. Fusion of the dorsal and ventral 
endocardial cushions results in septation of the AV canal. At HH 35 - HH 36 (8 - 10 
days), development of AV valves is nearly complete. 
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Appendix B: QPCR assays designed to candidate genes In the mouse 
Gene Accession 10 Primer name Primer sequence (5' - 3" Position Probe" 
Neurofilament F GGTGCGAGGCACTAAGGAG 1024 -1042 
Neurofilament 3 NM_008691.2 1 
Neurofilament R ATTTTCCAACTGCTGGATGG 1110-1129 
PMM2F ATGGATGGGACCCTGACTG 77 -95 
PMM2 NM_016881.2 29 
PMM2R TCTGACCCACCTACCACTCC 164 - 183 
VEGFB F CAACACCAAGTCCGAATGC 498 - 516 
VEGFB BC046303.1 76 
VEGFBR GGCTTCACAGCACTCTCCTT 603 - 622 
a2-
a2-macroglobulin F TGAGGAGGCGGTAAAAGAAG 3575 - 3594 
93 
macroglobulin NM_175628.3 
a2-macroglobulin R TGGCACTCTGGGTTTCTGA 3620 - 3638 
Galanin R2 F GAGAGGCATTTGCTTCTTGG 735 - 754 
Galanin R2 NM_Ol0254.4 1 
Galanin R2 R AGTACAGCTCAGTCCTAAGCCTAAA 787 - 811 
Glutaredoxin F TGGAGCTCTGCAGTTATAAAAGG 355 - 377 
Glutaredoxin AB013137.1 13 
Glutaredoxin R GCCATCAGCATGGTTAGACA 408 - 427 
S100A10 F AGTTCCCTGGGTTTTTGGA 228 - 246 
S100Al0 NM_009112.2 
76 
S100A10 R CACTGGTCCAGGTCCTTCAT 281 - 300 
AP4e1 F TGGCATCATCGCTGTTTG 531-548 
AP4e1 BC042530.1 93 
AP4el R AACATCTGCTTTTCCCAACAA 578 - 598 
mRbap46 F ACGCAAGATGGCGAGTAAAG 227 - 246 
mRbap46 NM_009031.3 25 
mRbap46 R TCCAGATTTTATACTCTTCGTTGATG 278 - 303 
Gamma Filamin F GGGTACACACACCCTCAGGA 3698 - 3717 
Gamma Filamin BC060276.1 25 
Gamma Filamin R TGAAGCGGATGGTATGCTTAT 3755 - 3775 
HNRPOL F AACCAGCAGGATGACGGTA 145 - 163 
HNRPOL NM_016690.4 13 
HNRPDL R ATTCAGTCAGATCTTTCTTGCTTG 194 - 217 
Calretlculin F TGAAGCTGTTTCCGAGTGGT 401-420 
Calreticulin NM_007591.3 93 
Calreticulin R GATGACATGAACCTTCTTGGTG 492 - 513 
AnnexinA4 F AGGCTCTACGGGAAGTCTTTG 944 - 964 
AnnexinA4 BC055871.1 25 
Annexin A4 R GCGGCGTCTTGTGTTAATC 1034 - 1052 
RBMS1 F GAAGCAAGTGGCCAGCAG 1461 -1478 
RBMSl BC057866.1 76 
RBMSl R GAACTCCCTTCGGTACATCTCA 1542 -1563 
a-tropomyosin F TCGTGCTCAGGAGCGTCT 354 - 371 
a-tropomyosin M22479.1 25 
a-tropomyosin R TTCAATGACTTTCATGCCTCTC 426 - 447 
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Fibronectin F TGATTGGGAGGAAGAAGACAG 3531 ·3551 
Fibronectin X93167.1 93 
Fibronectin R TGTGGAGGGAACATCCAAG 3607·3625 
FUCA1 F GCCAGAGCTGTATGACCTTGT 640-660 
FUCA1 NM_024243.4 93 
FUCAl R GGAGTTCCAGTACGTGTCAGG 710.730 
PETA·3 F CTCCATGATAACCCACCATGT 211-231 
PETA·3 AF033620.1 76 
PETA·3 R GCATTCCCAGGAACCTTATG 267·286 
PA2.26 F CAGTGTTGTTCTGGGTTTTGG 52·72 
PA2.26 AJ250246.1 95 
PA2.26 R TGGGGTCACAATATCATCTTCA 122.143 
Nono F GGTTATGCTAATGAGGCAGGA 1058·1078 
nono NM_023144.1 25 
NonoR TTCGCTTCTGAACCTCTTGG 1127·1146 
j3·tubulin 5 F GCTGGACCGAATCTCTGTGT 283·302 
!3-tubulin BC003825.1 95 
j3·tubulin 5 R GACCTGAGCGAACGGAGTC 374·392 
Rpl13a F GCCCCACAAGACCAAGAG 285·302 
Rpl13a NM_009438.3 1 
Rpl13a R GACCACCATCCGCTTTTTC 363·381 
Bola2 F GATTACCTCCGCGAGAAGC 53·71 
80la2 NM_175103.3 13 
80la2 R AACGGTTCAGAGTCGTGTCC 109 ·126 
Dynactin F TCCTCATCAGCACGATGAAC 2968·2987 
dynactin NM_007835.2 76 
Dynactin R CTGCGTCATACTCGCCTTCT 3008·3027 
Imem131 F AGTTCCAGCTCCCCAACC 5502·5519 
Imem131 NM_018872.2 76 
Imem131 R GAGCTGCTGAATGGAGTGGT 5565·5584 
*Probe identifiers refer to pre-designed Universal ProbeLibrary probes (Roche). Each 
probe binds to a specific nucleotide sequence. Probe sequence Information can be 
found online at https:/Iwww.roche-applied-science.com). 
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Appendix C: IUPAC-IUB consensus nucleotide definitions 
IUPAC-IUB consensus nucleotide definitions 
IUS Sase 
A A 
C C 
G G 
T T 
M AorC 
R AorG 
W AorT 
S CorG 
y CorT 
K G orT 
V AorC orG 
H A or C orT 
0 Aor G orT 
B CorG orT 
N G or A orC or T 
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Appendix 0 Cell transfection and luciferase reporter assays 
Cell transfection and luciferase reporter assays were performed by Dr Tushar Ghosh. 
COS7 cells were transfected (using Polyfect) with 1 I-Ig expression plasm ids (pcDNA-
TBX5 and / or pcDNA-GAT A-4). and 1.5 I-Ig reporter plasmid. Cells were harvested 
24 hours after transfection for measurement of cell lysate luciferase activity using the 
Dual Luciferase Reporter Assay system. Transfections were performed in duplicate. 
and each experiment carried out twice. Cells transfected with reporter plasmid but 
neither expression plasmid were used for normalisation. 
The results of reporter assays performed in the pGL3-basic vector containing the 
human ANF promoter are displayed in Table 3.7 and Figure 3.9. Luciferase activity of 
vectors with and without the intronic fragment was very similar in the presence of 
TBX5. This suggests that TBX5 does not bind to this region for regulation of promoter 
activity. In the presence of GATA-4. luciferase activity was over 2-fold lower In the 
PGL3/ANF vector containing the intronic fragment compared to the PGL3/ANF vector 
lacking it i.e. GAT A-4 has a strong repressive effect via this region. There was a 28% 
reduction in luciferase activity in the presence of both TBX5 and GATA-4, smaller than 
the effect of GAT A-4 alone. ruling out synergistic repression by both transcription 
factors via this region. Reporter assays were also performed using the pGL3-
promoter vector, but luciferase activity was too low for accurate quantification. 
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Effect of the RBMS1 intron 1 fragment on promoter activity 
Fold Activation 
Expression plasmid PGL3 + ANF PGL3 + ANF + RBMS1 intron 1 fragment 
TBX5 1.00 1.11 
GATA-4 1.91 0.82 
TBX5 + GAT A-4 1.86 1.33 
COS7 cells were transfected with 1 1-19 expression plasm ids (pcDNA-TBX5 and / or 
pcDNA-GATA-4), and 1.5 1-19 reporter plasmid. Cells were harvested 24 hours after 
transfection for measurement of luciferase activity. Each transfection was performed 
in duplicate, and each experiment carried out twice. Cells transfected with reporter 
plasmid, but neither expression plasmid, were used for normalisation. 
2 
c 1.5 
o 
'0:; 
III 
> 
'B 1 
III 
't:I 
'0 
... 0.5 
o 
TBXs GATA-4 TBXs + GATA-4 
Effect of the RBMS1 Intron 1 fragment on promoter activity 
• PGL3 + ANF 
• PGL3 + ANF + RBMSl 
intron 1 fragment 
COS7 cells were transfected with 1 1-19 expression plasm ids (pcDNA-TBX5 and / or 
pcDNA-GATA-4), and 1.5 1-19 reporter plasmid. Cells were harvested 24 hours after 
transfection for measurement of luciferase activity. Each transfection was performed 
in duplicate, and each experiment carried out twice. Cells transfected with reporter 
plasmid, but neither expression plasmid, were used for normalisation. 
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Appendix E: Negative RT controls performed in parallel to expression profiling 
of candidate genes in the chick heart 
PA2.26 
PETA-3 
FUCA 1 
RBMS1 
500 bp-
FN1 
100 bp-
500 bp-
TPM1 
100 bp-
500 bp-
-
-
..... ,. 
DES 
100 bp-
500 bp-
-
-. . 
GAPDH 
I 
100 bp-
Samples were electrophoresed on 2% agarose gels using Hyperladder IV as a size marker 
(500 bp and 100 bp bands are indicated). Negative RT controls (where reverse 
transcriptase enzyme was not added) did not display amplification for any of the assays . 
All products assays spanned a 60 - 90 bp region. 
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Appendix F: Relative sizes of products amplified for expression profiling of 
candidate genes in the chick heart 
~ ~ 0: 0: Ci: a: a: 
.0 a: .0 .0 .0 .0 Qj "<t a: .0 0: 0 0 f' M 
"0 t:::. .0 M .0 !e. ~ ~ t:::. t:::. "0 ...... !e. <0 J: <"l .... .... <") <0 L: a e .... t:::. U) (3 ~ ~ C\j Ql 0.. U) :E ..... :E (',j a. 
>. <l; UJ ~ ~ ~ ~ co :::> UJ ~ ~:r: (!) a u. a:: u.... Q 
Samples were electrophoresed on 2% agarose gels using Hyperladder IV as a size 
marker (500 bp and 100 bp bands are indicated). 
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Appendix G: Standard amino acid abbreviations 
Amino acid 3-letter abbreviation 1-letter abbreviation 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamic acid Glu E 
Glutamine Gin a 
Glycine Gly G 
Histidine His H 
Isoleucine lie I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
Selenocysteine Sec U 
Pyrrolysine Pyl 0 
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pGEM 1t·• T Easv 
Vector 
(3015bp) 
on 
Appendix 
T71 1 
Apal 14 
A.9tll 20 
Sphl 26 
BstZI 31 
Ncol 37 
BstZI 43 
Notl 43 
Sacll 49 
EcoRI 52 
~ e l l 64 
coRI 70 
Notl 77 
BstZI n 
Pst I 88 
Sail 90 
Ndel 97 
Sacl 100 
BstXI 118 
Nsil 127 
11 SP6 
141 
T7 Transcription Start 
I ~ ~
5' ... TGTAA TACGA. CTCAC TATAG GGCGA. ATTGG GCCCG ACGTC GCATG crecc GGCCG CCATG 
3' ... ACATT ATGCT GA.GTG ATATC CCGCT TAACC CGGGC TGCAG CGTAC GAG3G CCGGC GGTAC 
T7 Promoter I II II I I IL-
Apal Aalll Sphl BstZI Ncol 
GCGGC CGCGG GMTI CGA1T3Z I d' rt) ATCAC TAGTG MTIC GCGGC CGCCT GCAGG TCGAC 
CGCCG GCGCC CTIAAGCTA ,COO9 InSQ 3'TII'GTG ATCAC TTAAG CGCCG GCGGA CGTCC AGCTG 
WI I II II I I IL-J'I I' II I J !i.:JtI S cli EooRI S I [coR! Nol! Pall Sail ~ ~ a ~ ~ ~ ~
SP6 Transcription Start 
... I 
CAT AT GGGA GIIGCT CCCM CGCGT TGGA.T GCATA GCTTG AGTAT TCTAT AGTGT CACCT AMT ... 3' 
GTATA CCCT CTCGA GGGTT GCGCA ACCTA CGTAT CGAAC TCATA AGATA TCACA GTGGA. nTA ... 5' 
L-J I II ~ ~ I I SP6 Prcrn01er 
Ndel Sac! B.tXl Nail 
The position of the T7 and SP6 transcription start sites are marked in addition to 
restriction sites. T7 RNA polymerase was used for synthesis of antisense RNA 
probes from Spel linearised plasmid DNA, and SP6 RNA polymerase used for 
synthesis of sense control probes from Sacll linearised plasmid DNA (both inserts in 
forward orientation). 
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Appendix I Genes identified In microarray analysis of TBX5 and GATA·4 
knockdown 
SQX3 
SOX3 (SRY (sex determining region Y)-box 3) is a member of the SOX family of 
transcription factors that are important in embryonic development and determination 
of cell fate. This gene was up-regulated by 2-fold in double knockdown embryos. 
SOX3 null mice displayed a range of defects including craniofacial abnormalities, 
midline eNS defects, growth retardation, reduced fertility, and hypopituitarism [Rizzoti 
et aI., 2004]. Human mutations in SOX3 are associated with X-linked hypopituitarism 
and mental retardation [Laumonnier et aI., 2002]. 
ZIC1 
ZIC1 (Zic family member 1) is a member of the conserved ZIC family of C2H2·type 
zinc finger transcription factors which are important in early development. Transcripts 
of this gene displayed 2.6 and 26.6-fold up-regulation in TBX5 I GATA-4 knockdown 
embryos. ZIC1 is expressed in regions that give rise to the dorsal neural tube and 
neural crest [Nakata et aI., 1998], but not in migratory neural crest cells [Sun Rhodes 
and Merzdorf, 2006]. Whole mount in situ hybridisation expression analysis in the 
mouse embryo (E9.5 - E11.5) showed that ZIC1 is expressed along the dorsal 
midline of the cranial and spinal neural tube, and expression was not detected in the 
heart [Gaston-Massuet et aI., 2005; Nagai et aI., 1997). ZIC1 is involved in cerebellar 
development, and mouse knockout of this gene results in brain and axial skeletal 
abnormalities [Aruga et aI., 1998; Aruga et aI., 1999]. 
PAX6 
PAX6 (paired box 6) is a transcription factor which contains a paired box domain and 
homeodomain, with a crucial role in the development of the eyes, nose, central 
nervous system, and pancreas. This gene was up-regulated 2.7 fold in TBX51 GATA-
4 double knockdown embryonic hearts. PAX6 is expressed in the developing nervous 
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system [Krauss et aI., 1991; Walther and Gruss, 1991] and eyes [Ton et aI., 1991]. 
Mutations in this gene are linked to an array of ocular disorders including aniridia 
[Glaser et aI., 1992], Gillespie syndrome [Glaser et aI., 1994] and Peter's anomaly 
[Hanson et aI., 1994]. 
OTX2 
OTX2 (orthodenticle homeobox 2) is a member of the bicoid family of homeodomain 
transcription factors, and a homologue of the drosophila gene orthodenticle which is 
involved in formation of the brain and eyes [Finkelstein and Boncinelli, 1994]. OTX2 
transcripts displayed 2.8 and 16 fold up-regulation in TBX5 I GATA-4 double 
knockdown embryos. This gene is expressed in the developing nose, ear, eyes, and 
brain [Martinez-Morales et aI., 2001; Simeone et aI., 1993]. Mouse knockout of this 
gene results in embryonic lethality due to defects in gastrulation which cause severe 
brain malformations including deletion of large regions [Acampora et aI., 1995; Ang et 
aI., 1996]. Human mutations in OTX2 are associated with a range of ocular disorders 
including microphthalmia syndromic type 5 (MCOPS5) [Ragge et aI., 2005]. There is 
evidence that OTX2 interacts with other ocular transcription factors including PAX6 
[Zuber et aI., 2003]. 
FOXG1 
FOXG1 (forkhead box G1) belongs to the forkhead family of transcription factors. 
FOXG1 displayed 2.8 fold up-regulation in TBX5 I GATA-4 double knockdown 
embryos. This gene is expressed in the brain and testis where it acts as a 
transcriptional repressor crucial in brain development [Xuan et aI., 1995]. Mouse 
knockout of FOXG1 results in hypoplasia of the cerebral hemispheres and lethality at 
birth [Hanashima et aI., 2004; Xu an et aI., 1995]. Mutations in this gene are 
associated with the congenital variant of Rett syndrome, a neurodevelopmental 
disorder [Ariani et aI., 2008]. 
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NKX2-1 
NKX2-1 (NK2 homeobox 1), also called thyroid transcription factor 1 (TTF1), is a 
developmentally important homeodomain transcription factor which regulates 
expression of thyroid specific genes. NKX2-1 displayed 11.4 fold up-regulation in 
response to double knockdown of TBX5 and GATA-4. NKX2-1 null mice lack thyroid 
glands, lungs, and pituitary glands, and display defects of the ventral forebrain 
[Kimura et aI., 1996]. Mutations or deletions in this gene in both humans and mice are 
associated with neurological defects [Pohlenz et aI., 2002). 
CYTL1 
CYTL 1 (cytokine-like 1) is a secreted peptide classed as a novel cytokine based on its 
predicted secondary structure which indicates it contains four alpha helices, a 
common characteristic of cytokines [Liu et aI., 2000). This gene was up-regulated 2.3 
fold in TBX51 GATA-4 double knockdown embryos. The function of CYTL 1 is not well 
characterised. It is expressed in the cartilage tissue of the mouse inner ear [Ficker et 
aI., 2004) and articular cartilage in humans [Hermansson et aI., 2004], and has a 
function in chondrogenesis [Kim et aI., 2007). RT -PCR expression studies in the adult 
mouse show CYTL 1 expression is highest in cartilage and lungs, and is also observed 
in the heart, trachea, and testis [Kim et aI., 2007]. 
PLCH1 
PLCH 1 (phospholipase C, eta 1) is a member of the phosphoinositide-specific 
phospholipase C family of enzymes which are important in intracellular signal 
tranduction (via release of inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG», 
intracellular Ca2+ release, and protein kinase C activation [Hwang et aI., 2005]. 
PLCH1 displayed 2.8-fold up-regulation in response to TBX5 I GATA-4 double 
knockdown. This gene displays expression in several cell types and has a variety of 
functions [Stewart et aI., 2005). 
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TFAP2B 
TFAP2B (transcription factor AP-2 beta (activating enhancer binding protein 2 beta)) 
is a member of the AP-2 family of transcription factors which are important in retinoic 
acid-induced differentiation [Luscher et al., 1989; Mitchell et aI., 1991]. This gene 
displayed 2.3-fold up-regulation in TBX5 / GATA-4 double knockdown embryos. 
TFAP2B is expressed in migrating neural crest cells which move into the aortic arches 
and contribute to the formation of a number of structures including the ductus 
arteriosus [Moser et aI., 1997; Satoda et aI., 2000]. Mutations in this gene are 
associated with Char syndrome in humans, an autosomal dominant disorder whose 
anomalies arise in neural crest cell derived regions [Satoda et aI., 1999; Satoda et aI., 
2000]. These include patent ductus arteriosus (PDA), facial dysmorphism and hand 
abnormalities [Char, 1978]. Char syndrome is one of a number of 'heart-hand' 
disorders to include congenital heart defects and hand anomalies. 
PTPRZ1 
PTPRZ1 (protein tyrosine phosphatase, receptor-type, Z polypeptide 1) is a member 
of the receptor type protein tyrosine phosphatase family, encoding a single pass type I 
membrane protein. This gene displayed 6.1-fold up-regulation in response to double 
knockdown ofTBX5 and GATA-4. PTPRZ1 expression has been reported in the brain 
[Kaplan et al., 1990; Krueger and Saito, 1992] and human umbilical vein cells 
(HUVEC) [Polykratis et aI., 2005], and binds the developmentally regulated proteins 
midkine [Maeda et aI., 1999] and pleiotrophin [Maeda et aI., 1996]. These are 
heparin-binding growth factors with roles in neurite outgrowth [Li et aI., 1990; 
Muramatsu and Muramatsu, 1991; Rauvala, 1989], plasminogen activity [Kojima et 
aI., 1995]. and oncogenic transformation [Chauhan et aI., 1993; Kadomatsu et aI., 
1997]. Pleiotrophin has also been implicated in neuronal migration and EMT based 
on its expression pattern [Vanderwinden et aI., 1992], and stimulates angiogenesis 
[Papadimitriou et aI., 2001]. 
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FIGF 
FIGF (c-fos induced growth factor) or vascular endothelial growth factor 0 (VEGF-D) 
is a member of the POGFNEGF superfamily whose expression is induced by the 
nuclear oncogene c-fos [Orlandini et aI., 1996]. In this study FIGF was up-regulated 
by 2.2-fold in response to double knockdown of TBX5 and GATA-4. FIGF acts via 
VEGFR2 and VEGFR3 receptors [Achen et aI., 1998] to stimulate angiogenesis and 
Iymphangiogenesis [Marconcini et aI., 1999; Veikkola et aI., 2001]. Studies of limb 
development in the chick have shown that FIGF is highly expressed in this region 
during embryogenesis [Trelles et aI., 2002]. Broader studies in the developing mouse 
embryo have identified expression in various regions including the limbs, lungs, 
kidneys, liver, and presumptive endocardial cushions of the heart [Avantaggiato et aI., 
1998]. 
NR2E1 
NR2E1 (nuclear receptor subfamily 2, group E, member 1) was up-regulated 2.8-fold 
in double knockdown embryos. This gene is a member of the orphan nuclear receptor 
gene superfamily and is required for cellular proliferation and differentiation of 
forebrain progenitor cells [Monaghan et aI., 1997; Monaghan et aI., 1995]. Mouse 
knockout of this gene results in impaired development of forebrain derived structures. 
LOC420770 
LOC420nO is a hypothetical chicken gene supported by EST evidence (GenBank 10: 
CR390114), up-regulated by 2.6 fold in response to TBX5 and GATA-4 double 
knockdown. The mRNA of this gene is 648 nucleotides in length and encodes a 
protein of 108 amino acids. A function has not yet been assigned to this gene. 
LOC419390 
LOC419390 is a hypothetical chicken gene supported by EST evidence (GenBank 10: 
C0740249), with similarity to hairy-and-enhancer-of-split related protein-7 (HES7) 
[Kim et aI., 2009]. This gene was up-regulated by 2.7-fold in double knockdown 
319 
Appendix 
embryos. Hairy-and-enhancer-of-split genes belong to the basic helix-loop-helix 
superfamily, and the HES7 gene in humans acts as a repressor protein in Notch 
signalling [Davis and Turner, 2001]. Mutations in the human HES7 gene are 
associated with spondylocostal dystosis (SCD) [Sparrow et aI., 2008], a congenital 
disorder characterised by abnormal vertebral segmentation (AVS) [Turnpenny et aI., 
2007). LOC419390 may be a transcriptional repressor with a developmental function 
in the heart. 
SUZ12 
SUZ12 (suppressor of zeste 12 homolog) was up-regulated by 2-fold following double 
knockdown of TBX5 I GAT A-4. It encodes a zinc finger protein, recently classified as 
a member of the Polycomb group (PeG) of proteins which form multi-protein 
complexes that can regulate transcription through chromatin modification [Jenuwein 
and Allis, 2001]. SUZ12 is required for cell proliferation, and mouse knockout of this 
gene results in embryonic lethality [Pasini et aI., 2004]. 
CRABP1 
CRABP1 (cellular retinoic acid binding protein 1) is a small cytoplasmic protein which 
binds to and can modulate levels of retinoic acid [Fiorella and Napoli, 1991]. This 
gene displayed 4.9-fold up-regulation in response to TBX5 I GATA-4 knockdown. 
CRABP1 expression in the mouse embryo is observed in regions derived from the 
neural crest [lyn and Giguere, 1994]. Retinoic acid is a teratogen, and an excess 
leads to retinoic acid embryopathy (RAE), whose abnormalities include malformation 
of neural crest derived regions i.e. craniofacial, thymic and CNS structures, and 
conotruncal heart defects [lammer et aI., 1985]. CRABP1 levels are elevated in the 
cerebrospinal fluid of sufferers of Moyamoya disease (MMD) [Kim et aI., 2003], a 
cerebrovascular condition characterised by progressive occlusion of the carotid artery 
(as a result of fibrosis and excess proliferation of smooth muscle cells) and formation 
of abnormal collateral vessels at the base of the brain [Suzuki and Takaku, 1969]. 
Retinoid signalling has been implicated in ventricular formation [Dyson et aI., 1995]. 
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There is evidence that retinoids can modulate expression of growth factors [Boyle et 
al.. 2000]. and a number of growth factors are elevated in MMD including basic 
fibroblast growth factor (bFGF) [Malek et al.. 1997]. transforming growth factor f3 
(TGFf3) [Hojo et al.. 1998]. and platelet derived growth factor (PDGF) [Aoyagi et al.. 
1993; Aoyagi et al.. 1991]. 
GOlGA4 
GOLGA4 (golgi autoantigen. golgin subfamily a. 4) is a member of the golgin protein 
family which localise with the golgi apparatus. helping to maintain its structure [Diao et 
al.. 2003; Puthenveedu et al.. 2006; Sohda et al.. 2005]. with an additional role in 
vesicle tethering [Sonnichsen et al.. 1998]. GOLGA4 expression was up-regulated 2-
fold in TBX51 GATA-4 double knockdown embryos. GOLGA4 is important in protein 
transport [Kakinuma et al.. 2004; Lieu et al.. 2008]. 
GPC3 
GPC3 (glypican 3) is a member of the glypican family of cell surface heparan sulphate 
proteoglycans [David, 1993], which have roles in regulation of developmental growth 
and signalling [Selleck, 1999]. GPC3 was up-regulated 2.4-fold in TBX5 I GATA-4 
double knockdown embryos. Mutations in this gene are associated with Simpson-
Golabi-Behmel syndrome (SGBS) in humans [Pilia et al.. 1996], an X linked disorder 
characterised by pre- and post-natal overgrowth, a characteristic facial appearance, 
and multiple congenital abnormalities including cardiac defects [Behmel et al.. 1984; 
Golabi and Rosen. 1984; Neri et aI., 1988]. Cardiac anomalies occur in approximately 
50% of SGBS cases and include cardiovascular malformation, cardiomyopathy, and 
conduction defects [Lin et aI., 1999]. Developmental expression of GPC3 in the 
mouse is observed in the organs that overgrow in SGBS, correlating with the 
phenotype of this disorder [Pellegrini et al.. 1998]. GPC3 null mice display several of 
the clinical features of SGBS including developmental overgrowth. perinatal death, 
kidney malformations, and lung abnormalities [Cano-Gauci et aI., 1999]. Congenital 
cardiac malformations such as VSDs, common AV canal, and DORV are also 
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observed, along with coronary vasculature defects [Ng et aI., 2009]. There is 
evidence that GPC3 acts as a receptor for FGF9, a growth factor with a crucial role in 
mesenchymal differentiation [Colvin et aI., 2001]. 
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Appendix J: Negative RT controls performed in parallel to expression profiling 
of candidate genes chick embryonic segments at HH16, HH19 and HH24 
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Samples were electrophoresed on 2% agarose gels using Hyperladder IV as a size marker (500 bp and 
100 bp bands are indicated). Negative RT controls (where reverse transcriptase enzyme was not added) 
did not display amplification for any of the assays. 
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